PELLETIER Jean
Medical Doctor (MD)
Professor (MD, PhD)
at AMU and at AP-HMMD PhD, Professor in Neurology (CNU 49.01)
Head of the Mutiple Sclerosis Research Team (CRMBM CEMEREM UMRCNRS7339)
Head of the Department of Neurology, Timone University Hospital (APHM)
Medical School of Marseille, Neurosciences (AMU)
Medical Doctor (MD)
Professor (MD, PhD)
Detailed Activities
Keywords
- Artificial Intelligence
- Connectivity
- Dynamic MRI/MRS
- Image Processing
- k-space Acquisition
- Metabolism
- Microstructure/architecture
- New Contrasts
- New MR Biomarkers
- Parallel Transmit
- Perfusion Methods
- Quantitative MRI
- Quantitative MRS
- Sodium Homeostatis
- Ultra-high field MRI
- X-Nuclei
General Information
Research Projects
Publications :
180164
PELLETIER
1
harvard-cite-them-right-no-et-al
50
date
desc
year
2614
https://crmbm.univ-amu.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A100%2C%22request_next%22%3A50%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22C2999DIC%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stellmann%20et%20al.%22%2C%22parsedDate%22%3A%222025-11-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BStellmann%2C%20J.-P.%2C%20Maarouf%2C%20A.%2C%20Nicolescu%2C%20M.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Zaaraoui%2C%20W.%2C%20Guye%2C%20M.%2C%20Pelletier%2C%20J.%2C%20Ranjeva%2C%20J.-P.%20and%20Audoin%2C%20B.%20%282025%29%20%26%23x201C%3BEarly%20structural%20hub%20disruption%20leads%20to%20premature%20functional%20adaption%20in%20multiple%20sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BBrain%20Structure%20%26amp%3B%20Function%26lt%3B%5C%2Fi%26gt%3B%2C%20230%289%29%2C%20p.%20172.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00429-025-03023-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00429-025-03023-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Early%20structural%20hub%20disruption%20leads%20to%20premature%20functional%20adaption%20in%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mihaela%22%2C%22lastName%22%3A%22Nicolescu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Phillipe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22In%20Multiple%20Sclerosis%2C%20inflammation%20and%20neurodegeneration%20disrupt%20structural%20and%20functional%20brain%20networks.%20While%20the%20association%20between%20structural%20connectivity%20and%20disability%20is%20rather%20clear%2C%20functional%20connectivity%20changes%20are%20not%20yet%20characterised%20as%20a%20physiological%20response%20to%20the%20disease%2C%20as%20functionally%20meaningful%20adaptation%20or%20as%20a%20deceptive%20response.%20We%20explored%20the%20topology%20of%20brain%20networks%20of%2065%20Multiple%20Sclerosis%20patients%20over%20up%20to%20seven%20years%20in%20comparison%20to%2059%20controls.%20Connectomes%20based%20on%20probabilistic%20tractography%20from%20diffusion%20weighted%20imaging%20and%20resting-state%20MRI%2C%20were%20analysed%20with%20graph%20theory.%20The%20hub%20disruption%20index%20estimated%20connectivity%20perturbation%20in%20relation%20to%20the%20network%20hierarchy.%20In%20controls%2C%20we%20observed%20a%20transient%20increase%20in%20functional%20hub%20connectivity%20in%20the%205th%20and%206th%20age%20decade%20as%20a%20response%20to%20a%20subtle%20diffuse%20loss%20of%20structural%20connectivity%2C%20before%20structural%20and%20functional%20connectomes%20show%20a%20pronounced%20loss%20of%20hub%20connectivity.%20In%20Multiple%20Sclerosis%2C%20structural%20hub%20disruption%20was%20present%20from%20the%20disease%20onset%20while%20the%20transient%20upregulation%20of%20functional%20hub%20connectivity%20in%20the%20middle%20age%20was%20lacking.%20Patients%20seem%20to%20transition%20directly%20into%20an%20exhausted%20hub%20connectivity%20configuration.%20However%2C%20we%20observed%20the%20transient%20functional%20reorganisation%20of%20hubs%20in%20the%20first%20years%20after%20disease%20onset.%20Multiple%20Sclerosis%20patients%20present%20a%20probable%20physiological%20response%20to%20structural%20connectivity%20loss%20very%20early%20in%20the%20disease%2C%20potentially%20leading%20to%20an%20accelerated%20hub%20overload%20with%20accelerated%20neurodegeneration.%20The%20onset%20of%20chronic%20progression%20in%20the%205th%20age%20decade%20might%20be%20partially%20driven%20by%20the%20absence%20of%20the%20physiological%20increased%20hub%20connectivity%20observed%20in%20healthy%20individuals.%22%2C%22date%22%3A%222025-11-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00429-025-03023-2%22%2C%22ISSN%22%3A%221863-2661%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%229L2KHJ5X%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-11-06T15%3A36%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22MXJEKN4G%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wilson%20et%20al.%22%2C%22parsedDate%22%3A%222025-10-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWilson%2C%20S.%2C%20Leray%2C%20E.%2C%20Calocer%2C%20F.%2C%20Rollot%2C%20F.%2C%20Fauvernier%2C%20M.%2C%20Remontet%2C%20L.%2C%20Launay%2C%20L.%2C%20Vukusic%2C%20S.%2C%20Le%20Page%2C%20E.%2C%20Debouverie%2C%20M.%2C%20Ciron%2C%20J.%2C%20Ruet%2C%20A.%2C%20Seze%2C%20J.D.%2C%20Zephir%2C%20H.%2C%20Moreau%2C%20T.%2C%20Laplaud%2C%20D.-A.%2C%20Lebrun-Frenay%2C%20C.%2C%20Clavelou%2C%20P.%2C%20Labauge%2C%20P.%2C%20Berger%2C%20E.%2C%20Pelletier%2C%20J.%2C%20Heinzlef%2C%20O.%2C%20Thouvenot%2C%20E.%2C%20Camdessanch%26%23xE9%3B%2C%20J.P.%2C%20Arnaud%2C%20C.%2C%20Derache%2C%20N.%2C%20Branger%2C%20P.%2C%20Guittet%2C%20L.%2C%20Defer%2C%20G.%20and%20Dejardin%2C%20O.%20%282025%29%20%26%23x201C%3BInfluence%20of%20geographical%20accessibility%20to%20specialist%20and%20primary%20care%20givers%20on%20excess%20mortality%20of%20multiple%20sclerosis%20patients%20in%20France%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BBMC%20neurology%26lt%3B%5C%2Fi%26gt%3B%2C%2025%281%29%2C%20p.%20441.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12883-025-04459-z%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12883-025-04459-z%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Influence%20of%20geographical%20accessibility%20to%20specialist%20and%20primary%20care%20givers%20on%20excess%20mortality%20of%20multiple%20sclerosis%20patients%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Wilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Floriane%22%2C%22lastName%22%3A%22Calocer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Fauvernier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Remontet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludivine%22%2C%22lastName%22%3A%22Launay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debouverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%20De%22%2C%22lastName%22%3A%22Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David-Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Arnaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Derache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydia%22%2C%22lastName%22%3A%22Guittet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Dejardin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Access%20to%20healthcare%20and%20socioeconomic%20deprivation%20are%20intricately%20linked.%20No%20studies%20have%20been%20led%20to%20measure%20the%20effect%20of%20healthcare%20accessibility%20on%20mortality%20in%20patients%20with%20MS%20so%20far.%20The%20objective%20was%20to%20examine%20the%20influence%20of%20travel%20time%20to%20the%20expert%20MS%20centre%20and%20of%20the%20accessibility%20to%20primary%20healthcare%20services%20on%20excess%20mortality%20in%20MS.%5CnMETHODS%3A%20A%20retrospective%20observational%20cohort%20study%20recruited%20patients%20from%2018%20French%20MS%20expert%20centres%2C%20with%20an%20onset%20of%20MS%20between%201960%20and%202015%20and%20a%20follow-up%20of%20up%20to%2030%5Cu00a0years.%20Primary%20health%20facility%20accessibility%20was%20measured%20by%20the%20Spatial%20aCcessibility%20multiscAlar%20index.%20Specialist%20care%20accessibility%20was%20measured%20by%20road%20travel%20time%20to%20the%20expert%20MS%20centre.%20Excess%20death%20rates%20%28EDR%29%20and%20excess%20hazard%20ratios%20were%20studied%20using%20additive%20excess%20hazard%20models%20with%20multidimensional%20penalised%20splines.%5CnRESULTS%3A%20The%20study%20included%2033%2C697%20patients.%20Patients%20with%20relapsing-onset%20MS%20%28R-MS%29%20with%20a%20travel%20time%20of%2040%5Cu00a0min%20had%20the%20lowest%20EDR%20%28Men%3A%201.2%20deaths%20per%20100%20person-years%20%2895%25CI%20%5B0.8%3B1.8%5D%29%2C%20women%3A%200.8%20deaths%20per%20100%20person-years%2095%25CI%5B0.6%3B1.2%5D%29%2C%20lower%20than%20patients%20who%20lived%20further%20from%20the%20centre.%20No%20effect%20of%20primary%20care%20access%20was%20found%20for%20patients%20with%20R-MS%2C%20and%20no%20effect%20of%20accessibility%20to%20primary%20or%20specialised%20care%20was%20found%20for%20patients%20with%20primary%20progressive%20MS.%5CnCONCLUSION%3A%20This%20study%20reveals%20the%20impact%20of%20travel%20time%20to%20neurologists%20on%20excess%20mortality%20in%20patients%20with%20R-MS%20in%20France.%20This%20distance%20bias%20association%20highlights%20the%20importance%20of%20preventing%20a%20potential%20selection%20of%20patients%20followed%20in%20MS%20expert%20centres.%22%2C%22date%22%3A%222025-10-27%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12883-025-04459-z%22%2C%22ISSN%22%3A%221471-2377%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A05Z%22%7D%7D%2C%7B%22key%22%3A%226ZIM8H2R%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Perriguey%20et%20al.%22%2C%22parsedDate%22%3A%222025-10-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPerriguey%2C%20M.%2C%20Rigollet%2C%20C.%2C%20Freeman%2C%20S.A.%2C%20Graille-Avy%2C%20L.%2C%20Lafontaine%2C%20J.-C.%2C%20Lemarchant%2C%20B.%2C%20Alberto%2C%20T.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Hil%26%23xE9%3Bzian%2C%20F.%2C%20Durozard%2C%20P.%2C%20Pelletier%2C%20J.%2C%20Maarouf%2C%20A.%2C%20Z%26%23xE9%3Bphir%2C%20H.%20and%20Audoin%2C%20B.%20%282025%29%20%26%23x201C%3BPrevalence%20of%20hypogammaglobulinemia%20after%20non-anti-CD20%20therapies%20and%20impact%20of%20switching%20to%20rituximab%5C%2Focrelizumab%20in%20multiple%20sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurotherapeutics%26lt%3B%5C%2Fi%26gt%3B%2C%2022%286%29.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurot.2025.e00760%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.neurot.2025.e00760%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prevalence%20of%20hypogammaglobulinemia%20after%20non-anti-CD20%20therapies%20and%20impact%20of%20switching%20to%20rituximab%5C%2Focrelizumab%20in%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Rigollet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sean%20A.%22%2C%22lastName%22%3A%22Freeman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Graille-Avy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Lafontaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Lemarchant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tifanie%22%2C%22lastName%22%3A%22Alberto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Hil%5Cu00e9zian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Z%5Cu00e9phir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222025-10-01%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.neurot.2025.e00760%22%2C%22ISSN%22%3A%221878-7479%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.neurotherapeuticsjournal.org%5C%2Farticle%5C%2FS1878-7479%2825%2900238-7%5C%2Ffulltext%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-12-01T09%3A50%3A13Z%22%7D%7D%2C%7B%22key%22%3A%222EDLR7UJ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Melka%20et%20al.%22%2C%22parsedDate%22%3A%222025-09-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMelka%2C%20M.%2C%20Rotard%2C%20L.%2C%20Benstaali%2C%20C.%2C%20Brocard%2C%20J.%2C%20Giannesini%2C%20B.%2C%20Jouve%2C%20F.%2C%20Pelletier%2C%20L.%2C%20Faur%26%23xE9%3B%2C%20J.%2C%20Rendu%2C%20J.%2C%20Jacquemond%2C%20V.%20and%20Marty%2C%20I.%20%282025%29%20%26%23x201C%3BLimited%20pre-clinical%20relevance%20of%20the%20heterozygous%20RYR1-I4895T%5C%2F%2B%20mouse%20model%20due%20to%20its%20mild%20phenotype%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neuromuscular%20Diseases%26lt%3B%5C%2Fi%26gt%3B%2C%20p.%2022143602251339354.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F22143602251339354%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F22143602251339354%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Limited%20pre-clinical%20relevance%20of%20the%20heterozygous%20RYR1-I4895T%5C%2F%2B%20mouse%20model%20due%20to%20its%20mild%20phenotype%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margaux%22%2C%22lastName%22%3A%22Melka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludivine%22%2C%22lastName%22%3A%22Rotard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Benstaali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Brocard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Giannesini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Jouve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Faur%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Rendu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jacquemond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Marty%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Although%20genetically-engineered%20mouse%20models%20are%20revolutionizing%20our%20understanding%20of%20numerous%20human%20diseases%2C%20some%20of%20them%20fail%20to%20reproduce%20or%20to%20mimic%20the%20human%20condition%20or%20even%20exhibit%20distinct%20disease%20features%20depending%20on%20the%20mouse%20genetic%20background%2C%20on%20the%20environment%20conditions%2C%20and%5C%2For%20on%20unknown%20parameters.%5CnOBJECTIVE%3A%20Experiments%20aimed%20at%20further%20characterizing%20the%20muscle%20defects%20associated%20with%20the%20I-T%20substitution%20at%20position%204898%20of%20the%20human%20type%201%20ryanodine%20receptor%20%28RyR1%29%20protein%20sequence%2C%20responsible%20for%20central%20core%20disease%20in%20affected%20patients%2C%20to%20use%20this%20model%20for%20therapeutic%20development.%20RyR1%20is%20a%20cationic%20channel%20in%20the%20sarcoplasmic%20reticulum%20membrane%20that%20is%20responsible%20for%20the%20Ca2%2B%20release%20flux%20that%20triggers%20muscle%20contraction.%20The%20above%20I-T%20change%20was%20previously%20described%20to%20alter%20RyR1%20channel%20permeation%20so%20as%20to%20produce%20muscle%20weakness.%5CnMETHODS%3A%20We%20used%20the%20corresponding%20I4895T%20mouse%20model%2C%20previously%20shown%20unviable%20in%20the%20homozygous%20form%2C%20and%20with%20heterozygous%20animals%20suffering%20from%20depressed%20RyR1-mediated%20Ca2%2B%20flux%20and%20muscle%20force%20production.%20We%20performed%20a%20full%20characterization%2C%20at%20the%20molecular%20level%20of%20the%20RYR1%20gene%20and%20transcript%2C%20and%20at%20the%20functional%20level%20at%20the%20isolated%20fiber%20or%20whole%20animal%20levels.%5CnRESULTS%3A%20We%20found%20no%20significant%20deficit%20in%20the%20heterozygous%20animals%2C%20from%20force%20and%20activity%20parameters%20at%20the%20whole%20organism%20level%2C%20to%20contraction%20of%20isolated%20muscles%20and%20Ca2%2B%20release%20in%20single%20isolated%20muscle%20fibers.%5CnCONCLUSIONS%3A%20Our%20results%20prompt%20the%20need%20for%20caution%20when%20using%20this%20model%2C%20and%20point%20to%20its%20potential%20limited%20relevance%20for%20preclinical%20studies.%22%2C%22date%22%3A%222025-09-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F22143602251339354%22%2C%22ISSN%22%3A%222214-3602%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%226DHTGFMA%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A58%3A59Z%22%7D%7D%2C%7B%22key%22%3A%226L3SY3Y7%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gavoille%20et%20al.%22%2C%22parsedDate%22%3A%222025-09-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGavoille%2C%20A.%2C%20Nourredine%2C%20M.%2C%20Rollot%2C%20F.%2C%20Casey%2C%20R.%2C%20Mathey%2C%20G.%2C%20Kerbrat%2C%20A.%2C%20Ciron%2C%20J.%2C%20De%20S%26%23xE8%3Bze%2C%20J.%2C%20Stankoff%2C%20B.%2C%20Maillart%2C%20E.%2C%20Ruet%2C%20A.%2C%20Labauge%2C%20P.%2C%20Kwiatkowski%2C%20A.%2C%20Zephir%2C%20H.%2C%20Papeix%2C%20C.%2C%20Defer%2C%20G.%2C%20Lebrun-Frenay%2C%20C.%2C%20Moreau%2C%20T.%2C%20Laplaud%2C%20D.-A.%2C%20Berger%2C%20E.%2C%20Clavelou%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Pelletier%2C%20J.%2C%20Al%20Khedr%2C%20A.%2C%20Casez%2C%20O.%2C%20Bourre%2C%20B.%2C%20Wahab%2C%20A.%2C%20Magy%2C%20L.%2C%20Moulin%2C%20S.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Doghri%2C%20I.%2C%20Sarov%2C%20M.%2C%20Hankiewicz%2C%20K.%2C%20Pottier%2C%20C.%2C%20Dos%20Santos%2C%20A.%2C%20Manchon%2C%20E.%2C%20Tchikviladze%2C%20M.%2C%20Rabilloud%2C%20M.%2C%20Subtil%2C%20F.%20and%20Vukusic%2C%20S.%20%282025%29%20%26%23x201C%3BTarget%20trial%20emulation%20to%20replicate%20randomised%20clinical%20trials%20using%20registry%20data%20in%20multiple%20sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neurology%2C%20Neurosurgery%2C%20and%20Psychiatry%26lt%3B%5C%2Fi%26gt%3B%2C%20p.%20jnnp-2025-336762.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2025-336762%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2025-336762%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Target%20trial%20emulation%20to%20replicate%20randomised%20clinical%20trials%20using%20registry%20data%20in%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Gavoille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikail%22%2C%22lastName%22%3A%22Nourredine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Kwiatkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David-Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al%20Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Sarov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maia%22%2C%22lastName%22%3A%22Tchikviladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Rabilloud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Subtil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%5D%2C%22abstractNote%22%3A%22BackgroundTarget%20trial%20emulation%20%28TTE%29%20offers%20a%20formal%20framework%20for%20causal%20inference%20using%20observational%20data%2C%20but%20its%20validity%20must%20be%20evaluated%20in%20each%20research%20domain%20by%20replicating%20randomised%20clinical%20trials%20%28RCTs%29.%20We%20aimed%20to%20replicate%20eight%20RCTs%20evaluating%20the%20efficacy%20of%20disease-modifying%20therapies%20%28DMTs%29%20in%20multiple%20sclerosis%20%28MS%29%20using%20French%20registry%20data.%5CnMETHODS%3A%20This%20multicentre%2C%20retrospective%2C%20observational%20study%20was%20conducted%20using%20data%20extracted%20in%20December%202023%20from%20the%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20%28OFSEP%29%20database.%20For%20each%20emulated%20trial%2C%20patients%20were%20included%20when%20they%20initiated%20one%20of%20the%20DMT%20evaluated%20in%20the%20corresponding%20RCT%20and%20met%20its%20inclusion%20criteria.%20Clinical%20outcomes%20were%20the%20annualised%20relapse%20rate%20and%203-month%20confirmed%20Expanded%20Disability%20Status%20Scale%20progression.%20Radiological%20outcomes%20were%20new%5C%2Fenlarged%20T2-lesions%20and%20new%20gadolinium-enhanced%20T1-lesions%20on%20a%20brain%20MRI.%20A%20targeted%20maximum%20likelihood%20estimator%20was%20used%20to%20estimate%20the%20treatment%20effect%20adjusted%20for%20confounding%20factors%20between%20groups%20and%20corrected%20for%20censoring%20and%20missing%20outcome%20assessment.%5CnRESULTS%3A%2014%5Cu2009111%20patients%20were%20included%20in%20eight%20emulated%20trials%3A%20ASSESS%20%28fingolimod%20vs%20glatiramer%20acetate%29%2C%20BEYOND%20%28interferon%20beta%20vs%20glatiramer%20acetate%29%2C%20CONFIRM%20%28dimethyl%20fumarate%20%28DMF%29%20vs%20glatiramer%20acetate%29%2C%20OPERA%20%28ocrelizumab%20vs%20interferon%20beta%29%2C%20REGARD%20%28interferon%20beta%20vs%20glatiramer%20acetate%29%2C%20RIFUND-MS%20%28rituximab%20vs%20DMF%29%2C%20TENERE%20%28teriflunomide%20vs%20interferon%20beta%29%20and%20TRANSFORMS%20%28fingolimod%20vs%20interferon%20beta%29.%20Treatment%20effects%20estimated%20in%20emulated%20trials%20were%20concordant%20with%20RCT%20findings%20in%20seven%20of%20eight%20trials%20for%20relapse%20rate%2C%20and%20in%20all%20six%20trials%20assessing%20disability%20progression.%20Radiological%20outcomes%20were%20more%20challenging%20to%20replicate%3B%20concordance%20was%20achieved%20in%20three%20of%20five%20trials%20for%20new%20T2-lesions%2C%20and%20one%20of%20four%20trials%20for%20new%20gadolinium-enhanced%20T1-lesions.%5CnCONCLUSION%3A%20The%20combined%20use%20of%20a%20TTE%20methodology%20and%20high-quality%20registry%20data%20is%20a%20valid%20tool%20to%20evaluate%20treatment%20effectiveness%20in%20MS.%22%2C%22date%22%3A%222025-09-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fjnnp-2025-336762%22%2C%22ISSN%22%3A%221468-330X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22EBKNBNNG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gavoille%20et%20al.%22%2C%22parsedDate%22%3A%222025-08-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGavoille%2C%20A.%2C%20Leray%2C%20E.%2C%20Marignier%2C%20R.%2C%20Rollot%2C%20F.%2C%20Casey%2C%20R.%2C%20Mathey%2C%20G.%2C%20Michel%2C%20L.%2C%20De%20Seze%2C%20J.%2C%20Ciron%2C%20J.%2C%20Ruet%2C%20A.%2C%20Maillart%2C%20E.%2C%20Labauge%2C%20P.%2C%20Zephir%2C%20H.%2C%20Laplaud%2C%20D.A.%2C%20Papeix%2C%20C.%2C%20Defer%2C%20G.%2C%20Moreau%2C%20T.%2C%20Berger%2C%20E.%2C%20Dubessy%2C%20A.-L.%2C%20Clavelou%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Pelletier%2C%20J.%2C%20Al%20Khedr%2C%20A.%2C%20Casez%2C%20O.%2C%20Bourre%2C%20B.%2C%20Wahab%2C%20A.%2C%20Magy%2C%20L.%2C%20Camdessanche%2C%20J.-P.%2C%20Doghri%2C%20I.%2C%20Moulin%2C%20S.%2C%20Labeyrie%2C%20C.%2C%20Hankiewicz%2C%20K.%2C%20Dos%20Santos%2C%20A.%2C%20Pottier%2C%20C.%2C%20Manchon%2C%20E.%2C%20Tchikviladze%2C%20M.%2C%20Lebrun-Frenay%2C%20C.%2C%20Vukusic%2C%20S.%20and%20OFSEP%20investigators%20%282025%29%20%26%23x201C%3BSex-Related%20Gap%20in%20the%20Use%20of%20Disease-Modifying%20Therapies%20in%20Multiple%20Sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%2C%20105%284%29%2C%20p.%20e213907.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213907%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213907%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Sex-Related%20Gap%20in%20the%20Use%20of%20Disease-Modifying%20Therapies%20in%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Gavoille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Dubessy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al%20Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Labeyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maya%22%2C%22lastName%22%3A%22Tchikviladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22OFSEP%20investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20In%20women%20with%20multiple%20sclerosis%20%28MS%29%2C%20the%20therapeutic%20strategy%20may%20be%20influenced%20by%20the%20anticipation%20of%20future%20pregnancies%2C%20leading%20to%20underexposure%20to%20disease-modifying%20therapies%20%28DMTs%29%20and%20highly%20effective%20DMTs%20%28HEDMTs%29%20compared%20with%20men.%20We%20aimed%20to%20evaluate%20potential%20therapeutic%20inertia%20in%20women%20with%20MS%20and%20explore%20its%20causes.%5CnMETHODS%3A%20We%20performed%20a%20retrospective%20cohort%20study%20based%20on%20data%20extracted%20on%20June%202023%20from%20the%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20for%20all%20patients%20with%20a%20relapsing-remitting%20MS%20onset%20between%2018%20and%2040%20years.%20The%20primary%20outcome%20was%20the%20annual%20probability%20of%20receiving%20a%20DMT%2C%20accounting%20for%20sex%2C%20disease%20severity%2C%20and%20pregnancy%5C%2Fpostpartum%20periods.%20Secondary%20outcomes%20were%20the%20annual%20probability%20of%20receiving%20a%20HEDMT%2C%20each%20DMT%20separately%2C%20and%20interaction%20of%20the%20effect%20of%20sex%20with%20calendar%20year%2C%20patient%20age%2C%20and%20disease%20duration.%20We%20used%20a%20longitudinal%20logistic%20model%20with%20generalized%20estimating%20equations%20and%20an%20inverse-probability-of-censoring%20weighting.%5CnRESULTS%3A%20We%20included%2022%2C657%20patients%20with%20MS%3B%2016%2C857%20%2874.4%25%29%20were%20female%2C%20mean%20%28SD%29%20age%20at%20onset%20was%2029.0%20%286.0%29%20years%2C%20and%20median%20%28interquartile%20range%29%20follow-up%20duration%20was%2011.6%20%286.6-17.3%29%20years.%20Women%20were%20significantly%20less%20likely%20to%20receive%20a%20DMT%20%28odds%20ratio%20%5BOR%5D%200.92%2C%2095%25%20CI%200.87-0.97%29%20or%20a%20HEDMT%20%28OR%200.80%2C%2095%25%20CI%200.74-0.86%29.%20This%20difference%20appeared%202%20years%20after%20disease%20onset%20for%20DMTs%20and%201%20year%20for%20HEDMTs%2C%20and%20did%20not%20differ%20significantly%20according%20to%20patient%26%23039%3Bs%20age.%20Teriflunomide%2C%20sphingosine-1-phosphate%20receptor%20modulators%2C%20and%20anti-CD20s%20were%20significantly%20underused%20in%20women%20throughout%20their%20entire%20period%20of%20availability%3B%20interferons%20%5Cu03b2%20%28IFN-%5Cu03b2%29%20and%20natalizumab%20were%20initially%20less%20used%20and%20then%20equally%20after%20some%20time%3B%20glatiramer%20acetate%20and%20fumarates%20were%20first%20used%20equally%2C%20then%20more%20frequently%20in%20women.%20The%20proportion%20of%20treated%20women%2C%20analyzed%20from%20the%20first%20childbirth%20of%205%2C268%20women%2C%20began%20to%20decline%2018%20months%20before%20childbirth%2C%20from%2042.6%25%20to%2027.9%25%20at%20the%20estimated%20time%20of%20conception.%5CnDISCUSSION%3A%20Women%20with%20MS%20were%20significantly%20less%20exposed%20to%20DMTs%20compared%20with%20men.%20Anticipation%20of%20pregnancy%20was%20probably%20an%20important%20factor%20underlying%20this%20difference%2C%20but%20also%20sex-specific%20therapeutic%20inertia.%20Neurologists%20and%20patients%20should%20be%20educated%20on%20the%20most%20recent%20recommendations%20on%20the%20use%20of%20DMTs%20in%20the%20context%20of%20pregnancy%20to%20avoid%20deleterious%20therapeutic%20inertia.%22%2C%22date%22%3A%222025-08-26%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000213907%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22T4W95BS2%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Robin%20et%20al.%22%2C%22parsedDate%22%3A%222025-08-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRobin%2C%20C.%2C%20Rollot%2C%20F.%2C%20Lefort%2C%20M.%2C%20Casey%2C%20R.%2C%20Vukusic%2C%20S.%2C%20Mathey%2C%20G.%2C%20Ciron%2C%20J.%2C%20De%20Seze%2C%20J.%2C%20Stankoff%2C%20B.%2C%20Maillart%2C%20E.%2C%20Ruet%2C%20A.%2C%20Labauge%2C%20P.M.%2C%20Kwiatkowski%2C%20A.%2C%20Zephir%2C%20H.%2C%20Papeix%2C%20C.%2C%20Defer%2C%20G.%2C%20Lebrun-Frenay%2C%20C.%2C%20Moreau%2C%20T.%2C%20Laplaud%2C%20D.A.%2C%20Berger%2C%20E.%2C%20Clavelou%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Pelletier%2C%20J.%2C%20Casez%2C%20O.%2C%20Bourre%2C%20B.%2C%20Wahab%2C%20A.%2C%20Magy%2C%20L.%2C%20Moulin%2C%20S.%2C%20Camdessanche%2C%20J.-P.%2C%20Doghri%2C%20I.%2C%20Sarov%2C%20M.%2C%20Hankiewicz%2C%20K.%2C%20Pottier%2C%20C.%2C%20Dos%20Santos%2C%20A.%2C%20Manchon%2C%20E.%2C%20Tchikviladze%2C%20M.%2C%20Nifle%2C%20C.%2C%20Kerbrat%2C%20A.%2C%20Edan%2C%20G.%2C%20Le%20Page%2C%20E.%2C%20Michel%2C%20L.%20and%20as%20the%20OFSEP%20Investigators%20%282025%29%20%26%23x201C%3BUse%20of%20Disease-Modifying%20Therapies%20in%20Patients%20With%20Late-Onset%20Multiple%20Sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%2C%20105%283%29%2C%20p.%20e213744.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213744%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000213744%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Use%20of%20Disease-Modifying%20Therapies%20in%20Patients%20With%20Late-Onset%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Robin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Lefort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%20M.%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Kwiatkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Sarov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maya%22%2C%22lastName%22%3A%22Tchikviladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22as%20the%20OFSEP%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20The%20therapeutic%20strategy%20in%20patients%20with%20late-onset%20MS%20%28LOMS%29%20remains%20poorly%20defined.%20In%20this%20study%2C%20we%20aimed%20to%20evaluate%20both%20clinical%20and%20MRI%20outcomes%20between%202%20cohorts%20of%20patients%20with%20relapsing-remitting%20LOMS%20treated%20or%20not%20yet%20treated.%5CnMETHODS%3A%20Patients%20with%20relapsing-remitting%20MS%20were%20included%20for%20the%20analysis%20if%20disease%20onset%20occurred%20after%2055%20years%20and%20if%20they%20had%20at%20least%20one%20follow-up%20visit.%20The%20primary%20outcome%20was%20time%20to%20first%20relapse%20between%202%20matched%20groups%20of%20patients%20with%20LOMS%20%28treated%20and%20not%20yet%20treated%29.%20Secondary%20outcomes%20were%20as%20follows%3A%20%281%29%20time%20to%20first%20confirmed%20disability%20progression%20%28CDP%29%2C%20%282%29%20time%20to%20first%20progression%20independent%20of%20relapse%20activity%20%28PIRA%29%20event%2C%20%283%29%20time%20to%20secondary%20progression%20%28SPMS%29%2C%20%284%29%20time%20to%20first%20MRI%20activity%2C%20and%20%285%29%20serious%20infection%20incidence%20rates%20%28IIRs%29.%20For%20the%20comparative%20analyses%2C%20we%20adopted%20a%20time-dependent%20propensity%20score%20matching%20approach.%5CnRESULTS%3A%20A%20total%20of%20881%20patients%20fulfilled%20the%20inclusion%20criteria.%20The%20mean%20%28SD%29%20age%20at%20onset%20was%2059.9%20%284.43%29%20years.%20After%20applying%20propensity%20score%20matching%2C%20436%20patients%20were%20matched.%20The%20mean%20%28SD%29%20follow-up%20duration%20was%205.2%20%284.27%29%20years%20in%20the%20treated%20group%20and%205.0%20%283.86%29%20years%20in%20the%20not-yet-treated%20group.%20Mean%20%28SD%29%20time%20to%20first%20relapse%20was%20significantly%20longer%20in%20the%20treated%20group%20compared%20with%20the%20not-yet-treated%20group%20%287.0%20years%20%5B0.33%5D%20vs%205.4%20years%20%5B0.33%5D%3B%20p%20%3D%200.001%29.%20Mean%20%28SD%29%20time%20to%20first%20MRI%20activity%20was%20significantly%20longer%20in%20the%20treated%20group%20%285.9%20years%20%5B0.33%5D%20vs%205.0%20years%20%5B0.33%5D%3B%20p%20%3D%200.049%29.%20However%2C%20the%20mean%20time%20to%20CDP%2C%20PIRA%2C%20or%20SPMS%20was%20not%20different%20between%20the%202%20groups%20%28difference%20%3D%200.32%20years%3B%20p%20%3D%200.585%20for%20CDP%3B%20difference%20%3D%200.40%20years%3B%20p%20%3D%200.442%20for%20PIRA%3B%20difference%20%3D%20-0.02%20years%3B%20p%20%3D%200.952%20for%20SPMS%29.%20No%20increase%20in%20serious%20IIRs%20was%20observed%20with%20an%20incidence%20rate%20ratio%20of%200.38%20%2895%25%20CI%200.07-2.10%2C%20p%20%3D%200.265%29%20in%20the%20never-treated%20group%20compared%20with%20the%20treated%20one.%5CnDISCUSSION%3A%20This%20study%20demonstrates%20a%20beneficial%20effect%20of%20disease-modifying%20therapy%20%28DMT%29%20on%20disease%20activity%20in%20patients%20with%20LOMS%20but%20without%20significant%20impact%20on%20disability%20progression.%20Main%20limitations%20are%20linked%20to%20the%20challenge%20of%20data%20collection%20and%20to%20the%20baseline%20imbalances%20between%20the%202%20groups.%5CnCLASSIFICATION%20OF%20EVIDENCE%3A%20This%20study%20provides%20Class%20III%20evidence%20that%20in%20patients%20with%20LOMS%2C%20treatment%20with%20DMTs%20is%20associated%20with%20a%20longer%20time%20to%20first%20relapse%20compared%20with%20those%20not%20treated%20with%20DMTs.%22%2C%22date%22%3A%222025-08-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000213744%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22F2BXABSJ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gavoille%20et%20al.%22%2C%22parsedDate%22%3A%222025-08-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGavoille%2C%20A.%2C%20Rollot%2C%20F.%2C%20Casey%2C%20R.%2C%20Mathey%2C%20G.%2C%20Le%20Page%2C%20E.%2C%20Ciron%2C%20J.%2C%20De%20S%26%23xE8%3Bze%2C%20J.%2C%20Ruet%2C%20A.%2C%20Maillart%2C%20E.%2C%20Labauge%2C%20P.%2C%20Zephir%2C%20H.%2C%20Kwiatkowski%2C%20A.%2C%20Papeix%2C%20C.%2C%20Defer%2C%20G.%2C%20Lebrun-Frenay%2C%20C.%2C%20Moreau%2C%20T.%2C%20Laplaud%2C%20D.-A.%2C%20Berger%2C%20E.%2C%20Dubessy%2C%20A.-L.%2C%20Clavelou%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Pelletier%2C%20J.%2C%20Al-Khedr%2C%20A.%2C%20Casez%2C%20O.%2C%20Bourre%2C%20B.%2C%20Wahab%2C%20A.%2C%20Magy%2C%20L.%2C%20Moulin%2C%20S.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Doghri%2C%20I.%2C%20Sarov-Riviere%2C%20M.%2C%20Hankiewicz%2C%20K.%2C%20Pottier%2C%20C.%2C%20Dos%20Santos%2C%20A.%2C%20Nifle%2C%20C.%2C%20Subtil%2C%20F.%2C%20Vukusic%2C%20S.%20and%20OFSEP%20Investigators%20%282025%29%20%26%23x201C%3BTherapeutic%20Management%20During%20Pregnancy%20and%20Relapse%20Risk%20in%20Women%20With%20Multiple%20Sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJAMA%20neurology%26lt%3B%5C%2Fi%26gt%3B%20%5BPreprint%5D.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamaneurol.2025.2550%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamaneurol.2025.2550%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Therapeutic%20Management%20During%20Pregnancy%20and%20Relapse%20Risk%20in%20Women%20With%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Gavoille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Kwiatkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David-Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Dubessy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al-Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e8s%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Sarov-Riviere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Subtil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22OFSEP%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22IMPORTANCE%3A%20In%20women%20with%20multiple%20sclerosis%20%28MS%29%2C%20disease-modifying%20therapy%20%28DMT%29%20management%20during%20pregnancy%20might%20impact%20relapse%20risk.%5CnOBJECTIVE%3A%20To%20estimate%20the%20effect%20of%20DMT%20management%20during%20pregnancy%20on%20MS%20relapse%20rate%20and%20compare%20different%20therapeutic%20strategies.%5CnDESIGN%2C%20SETTING%2C%20AND%20PARTICIPANTS%3A%20This%20was%20a%20multicenter%20retrospective%20cohort%20study%20using%20data%20from%20January%201990%20to%20December%202023.%20Data%20were%20extracted%20in%20December%202023%20from%20the%20French%20MS%20registry.%20Among%2052%5Cu202f955%20women%20in%20the%20registry%2C%20we%20included%20pregnancies%20identified%20through%20childbirths%20in%20patients%20with%20relapsing-onset%20MS%20who%20were%20monitored%20for%20at%20least%2018%20months%20before%20delivery%20and%209%20months%20after.%20Pregnancies%20occurring%20less%20than%2018%20months%20apart%20or%20with%20missing%20month%20of%20birth%20were%20excluded.%5CnEXPOSURES%3A%20Mediation%20analysis%20was%20used%20to%20estimate%20the%20total%2C%20direct%2C%20and%20indirect%20%28mediated%20by%20DMT%20management%29%20effects%20of%20pregnancy.%20Different%20therapeutic%20strategies%20were%20compared%3A%20DMT%20interruption%2C%20switching%20to%20or%20maintaining%20interferon%20%5Cu03b2%20or%20glatiramer%20acetate%2C%20switching%20to%20or%20maintaining%20natalizumab%20until%20the%20third%20trimester%2C%20and%20switching%20to%20or%20maintaining%20intravenous%20anti-CD20%20and%20interrupting%20it%203%20months%20before%20conception.%5CnMAIN%20OUTCOMES%20AND%20MEASURES%3A%20The%20primary%20outcome%20was%20the%20annualized%20relapse%20rate%20%28ARR%29%20during%20the%20preconception%2C%20gestation%2C%20and%20postpartum%20periods.%20Within%20a%20causal%20inference%20framework%2C%20counterfactual%20ARRs%20were%20estimated%20using%20longitudinal%20g-computation%2C%20combining%20a%20random%20forest%20algorithm%20for%20predicting%20DMTs%2C%20and%20a%20mixed-effects%20Poisson%20model%20for%20relapses.%5CnRESULTS%3A%20We%20included%206341%20pregnancies%20occurring%20in%204998%20women%20%28mean%20%5BSD%5D%20age%20at%20conception%2C%2031.5%20%5B4.5%5D%20years%29.%20DMT%20management%20during%20pregnancy%20significantly%20increased%20ARR%20during%20gestation%20%28causal%20rate%20ratio%20%5BcRR%5D%2C%201.13%3B%2095%25%20CI%2C%201.06-1.22%29%20and%20postpartum%20%28cRR%2C%201.08%3B%2095%25%20CI%2C%201.01-1.16%29%20periods.%20This%20led%20to%20a%20deleterious%20total%20effect%20of%20pregnancy%20on%20ARR%2C%20particularly%20in%20women%20receiving%20natalizumab%20before%20pregnancy%20with%20prolonged%20interruption%20%28ie%2C%20interruption%20before%20the%20second%20trimester%20or%20resumption%20more%20than%203%20months%20after%20delivery%3B%20cRR%2C%202.18%3B%2095%25%20CI%2C%201.76-2.69%29%2C%20and%20in%20women%20receiving%20fingolimod%20%28cRR%2C%202.15%3B%2095%25%20CI%2C%201.60-2.93%29.%20Compared%20to%20DMT%20interruption%2C%20anti-CD20%20strategy%20was%20the%20most%20effective%20%28cRR%2C%200.38%3B%2095%25%20CI%2C%200.25-0.52%29%2C%20followed%20by%20the%20natalizumab%20strategy%20with%20short%20interruption%20%28cRR%2C%200.80%3B%2095%25%20CI%2C%200.71-0.90%29%2C%20whereas%20interferon%20%5Cu03b2%20%28cRR%2C%200.93%3B%2095%25%20CI%2C%200.86-0.99%29%20and%20glatiramer%20acetate%20strategies%20%28cRR%2C%200.91%3B%2095%25%20CI%2C%200.84-0.99%29%20were%20less%20effective.%5CnCONCLUSION%3A%20In%20this%20study%2C%20DMT%20management%20during%20pregnancy%20significantly%20increased%20relapse%20risk%2C%20particularly%20in%20patients%20receiving%20natalizumab%20with%20prolonged%20interruption%20or%20fingolimod.%20The%20strategy%20based%20on%20the%20use%20of%20anti-CD20%20before%20pregnancy%20was%20the%20most%20effective%20to%20mitigate%20this%20risk.%22%2C%22date%22%3A%222025-08-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1001%5C%2Fjamaneurol.2025.2550%22%2C%22ISSN%22%3A%222168-6157%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22JITMD4XG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Demortiere%20et%20al.%22%2C%22parsedDate%22%3A%222025-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDemortiere%2C%20S.%2C%20Stolowy%2C%20N.%2C%20Perriguey%2C%20M.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Hilezian%2C%20F.%2C%20Ndjomo-Ndjomo%2C%20B.-R.%2C%20Durozard%2C%20P.%2C%20Stellmann%2C%20J.-P.%2C%20Marignier%2C%20R.%2C%20Boucraut%2C%20J.%2C%20Pelletier%2C%20J.%2C%20Maarouf%2C%20A.%20and%20Audoin%2C%20B.%20%282025%29%20%26%23x201C%3BDiagnostic%20Utility%20of%20Kappa%20Free%20Light%20Chain%20Index%20in%20Adults%20With%20Inaugural%20Optic%20Neuritis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2012%283%29%2C%20p.%20e200386.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200386%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200386%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnostic%20Utility%20of%20Kappa%20Free%20Light%20Chain%20Index%20in%20Adults%20With%20Inaugural%20Optic%20Neuritis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Stolowy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Blaise-Roger%22%2C%22lastName%22%3A%22Ndjomo-Ndjomo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Boucraut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20A%20simple%2C%20quick%2C%20and%20reproducible%20procedure%20for%20distinguishing%20multiple%20sclerosis%20%28MS%29%2C%20myelin%20oligodendrocyte%20glycoprotein%20antibody-associated%20disease%20%28MOGAD%29%2C%20and%20neuromyelitis%20optica%20spectrum%20disorder%20%28NMOSD%29%20at%20inaugural%20optic%20neuritis%20%28ION%29%20could%20be%20highly%20valuable%20in%20guiding%20early%20management.%5CnMETHODS%3A%20We%20included%20all%20adults%20admitted%20to%20the%20MS%20center%20of%20Marseille%20for%20ION%20between%20March%202016%20and%20April%202024%2C%20with%20CSF%20analysis%20including%20the%20kappa%20free%20light%20chain%20%28K-FLC%29%20index.%20Receiver%20operating%20characteristic%20curves%20were%20used%20to%20measure%20the%20diagnostic%20ability%20of%20the%20K-FLC%20index.%5CnRESULTS%3A%20Two%20hundred%20twenty-seven%20adults%20were%20admitted%20for%20ION%3B%20210%20%2893%25%29%20had%20a%20K-FLC%20index%20measurement.%20MS%20was%20diagnosed%20in%2084%20%2840%25%29%3B%20clinically%20isolated%20syndrome%20suggestive%20of%20MS%20in%2077%20%2836.5%25%29%2C%20including%2020%20with%20future%20conversion%20to%20MS%20%28CISwc%29%3B%20MOGAD%20in%2026%20%2812.5%25%29%3B%20NMOSD%20in%2013%20%286%25%29%3B%20and%20other%20inflammatory%20disorders%20in%2010%20%285%25%29.%20A%20K-FLC%20index%20%5Cu22656.7%20differentiated%20MS%5C%2FCISwc%20from%20other%20diagnoses%20with%20specificity%2086%25%20and%20sensitivity%2095%25%20%28area%20under%20the%20curve%20%5BAUC%5D%200.94%29.%20A%20K-FLC%20index%20%26lt%3B4.9%20differentiated%20MOGAD%20from%20other%20diagnoses%20with%20specificity%2063%25%20and%20sensitivity%2092%25%20%28AUC%200.78%29%20and%20MOGAD%20from%20MS%5C%2FCISwc%20with%20specificity%2096%25%20and%20sensitivity%2092%25%20%28AUC%200.97%29.%20Among%20all%20patients%2C%2093%20%2844%25%29%20had%20a%20K-FLC%20index%20%26lt%3B4.9%3A%2024%20of%20these%20%2826%25%29%20had%20MOGAD%20and%205%20%285.5%25%29%20MS%5C%2FCISwc.%20Among%20the%20remaining%20patients%20with%20a%20K-FLC%20index%20%5Cu22654.9%20%28n%20%3D%20117%29%2C%202%20%281.7%25%29%20had%20MOGAD%20%28K-FLC%20index%20of%207.9%20and%2016.2%29%20and%2099%20%2885%25%29%20MS%5C%2FCISwc.%20Among%20patients%20with%20normal%20MRI%20%28n%20%3D%2096%29%2C%2073%20%2876%25%29%20had%20a%20K-FLC%20index%20%26lt%3B4.9%3A%2022%20of%20these%20%2830%25%29%20had%20MOGAD%2C%20and%20none%20showed%20conversion%20to%20MS.%20Among%20the%20remaining%20patients%20with%20a%20K-FLC%20index%20%5Cu22654.9%20%28n%20%3D%2023%29%2C%202%20%288.5%25%29%20had%20MOGAD%20and%207%20%2830.5%25%29%20showed%20conversion%20to%20MS.%20The%20K-FLC%20index%20did%20not%20differentiate%20NMOSD%20from%20other%20diagnoses%20and%20only%20moderately%20differentiated%20NMO%20from%20MS%5C%2FCISwc%20%28AUC%200.80%29.%5CnDISCUSSION%3A%20The%20K-FLC%20index%20is%20an%20accessible%20biomarker%20to%20guide%20early%20diagnosis%20in%20patients%20with%20ION.%20The%20probability%20of%20MOGAD%20in%20patients%20with%20ION%20and%20a%20K-FLC%20index%20%5Cu22654.9%20is%20low%20even%20in%20case%20of%20normal%20brain%5C%2Fspinal%20cord%20MRI.%5CnCLASSIFICATION%20OF%20EVIDENCE%3A%20This%20study%20provides%20Class%20II%20evidence%20that%20for%20patients%20with%20ION%2C%20the%20K-FLC%20index%20can%20distinguish%20between%20MS%5C%2FCISwc%20and%20MOGAD.%22%2C%22date%22%3A%222025-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200386%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222025-12-01T09%3A50%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22XVGGM5PL%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cohen%20et%20al.%22%2C%22parsedDate%22%3A%222025-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCohen%2C%20M.%2C%20Rollot%2C%20F.%2C%20Debouverie%2C%20M.%2C%20Zephir%2C%20H.%2C%20Vukusic%2C%20S.%2C%20De%20Seze%2C%20J.%2C%20Labauge%2C%20P.%2C%20Landes-Chateau%2C%20C.%2C%20Mondot%2C%20L.%2C%20Levraut%2C%20M.%2C%20Ruet%2C%20A.%2C%20Berger%2C%20E.%2C%20Laplaud%2C%20D.%2C%20Ciron%2C%20J.%2C%20Bourre%2C%20B.%2C%20Le%20Page%2C%20E.%2C%20Papeix%2C%20C.%2C%20Thouvenot%2C%20E.%2C%20Al%20Khedr%2C%20A.%2C%20Stankoff%2C%20B.%2C%20Pelletier%2C%20J.%2C%20Maillart%2C%20E.%2C%20Casez%2C%20O.%2C%20Moreau%2C%20T.%2C%20Defer%2C%20G.%2C%20Clavelou%2C%20P.%2C%20Cabre%2C%20P.%2C%20Moulin%2C%20S.%2C%20Neau%2C%20J.P.%2C%20Zedet%2C%20M.%2C%20Hankiewicz%2C%20K.%2C%20Doghri%2C%20I.%2C%20Nasr%2C%20H.B.%2C%20Pottier%2C%20C.%2C%20Magy%2C%20L.%2C%20Boulos%2C%20D.D.%2C%20Heinzlef%2C%20O.%2C%20Camdessanche%2C%20J.P.%2C%20Coustans%2C%20M.%2C%20Nifle%2C%20C.%2C%20Brassat%2C%20D.%2C%20Casey%2C%20R.%2C%20Lebrun-Frenay%2C%20C.%20and%20OFSEP%20and%20SFSEP%20study%20groups%20%282025%29%20%26%23x201C%3BSecondary%20progression%20activity%20monitoring%20in%20MS%20despite%20an%20early%20highly%20active%20treatment%20the%20SPAM%20study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2C%2032%285%29%2C%20p.%20e16583.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.16583%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.16583%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Secondary%20progression%20activity%20monitoring%20in%20MS%20despite%20an%20early%20highly%20active%20treatment%20the%20SPAM%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debouverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9rome%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cassandre%22%2C%22lastName%22%3A%22Landes-Chateau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lydiane%22%2C%22lastName%22%3A%22Mondot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Levraut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al%20Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Cabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Philippe%22%2C%22lastName%22%3A%22Neau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mickael%22%2C%22lastName%22%3A%22Zedet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e8s%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Haifa%20Ben%22%2C%22lastName%22%3A%22Nasr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dalia%20Dimitri%22%2C%22lastName%22%3A%22Boulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Philippe%22%2C%22lastName%22%3A%22Camdessanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Coustans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Brassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22OFSEP%20and%20SFSEP%20study%20groups%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Real-world%20data%20suggest%20that%20the%20early%20use%20of%20highly%20active%20therapies%20%28HAT%29%20may%20reduce%20the%20risk%20of%20transition%20to%20secondary%20progressive%20MS%20%28SPMS%29.%20However%2C%20current%20knowledge%20about%20predictive%20factors%20of%20outcomes%20needs%20to%20be%20improved.%20The%20primary%20objective%20of%20this%20study%20was%20to%20determine%20factors%20associated%20with%20the%20occurrence%20of%20SPMS%20in%20patients%20treated%20early%20after%20MS%20onset%20with%20an%20HAT.%5CnMETHODS%3A%20Retrospective%2C%20multicentric%20study%20based%20on%20the%20French%20MS%20database.%20Patients%20who%20initiated%20a%20HAT%20within%205%5Cu2009years%20after%20MS%20onset%2C%20EDSS%20%5Cu2a7d4%2C%20and%20had%20a%20follow-up%20%26gt%3B5%5Cu2009years%20were%20included.%20The%20association%20of%20each%20covariate%20at%20baseline%20with%20time%20to%20the%20occurrence%20of%20SPMS%20was%20quantified%20by%20hazard%20ratios%20%28HRs%29%20in%20unadjusted%20and%20adjusted%20Cox%20proportional%20hazards%20models.%5CnRESULTS%3A%20Two%20thousand%20two%20hundred%20and%20thirty-seven%20patients%20were%20included%20in%20the%20analysis%3A%20mean%20age%2031.6%5Cu2009years%2C%20female%5C%2Fmale%20sex%20ratio%202.3%2C%20and%20median%20EDSS%202.0.%20The%20estimated%20probability%20of%20reaching%20SPMS%2C%20progression%20independent%20of%20relapse%20activity%20%28PIRA%29%20and%20progression%20independent%20of%20activity%20%28PIA%29%20at%2010%5Cu2009years%20was%208%25%2C%2022%25%2C%20and%2011%25%2C%20respectively.%20After%20adjustment%2C%20we%20found%20that%20female%20patients%20%28HR%200.64%2C%20p%5Cu2009%3D%5Cu20090.036%29%20had%20a%20lower%20risk%20of%20developing%20SPMS.%20Older%20age%2C%20EDSS%20%26gt%3B0%20%28HR%207.44%2C%20p%5Cu2009%26lt%3B%5Cu20090.001%29%2C%20and%20oral%20versus%20intravenous%20HAT%20%28HR%201.97%2C%20p%5Cu2009%3D%5Cu20090.003%29%20were%20significantly%20associated%20with%20an%20increased%20SPMS%20risk.%20Early%20PIRA%20and%20PIA%20predicted%20conversion%20to%20SPMS.%5CnCONCLUSIONS%3A%20Early%20HAT%20use%20resulted%20in%20a%20low%20risk%20of%20developing%20SPMS%20over%2010%5Cu2009years.%20Introducing%20the%20HAT%20before%20any%20residual%20disability%20was%20associated%20with%20a%20lower%20risk%20of%20progression.%22%2C%22date%22%3A%222025-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fene.16583%22%2C%22ISSN%22%3A%221468-1331%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22NCYFCF6W%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hong%20et%20al.%22%2C%22parsedDate%22%3A%222025-04-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHong%2C%20J.%2C%20Gaubert%2C%20M.%2C%20Lefort%2C%20M.%2C%20Ferr%26%23xE9%3B%2C%20J.C.%2C%20Le%20Page%2C%20E.%2C%20Michel%2C%20L.%2C%20Labauge%2C%20P.%2C%20Pelletier%2C%20J.%2C%20de%20Seze%2C%20J.%2C%20Durand-Dubief%2C%20F.%2C%20Cotton%2C%20F.%2C%20Edan%2C%20G.%2C%20Bannier%2C%20E.%2C%20Comb%26%23xE8%3Bs%2C%20B.%20and%20Kerbrat%2C%20A.%20%282025%29%20%26%23x201C%3BLimited%20added%20value%20of%20systematic%20spinal%20cord%20MRI%20vs%20brain%20MRI%20alone%20to%20classify%20patients%20with%20MS%20as%20active%20or%20inactive%20during%20follow-up%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2C%20272%284%29%2C%20p.%20316.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00415-025-13068-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00415-025-13068-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Limited%20added%20value%20of%20systematic%20spinal%20cord%20MRI%20vs%20brain%20MRI%20alone%20to%20classify%20patients%20with%20MS%20as%20active%20or%20inactive%20during%20follow-up%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9my%22%2C%22lastName%22%3A%22Hong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Malo%22%2C%22lastName%22%3A%22Gaubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Lefort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Christophe%22%2C%22lastName%22%3A%22Ferr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22de%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Durand-Dubief%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Cotton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elise%22%2C%22lastName%22%3A%22Bannier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Comb%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20utility%20of%20systematic%20spinal%20cord%20%28SC%29%20MRI%20for%20monitoring%20disease%20activity%20after%20a%20multiple%20sclerosis%20%28MS%29%20diagnosis%20remains%20a%20topic%20of%20debate.%5CnOBJECTIVES%3A%20To%20evaluate%20the%20frequency%20of%20disease%20activity%20when%20considering%20brain%20MRI%20alone%20versus%20both%20brain%20and%20SC%20MRI%20and%20to%20identify%20factors%20associated%20with%20the%20occurrence%20of%20new%20SC%20lesions.%5CnMETHODS%3A%20We%20conducted%20a%20retrospective%20analysis%20of%20clinical%20and%20imaging%20data%20prospectively%20collected%20over%205%5Cu00a0years%20as%20part%20of%20the%20EMISEP%20cohort%20study.%20A%20total%20of%20221%20intervals%20%28with%20both%20brain%20and%20spinal%20cord%20MRI%20scans%20available%20at%202%20consecutive%20time-points%29%20from%2068%20patients%20were%20analysed.%20For%20each%20interval%2C%20brain%20%283D%20Fluid-Attenuated%20Inversion%20Recovery%20%28FLAIR%2C%20axial%20T2%20and%20axial%20PD%29%20and%20SC%20MRI%20%28sagittal%20T2%20and%20phase-sensitive%20inversion%20recovery%2C%20axial%20T2%2Aw%20and%203D%20T1%29%20were%20reviewed%20to%20detect%20new%20lesions.%20Each%20interval%20was%20classified%20as%20symptomatic%20%28with%20relapse%29%20or%20asymptomatic.%20The%20baseline%20brain%20and%20SC%20lesion%20numbers%20were%20computed.%5CnRESULTS%3A%20SC%20MRI%20activity%20without%20clinical%20relapse%20and%5C%2For%20brain%20MRI%20activity%20was%20rare%20%284%20out%20of%20221%20intervals%2C%202%25%29.%20The%20occurrence%20of%20a%20new%20SC%20lesion%20was%20associated%20with%20the%20number%20of%20brain%20lesions%20at%20baseline%20%28OR%20%3D%5Cu20091.002%20%5B1.000%3B%201.0004%5D%2C%20p%5Cu2009%3D%200.015%29%20and%20the%20occurrence%20of%20a%20new%20brain%20lesion%20during%20the%20interval%20%28OR%20%3D%5Cu20091.170%20%5B1.041%3B%201.314%5D%2C%20p%5Cu2009%3D%200.009%29%2C%20but%20not%20with%20the%20baseline%20SC%20lesion%20number%20%28p%5Cu2009%3D%200.6%29.%5CnCONCLUSION%3A%20These%20findings%20support%20the%20current%20guidelines%20recommending%20routine%20disease%20monitoring%20with%20brain%20MRI%20alone%2C%20even%20in%20patients%20with%20a%20high%20SC%20lesion%20load.%22%2C%22date%22%3A%222025-04-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00415-025-13068-2%22%2C%22ISSN%22%3A%221432-1459%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22J9GHBINL%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guttieres%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGuttieres%2C%20L.%2C%20Vannelli%2C%20L.%2C%20Demortiere%2C%20S.%2C%20Perriguey%2C%20M.%2C%20Elziere%2C%20M.%2C%20Durozard%2C%20P.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Hilezian%2C%20F.%2C%20Stellmann%2C%20J.-P.%2C%20Pelletier%2C%20J.%2C%20Maarouf%2C%20A.%2C%20Stolowy%2C%20N.%20and%20Audoin%2C%20B.%20%282025%29%20%26%23x201C%3BFluorescein%20Angiography%20as%20a%20Surrogate%20Marker%20of%20Disease%20Activity%20in%20Susac%20Syndrome%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2012%282%29%2C%20p.%20e200379.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200379%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200379%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Fluorescein%20Angiography%20as%20a%20Surrogate%20Marker%20of%20Disease%20Activity%20in%20Susac%20Syndrome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Guttieres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lea%22%2C%22lastName%22%3A%22Vannelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maya%22%2C%22lastName%22%3A%22Elziere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Stolowy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20To%20evaluate%20the%20sensitivity%20of%20fluorescein%20angiography%20%28FA%29%20in%20detecting%20disease%20activity%20in%20Susac%20syndrome.%5CnMETHODS%3A%20We%20conducted%20a%20blinded%20analysis%20of%20all%20FA%2C%20brain%20MRI%2C%20and%20audiogram%20examinations%20performed%20throughout%20the%20follow-up%20of%20patients%20with%20Susac%20syndrome.%5CnRESULTS%3A%20A%20total%20of%2079%20FA%20examinations%2C%2085%20brain%20MRI%20scans%2C%20and%2049%20audiograms%20were%20analyzed%20from%209%20patients%20followed%20for%20a%20mean%20%28SD%29%20period%20of%206%20%284%29%20years.%20Disease%20activity%20was%20detected%20in%2041.5%25%20of%20FA%20examinations%2C%2010.5%25%20of%20MRI%20scans%2C%20and%2025%25%20of%20audiograms%20%28FA%20vs%20MRI%2C%20p%20%26lt%3B%200.0001%3B%20FA%20vs%20audiogram%2C%20p%20%3D%200.06%3B%20audiogram%20vs%20MRI%2C%20p%20%26lt%3B%200.05%29.%20Within%203%20months%20of%20clinical%20relapses%2C%20activity%20was%20observed%20in%2057%25%2C%2024%25%2C%20and%2027%25%20of%20FA%2C%20MRI%2C%20and%20audiogram%20examinations%2C%20respectively%20%28FA%20vs%20MRI%2C%20p%20%26lt%3B%200.05%3B%20FA%20vs%20audiogram%2C%20p%20%3D%200.09%3B%20audiogram%20vs%20MRI%2C%20p%20%3D%201%29.%20Quantitative%20analysis%20of%20FA%20showed%20a%20mean%20%28SD%29%20of%202.5%20%282.5%29%20leakages%20%28both%20eyes%29%20during%20relapses%20compared%20with%201.2%20%281.4%29%20during%20remission%20%28p%20%26lt%3B%200.05%29.%5CnDISCUSSION%3A%20FA%2C%20particularly%20arterial%20leakage%2C%20demonstrated%20the%20highest%20sensitivity%20in%20detecting%20disease%20activity%20and%20may%20be%20a%20valuable%20tool%20for%20treatment%20management%20in%20Susac%20syndrome.%20Future%20studies%20with%20larger%20samples%20should%20aim%20to%20identify%20the%20optimal%20threshold%20of%20FA%20changes%20associated%20with%20an%20increased%20risk%20of%20relapse.%22%2C%22date%22%3A%222025-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200379%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222025-12-01T09%3A50%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22ZA2SCPEV%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mainguy%20et%20al.%22%2C%22parsedDate%22%3A%222025-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMainguy%2C%20M.%2C%20Casey%2C%20R.%2C%20Vukusic%2C%20S.%2C%20Lebrun-Frenay%2C%20C.%2C%20Berger%2C%20E.%2C%20Kerbrat%2C%20A.%2C%20Al%20Khedr%2C%20A.%2C%20Bourre%2C%20B.%2C%20Ciron%2C%20J.%2C%20Clavelou%2C%20P.%2C%20De%20Seze%2C%20J.%2C%20Defer%2C%20G.%2C%20Doghri%2C%20I.%2C%20Dos%20Santos%2C%20A.%2C%20Hankiewicz%2C%20K.%2C%20Labauge%2C%20P.M.%2C%20Le%20Page%2C%20E.%2C%20Magy%2C%20L.%2C%20Maillart%2C%20E.%2C%20Manchon%2C%20E.%2C%20Michel%2C%20L.%2C%20Moreau%2C%20T.%2C%20Moulin%2C%20S.%2C%20Pelletier%2C%20J.%2C%20Pottier%2C%20C.%2C%20Ruet%2C%20A.%2C%20Sarov%2C%20M.%2C%20Stankoff%2C%20B.%2C%20Thouvenot%2C%20E.%2C%20Wahab%2C%20A.%2C%20Zephir%2C%20H.%2C%20Leray%2C%20E.%20and%20Laplaud%2C%20D.A.%20%282025%29%20%26%23x201C%3BAssessing%20the%20Risk%20of%20Relapse%20After%20In%20Vitro%20Fertilization%20in%20Women%20With%20Multiple%20Sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2012%282%29%2C%20p.%20e200371.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200371%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200371%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Assessing%20the%20Risk%20of%20Relapse%20After%20In%20Vitro%20Fertilization%20in%20Women%20With%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Mainguy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al%20Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Dos%20Santos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%20M.%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mariana%22%2C%22lastName%22%3A%22Sarov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Older%20studies%20reported%20an%20increased%20risk%20of%20relapse%20after%20in%20vitro%20fertilization%20%28IVF%29%20in%20women%20with%20multiple%20sclerosis%20%28MS%29%2C%20which%20has%20not%20been%20confirmed%20by%20more%20recent%20works.%20All%20these%20studies%20had%20several%20limitations%2C%20such%20as%20small%20sample%20sizes%2C%20absence%20of%20a%20control%20population%2C%20or%20lack%20of%20neurologic%20validation%20of%20the%20relapses.%20The%20aim%20of%20this%20study%20was%20to%20determine%20the%20risk%20of%20relapse%20after%20IVF%20in%20women%20with%20MS.%5CnMETHODS%3A%20This%20retrospective%20cohort%20study%20included%20all%20women%20with%20MS%20who%20underwent%20IVF%20between%202009%20and%202019%20and%20a%20control%20group%20of%20women%20with%20MS%20who%20did%20not%20undergo%20IVF%20matched%20on%20age%2C%20MS%20duration%2C%20number%20of%20relapses%2C%20and%20MS-specific%20treatments%20in%20the%20previous%20year.%20Data%20on%20MS%20%28disease%20duration%2C%20treatments%2C%20and%20relapses%29%20were%20from%20the%20French%20MS%20Registry%20%28OFSEP%29%2C%20whereas%20data%20on%20IVF%20%28number%20of%20procedures%2C%20stimulation%20protocol%20type%2C%20and%20outcomes%29%20were%20from%20the%20French%20national%20health%20insurance%20database.%20For%20this%2C%20the%202%20databases%20were%20linked%20by%20indirect%20matching.%5CnRESULTS%3A%20In%20total%2C%20115%20women%20with%20MS%20underwent%20199%20IVF%20procedures%20%28mean%20age%20at%20first%20IVF%3A%2033.9%20%5Cu00b1%204.0%20years%3B%2045.2%25%20had%20%5Cu22652%20IVF%20procedures%29%2C%20and%20175%20IVFs%20%2888.0%25%29%20could%20be%20matched%20to%20specific%20patients.%20The%20risk%20of%20relapse%20in%20the%203%20months%20after%20index%20date%20was%20the%20same%20in%20both%20IVF%20group%20and%20control%20group%20%280.06%20relapse%20per%20patient-year%29%2C%20as%20confirmed%20also%20by%20the%20before-after%20analysis%20in%20the%20IVF%20group%20%280.06%20vs%200.08%29.%5CnDISCUSSION%3A%20This%20study%2C%20using%20a%2010-year%20clinical%20and%20administrative%20dataset%2C%20did%20not%20find%20any%20increased%20risk%20of%20relapse%20after%20IVF.%20The%20maintenance%20of%20disease-modifying%20therapies%20until%20IVF%20was%20a%20determining%20factor%20in%20reducing%20the%20risk%20of%20relapse.%22%2C%22date%22%3A%222025-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200371%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A10Z%22%7D%7D%2C%7B%22key%22%3A%22MKSZ2T58%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22de%20S%5Cu00e8ze%20et%20al.%22%2C%22parsedDate%22%3A%222025-02-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3Bde%20S%26%23xE8%3Bze%2C%20J.%2C%20Labauge%2C%20P.%2C%20Liblau%2C%20R.%2C%20Martinez%2C%20M.%2C%20Moreau%2C%20T.%2C%20Suchet%2C%20L.%2C%20Vermersch%2C%20P.%2C%20Vukusic%2C%20S.%2C%20Mathey%2C%20G.%2C%20Michel%2C%20L.%2C%20Ciron%2C%20J.%2C%20Ruet%2C%20A.%2C%20Maillart%2C%20E.%2C%20Zephir%2C%20H.%2C%20Papeix%2C%20C.%2C%20Defer%2C%20G.%2C%20Cohen%2C%20M.%2C%20Laplaud%2C%20D.A.%2C%20Berger%2C%20E.%2C%20Clavelou%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Pelletier%2C%20J.%2C%20Giannesini%2C%20C.%2C%20Casez%2C%20O.%2C%20Bourre%2C%20B.%2C%20Wahab%2C%20A.%2C%20Magy%2C%20L.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Doghri%2C%20I.%2C%20Labeyrie%2C%20C.%2C%20Hankiewicz%2C%20K.%2C%20Neau%2C%20J.-P.%2C%20Pottier%2C%20C.%2C%20Dobay%2C%20P.%2C%20Li%2C%20H.%2C%20Levin%2C%20S.%2C%20Gros%2C%20M.%2C%20Ruiz%2C%20M.%20and%20Rollot%2C%20F.%20%282025%29%20%26%23x201C%3BLymphoTEC%3A%20a%20Retrospective%20Real-World%20Study%20on%20Lymphocyte%20Reconstitution%20After%20Lymphopenia%20in%20Patients%20with%20Multiple%20Sclerosis%20Treated%20with%20Dimethyl%20Fumarate%20in%20France%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BAdvances%20in%20Therapy%26lt%3B%5C%2Fi%26gt%3B%20%5BPreprint%5D.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs12325-024-03092-5%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs12325-024-03092-5%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22LymphoTEC%3A%20a%20Retrospective%20Real-World%20Study%20on%20Lymphocyte%20Reconstitution%20After%20Lymphopenia%20in%20Patients%20with%20Multiple%20Sclerosis%20Treated%20with%20Dimethyl%20Fumarate%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22de%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roland%22%2C%22lastName%22%3A%22Liblau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikel%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Suchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Vermersch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Giannesini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e8s%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Labeyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Neau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%22%2C%22lastName%22%3A%22Dobay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hanyue%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Seth%22%2C%22lastName%22%3A%22Levin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marilyn%22%2C%22lastName%22%3A%22Gros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Ruiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%5D%2C%22abstractNote%22%3A%22INTRODUCTION%3A%20Dimethyl%20fumarate%20%28DMF%29%20has%20demonstrated%20a%20favorable%20benefit-risk%20profile%20in%20patients%20with%20relapsing-remitting%20multiple%20sclerosis%20%28RRMS%29.%20Some%20patients%20may%20develop%20lymphopenia%20on%20DMF%3B%20therefore%2C%20LymphoTEC%20evaluated%20absolute%20lymphocyte%20count%20%28ALC%29%20reconstitution%20after%20DMF%20discontinuation.%5CnMETHODS%3A%20LymphoTEC%20was%20a%20retrospective%2C%20multicenter%20study%20of%20patients%20with%20RRMS%20in%20the%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20registry.%20Times%20to%20ALC%20reconstitution%20and%20lymphopenia%20were%20estimated%20by%20the%20Kaplan-Meier%20method.%20Univariate%20and%20multivariate%20analyses%20evaluated%20factors%20associated%20with%20ALC%20reconstitution%20after%20DMF%20discontinuation%20or%20lymphopenia%20after%20DMF%20initiation.%20Patients%20treated%20with%20DMF%20for%5Cu00a0%5Cu2265%5Cu00a03%5Cu00a0months%20with%5Cu00a0%5Cu2265%5Cu00a01%20ALC%20in%20the%206%5Cu00a0months%20before%5C%2Fclose%20to%20DMF%20initiation%20and%5Cu00a0%5Cu2265%5Cu00a01%20ALC%20during%20treatment%20were%20included.%5CnRESULTS%3A%20Overall%2C%201429%20RRMS%20patients%20were%20included%3B%20356%20patients%20developed%20lymphopenia%2C%20of%20whom%20183%20discontinued%20DMF.%20Overall%2C%20ALC%20decreased%20by%2033%25%20over%20the%20first%20year%20and%20plateaued%20thereafter.%20The%20probability%20of%20developing%20lymphopenia%20was%2018.2%25%20after%201%5Cu00a0year.%20In%20patients%20with%20lymphopenia%2C%20median%20times%20to%20ALC%20reconstitution%20after%20DMF%20discontinuation%20were%203.8%5Cu00a0months%20overall%2C%204.0%5Cu00a0months%20for%20Grade%201%20lymphopenia%2C%203.0%5Cu00a0months%20for%20Grade%202%2C%20and%209.7%5Cu00a0months%20for%20Grade%203.%20At%2012%5Cu00a0months%2C%2083.0%25%20had%20reconstituted%20ALC.%20In%20DMF%20discontinuers%2C%20median%20time%20to%20discontinuation%20was%201.2%5Cu00a0years.%20There%20was%20no%20increased%20risk%20of%20serious%20or%20opportunistic%20infections%20in%20patients%20with%20lymphopenia.%20No%20cases%20of%20progressive%20multifocal%20leukoencephalopathy%20were%20reported.%20First%20ALC%20reconstitution%20after%20DMF%20discontinuation%20was%20associated%20with%20diabetes%2C%20DMF%20duration%2C%20DMF%20duration%20before%20lymphopenia%2C%20and%20DMF%20duration%20after%20lymphopenia%3B%20first%20lymphopenia%20after%20DMF%20initiation%20was%20associated%20with%20age%20and%20ALC%20at%20DMF%20initiation.%5CnCONCLUSION%3A%20LymphoTEC%20confirms%20previous%20reports%20on%20DMF-induced%20lymphopenia%3B%20the%20benefit-risk%20profile%20of%20DMF%20remains%20favorable.%20Most%20cases%20of%20lymphopenia%20were%20not%20severe%20and%20ALC%20reconstitution%20typically%20occurred%20within%204%5Cu00a0months%20of%20DMF%20discontinuation.%20Patients%20with%20shorter%20and%20milder%20lymphopenia%20had%20faster%20ALC%20reconstitution.%5CnTRIAL%20REGISTRATION%3A%20ClinicalTrials.gov%20NCT04756687.%22%2C%22date%22%3A%222025-02-19%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs12325-024-03092-5%22%2C%22ISSN%22%3A%221865-8652%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%5D%2C%22dateModified%22%3A%222025-11-19T13%3A59%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22CHX847WV%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Durozard%20et%20al.%22%2C%22parsedDate%22%3A%222024-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDurozard%2C%20P.%2C%20Maarouf%2C%20A.%2C%20Zaaraoui%2C%20W.%2C%20Stellmann%2C%20J.-P.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Rico%2C%20A.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Guye%2C%20M.%2C%20Le%20Troter%2C%20A.%2C%20Dary%2C%20H.%2C%20Ranjeva%2C%20J.-P.%2C%20Audoin%2C%20B.%20and%20Pelletier%2C%20J.%20%282024%29%20%26%23x201C%3BCortical%20Lesions%20as%20an%20Early%20Hallmark%20of%20Multiple%20Sclerosis%3A%20Visualization%20by%207%20T%20MRI%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BInvestigative%20Radiology%26lt%3B%5C%2Fi%26gt%3B%2C%2059%2811%29%2C%20p.%20747.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FRLI.0000000000001082%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FRLI.0000000000001082%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cortical%20Lesions%20as%20an%20Early%20Hallmark%20of%20Multiple%20Sclerosis%3A%20Visualization%20by%207%20T%20MRI%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Le%20Troter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Dary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%5Cu00a0%5Cn%20%20%20%20%20%20%20%20%20%20Compelling%20evidence%20indicates%20a%20significant%20involvement%20of%20cortical%20lesions%20in%20the%20progressive%20phase%20of%20multiple%20sclerosis%20%28MS%29%2C%20significantly%20contributing%20to%20late-stage%20disability.%20Despite%20the%20promise%20of%20ultra-high-field%20magnetic%20resonance%20imaging%20%28MRI%29%20in%20detecting%20cortical%20lesions%2C%20current%20evidence%20falls%20short%20in%20providing%20insights%20into%20the%20existence%20of%20such%20lesions%20during%20the%20early%20stages%20of%20MS%20or%20their%20underlying%20cause.%20This%20study%20delineated%2C%20at%20the%20early%20stage%20of%20MS%2C%20%281%29%20the%20prevalence%20and%20spatial%20distribution%20of%20cortical%20lesions%20identified%20by%207%20T%20MRI%2C%20%282%29%20their%20relationship%20with%20white%20matter%20lesions%2C%20and%20%283%29%20their%20clinical%20implications.%5Cn%20%20%20%20%20%20%20%20%20%20Materials%20and%20Methods%5Cu00a0%5Cn%20%20%20%20%20%20%20%20%20%20Twenty%20individuals%20with%20early-stage%20relapsing-remitting%20MS%20%28disease%20duration%20%26lt%3B1%20year%29%20underwent%20a%207%20T%20MRI%20session%20involving%20T1-weighted%20MP2RAGE%2C%20T2%2A-weighted%20multiGRE%2C%20and%20T2-weighted%20FLAIR%20sequences%20for%20cortical%20and%20white%20matter%20segmentation.%20Disability%20assessments%20included%20the%20Expanded%20Disability%20Status%20Scale%2C%20the%20Multiple%20Sclerosis%20Functional%20Composite%2C%20and%20an%20extensive%20evaluation%20of%20cognitive%20function.%5Cn%20%20%20%20%20%20%20%20%20%20Results%5Cu00a0%5Cn%20%20%20%20%20%20%20%20%20%20Cortical%20lesions%20were%20detected%20in%2015%20of%2020%20patients%20%2875%25%29.%20MP2RAGE%20revealed%20a%20total%20of%20190%20intracortical%20lesions%20%28median%2C%204%20lesions%5C%2Fcase%20%5Brange%2C%200%5Cu201344%5D%29%20and%20216%20leukocortical%20lesions%20%28median%2C%202%20lesions%5C%2Fcase%20%5Brange%2C%200%5Cu201375%5D%29.%20Although%20the%20number%20of%20white%20matter%20lesions%20correlated%20with%20the%20total%20number%20of%20leukocortical%20lesions%20%28r%20%3D%200.91%2C%20P%20%26lt%3B%200.001%29%2C%20no%20correlation%20was%20observed%20between%20the%20number%20of%20white%20matter%20or%20leukocortical%20lesions%20and%20the%20number%20of%20intracortical%20lesions.%20Furthermore%2C%20the%20number%20of%20leukocortical%20lesions%20but%20not%20intracortical%20or%20white-matter%20lesions%20was%20significantly%20correlated%20with%20cognitive%20impairment%20%28r%20%3D%200.63%2C%20P%20%3D%200.04%2C%20corrected%20for%20multiple%20comparisons%29.%5Cn%20%20%20%20%20%20%20%20%20%20Conclusions%5Cu00a0%5Cn%20%20%20%20%20%20%20%20%20%20This%20study%20highlights%20the%20notable%20prevalence%20of%20cortical%20lesions%20at%20the%20early%20stage%20of%20MS%20identified%20by%207%20T%20MRI.%20There%20may%20be%20a%20potential%20divergence%20in%20the%20underlying%20pathophysiological%20mechanisms%20driving%20distinct%20lesion%20types%2C%20notably%20between%20intracortical%20lesions%20and%20white%20matter%5C%2Fleukocortical%20lesions.%20Moreover%2C%20during%20the%20early%20disease%20phase%2C%20leukocortical%20lesions%20more%20effectively%20accounted%20for%20cognitive%20deficits.%22%2C%22date%22%3A%22November%202024%22%2C%22language%22%3A%22en-US%22%2C%22DOI%22%3A%2210.1097%5C%2FRLI.0000000000001082%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.lww.com%5C%2Finvestigativeradiology%5C%2Fabstract%5C%2F2024%5C%2F11000%5C%2Fcortical_lesions_as_an_early_hallmark_of_multiple.1.aspx%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%225P5FWCR9%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22TVTUEVRR%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hay%20et%20al.%22%2C%22parsedDate%22%3A%222024-10-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHay%2C%20M.%2C%20Rollot%2C%20F.%2C%20Casey%2C%20R.%2C%20Kerbrat%2C%20A.%2C%20Edan%2C%20G.%2C%20Mathey%2C%20G.%2C%20Labauge%2C%20P.%2C%20De%20S%26%23xE8%3Bze%2C%20J.%2C%20Vukusic%2C%20S.%2C%20Laplaud%2C%20D.-A.%2C%20Papeix%2C%20C.%2C%20Moreau%2C%20T.%2C%20Thouvenot%2C%20E.%2C%20Defer%2C%20G.%2C%20Lebrun-Fr%26%23xE9%3Bnay%2C%20C.%2C%20Ciron%2C%20J.%2C%20Berger%2C%20E.%2C%20Stankoff%2C%20B.%2C%20Clavelou%2C%20P.%2C%20Maillart%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Z%26%23xE9%3Bphir%2C%20H.%2C%20Ruet%2C%20A.%2C%20Casez%2C%20O.%2C%20Moulin%2C%20S.%2C%20Al-Khedr%2C%20A.%2C%20Bourre%2C%20B.%2C%20Pelletier%2C%20J.%2C%20Magy%2C%20L.%2C%20Neau%2C%20J.-P.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Doghri%2C%20I.%2C%20Wahab%2C%20A.%2C%20Tchikviladz%26%23xE9%3B%2C%20M.%2C%20Labeyrie%2C%20C.%2C%20Hankiewicz%2C%20K.%2C%20Le%20Page%2C%20E.%2C%20Michel%2C%20L.%20and%20as%20the%20OFSEP%20Investigators%20%282024%29%20%26%23x201C%3BAnti-CD20%20Therapies%20in%20Drug-Naive%20Patients%20With%20Primary%20Progressive%20Multiple%20Sclerosis%3A%20A%20Multicenter%20Real-Life%20Study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%2C%20103%288%29%2C%20p.%20e209886.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000209886%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000209886%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anti-CD20%20Therapies%20in%20Drug-Naive%20Patients%20With%20Primary%20Progressive%20Multiple%20Sclerosis%3A%20A%20Multicenter%20Real-Life%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Hay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David-Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Fr%5Cu00e9nay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Z%5Cu00e9phir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al-Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Neau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e8s%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maia%22%2C%22lastName%22%3A%22Tchikviladz%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Labeyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22as%20the%20OFSEP%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Although%20rituximab%20failed%20to%20demonstrate%20a%20significant%20effect%20on%20disability%20progression%20in%20primary%20progressive%20multiple%20sclerosis%20%28PPMS%29%2C%20ocrelizumab%20succeeded.%20Our%20main%20objective%20was%20to%20analyze%20confirmed%20disability%20progression%20%28CDP%29%20in%20a%20cohort%20of%20patients%20with%20PPMS%20treated%20with%20anti-CD20%20therapies%20compared%20with%20a%20weighted%20untreated%20control%20cohort.%5CnMETHODS%3A%20This%20was%20a%20retrospective%20study%20using%20data%20from%20the%20French%20MS%20registry%20%28Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20En%20Plaques%29.%20We%20included%20patients%20with%20PPMS%20treated%20or%20never%20treated%20with%20anti-CD20%20therapies%20from%202016%20to%202021%2C%20with%20an%20Expanded%20Disability%20Status%20Scale%20score%20of%20%5Cu22646.5%20at%20baseline.%20The%20primary%20outcome%20was%20time%20to%20first%20CDP.%20The%20secondary%20outcomes%20were%20time%20to%20first%20relapse%2C%20MRI%20activity%20at%202%20years%2C%20identification%20of%20risk%20factors%20associated%20with%20CDP%2C%20and%20serious%20infection%20incidence%20rates%20%28IIRs%29.%20Each%20outcome%20was%20studied%20using%20an%20inverse%20probability%20of%20treatment%20weighting%20method.%20The%20outcomes%20were%20modeled%20using%20a%20weighted%20proportional%20Cox%20model%20for%20the%20time-to-event%20outcomes%20and%20by%20a%20logistic%20regression%20regarding%20the%20MRI%20activity.%5CnRESULTS%3A%20A%20total%20of%201%2C184%20patients%20%28426%20treated%20and%20758%20untreated%29%20fulfilled%20the%20inclusion%20criteria.%20Median%20age%20%28Q1-Q3%29%20was%2056%20years%20%2849.3-63.8%29%2C%20and%2052.7%25%20were%20female.%20Among%20treated%20patients%2C%20295%20received%20rituximab%2C%20whereas%20131%20received%20ocrelizumab.%20At%20baseline%2C%20anti-CD20-treated%20patients%20were%20younger%20%28median%2051.9%20vs%2058.6%20years%2C%20Cohen%20d%20%3D%200.683%29%20and%20had%20more%20active%20disease%20%2854.5%20vs%2027.8%25%2C%20Cohen%20d%20%3D%200.562%29.%2091.6%25%20were%20drug-naive%20at%20inclusion.%20In%20time%20to%20first%20CDP%20analysis%2C%20no%20statistical%20significance%20was%20observed%20%28hazard%20ratio%20%5BHR%5D%2C%201.13%3B%2095%25%20CI%200.93-1.36%2C%20p%20%3D%200.2113%29.%20In%20time%20to%20first%20relapse%20analysis%2C%20a%20nonsignificant%20trend%20toward%20fewer%20patients%20relapsing%20in%20the%20treated%20group%20was%20observed%20%28HR%200.83%3B%2095%25%20CI%200.48-1.28%2C%20p%20%3D%200.0809%29.%20For%20MRI%20activity%2C%20no%20significant%20difference%20was%20found%20between%20the%202%20groups.%20Risk%20factors%20associated%20with%20CDP%20in%20the%20treated%20group%20were%20male%20sex%20and%20MS%20duration.%20IIR%20was%206.67%20%2895%25%20CI%203.12-14.25%29%20per%20100%20person-years%20in%20the%20treated%20group%20vs%202.67%20%2895%25%20CI%200.80-8.86%29%20in%20the%20untreated%20group.%5CnDISCUSSION%3A%20Time%20to%20first%20CDP%20was%20not%20different%20between%20anti-CD20%20treated%20and%20untreated%20patients%20with%20PPMS.%20Although%20our%20study%20is%20retrospective%20and%20mainly%20included%20patients%20treated%20by%20rituximab%2C%20our%20results%20indicate%20that%20there%20should%20be%20a%20constant%20evaluation%20of%20all%20available%20data%20to%20ascertain%20the%20best%20risk%5C%2Fbenefit%20ratio%20for%20patients%20with%20PPMS.%5CnCLASSIFICATION%20OF%20EVIDENCE%3A%20This%20study%20provides%20Class%20III%20evidence%20that%20anti-CD20%20therapy%20of%20previously%20untreated%20patients%20with%20PPMS%20was%20not%20superior%20to%20no%20therapy%20in%20delaying%20time%20to%20first%20CDP.%22%2C%22date%22%3A%222024-10-22%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000209886%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22EFR2IKPY%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maarouf%20et%20al.%22%2C%22parsedDate%22%3A%222024-05-06%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMaarouf%2C%20A.%2C%20Stellmann%2C%20J.P.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Zaaraoui%2C%20W.%2C%20Ranjeva%2C%20J.-P.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282024%29%20%26%23x201C%3BActive%20and%20non-active%20progression%20independent%20of%20relapse%20activity%20within%20the%20first%2020%20years%20of%20relapsing%20multiple%20sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neurology%2C%20Neurosurgery%2C%20and%20Psychiatry%26lt%3B%5C%2Fi%26gt%3B%2C%20p.%20jnnp-2024-333597.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2024-333597%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2024-333597%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Active%20and%20non-active%20progression%20independent%20of%20relapse%20activity%20within%20the%20first%2020%20years%20of%20relapsing%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%20Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Progression%20independent%20of%20relapse%20activity%20%28PIRA%29%20has%20been%20described%20since%20the%20early%20stage%20of%20relapsing%20multiple%20sclerosis%20%28RMS%29.%20However%2C%20little%20is%20known%20about%20the%20relation%20between%20PIRA%20and%20inflammatory%20activity%20that%20is%20particularly%20important%20at%20this%20stage%20of%20the%20disease.%5CnMETHOD%3A%20We%20included%20110%20patients%20in%20a%20prospective%20study%20within%2018%20months%20of%20RMS%20onset.%20MRI%20examinations%20and%20clinical%20visits%20were%20scheduled%20on%20the%20same%20day%20for%20months%200%2C%206%2C%2012%2C%2024%2C%2036%2C%2060%2C%2084%2C%20120%2C%20180%20and%20240.%5CnRESULTS%3A%20The%20mean%20%28SD%29%20age%20of%20patients%20was%2030%20%286.7%29%20years%20at%20inclusion%20and%20median%20%28range%29%20follow-up%2015%20%289-20%29%20years.%20Analysis%20of%201118%20between-visit%20intervals%20revealed%2093%20confirmed%20disability%20accumulation%20events%20in%2068%20%2862%25%29%20patients%3A%2050%20%2854%25%29%20events%20related%20to%20relapse%20activity%20worsening%20and%2043%20%2846%25%29%20PIRA%20events%2C%20including%2017%20%2818%25%29%20with%20MRI%20activity.%20The%20risk%20of%20PIRA%20between%20two%20visits%20%28stable%20event%20as%20the%20reference%20category%29%20was%20associated%20with%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%20score%20%28HR%3A%201.41%3B%2095%25%20CI%3A%201.18%20to%201.69%3B%20p%26lt%3B0.001%29%2C%20disease%20duration%20%28HR%3A%200.75%3B%2095%25%5Cu2009CI%3A%200.62%20to%200.90%3B%20p%26lt%3B0.005%29%20and%20new%20lesions%20between%20the%20visits%20%28HR%3A%201.09%20per%20lesion%3B%2095%25%5Cu2009CI%3A%201.01%20to%201.17%3B%20p%26lt%3B0.05%29.%20As%20compared%20with%20PIRA%20events%20with%20MRI%20activity%2C%20PIRA%20events%20without%20such%20activity%20occurred%20in%20patients%20with%20more%20disability%20%28mean%20EDSS%20score%203%2C%20p%26lt%3B0.05%29%2C%20longer%20disease%20duration%20%28mean%2011%20years%2C%20p%26lt%3B0.001%29%20and%20greater%20number%20of%20T2-weighted%20lesions%20%28p%26lt%3B0.05%29.%5CnCONCLUSION%3A%20This%20study%20evidenced%20that%20inflammatory%20activity%20increases%20the%20risk%20of%20PIRA%20in%20early%20RMS%2C%20arguing%20that%20a%20significant%20part%20of%20PIRA%20is%20accessible%20to%20treatment%20targeting%20inflammation%20in%20these%20patients.%22%2C%22date%22%3A%222024-05-06%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1136%5C%2Fjnnp-2024-333597%22%2C%22ISSN%22%3A%221468-330X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%22P66W67T8%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A58%3A59Z%22%7D%7D%2C%7B%22key%22%3A%225G3SGMDG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Graille-Avy%20et%20al.%22%2C%22parsedDate%22%3A%222024-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGraille-Avy%2C%20L.%2C%20Boutiere%2C%20C.%2C%20Rigollet%2C%20C.%2C%20Perriguey%2C%20M.%2C%20Rico%2C%20A.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Hilezian%2C%20F.%2C%20Vely%2C%20F.%2C%20Bertault-Peres%2C%20P.%2C%20Pelletier%2C%20J.%2C%20Maarouf%2C%20A.%20and%20Audoin%2C%20B.%20%282024%29%20%26%23x201C%3BEffect%20of%20Prior%20Treatment%20With%20Fingolimod%20on%20Early%20and%20Late%20Response%20to%20Rituximab%5C%2FOcrelizumab%20in%20Patients%20With%20Multiple%20Sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2011%283%29%2C%20p.%20e200231.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200231%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200231%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effect%20of%20Prior%20Treatment%20With%20Fingolimod%20on%20Early%20and%20Late%20Response%20to%20Rituximab%5C%2FOcrelizumab%20in%20Patients%20With%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Graille-Avy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Rigollet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Vely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bertault-Peres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Real-life%20studies%20noted%20that%20the%20risk%20of%20disease%20activity%20in%20multiple%20sclerosis%20%28MS%29%20after%20switching%20to%20rituximab%20%28RTX%29%20or%20ocrelizumab%20%28OCR%29%20may%20be%20unequal%20depending%20on%20prior%20disease-modifying%20therapy%20%28DMT%29%2C%20with%20a%20higher%20risk%20associated%20with%20fingolimod%20%28FING%29.%5CnMETHODS%3A%20We%20performed%20a%20retrospective%20analysis%20of%20a%20structured%20prospective%20data%20collection%20including%20all%20consecutive%20patients%20with%20relapsing%20MS%20who%20were%20prescribed%20RTX%5C%2FOCR%20in%20the%20MS%20center%20of%20Marseille.%20Cox%20proportional%20hazards%20models%20were%20applied%20to%20clinical%20and%20MRI%20outcomes.%5CnRESULTS%3A%20We%20included%20321%20patients%20with%20a%20median%20%28interquartile%20range%20%5BIQR%5D%29%20follow-up%20of%203.5%20years%20%281.5-5%29%20after%20RTX%5C%2FOCR%20initiation.%20At%20the%20first%20RTX%5C%2FOCR%20infusion%2C%20the%20mean%20%28SD%29%20age%20of%20patients%20was%2037%20%2810%29%20years%2C%20and%20the%20median%20%28IQR%29%20disease%20duration%20was%208%20years%20%283-15%29%3A%2068%20patients%20did%20not%20receive%20treatment%20before%20RTX%5C%2FOCR%20and%20108%20switched%20from%20FING%2C%2047%20from%20low%20efficacy%20therapy%2C%20and%2098%20from%20natalizumab.%20For%20statistical%20analysis%2C%20the%20group%20%26quot%3BFING%26quot%3B%20was%20divided%20into%20%26quot%3Bshort-FING%26quot%3B%20and%20%26quot%3Blong-FING%26quot%3B%20groups%20according%20to%20the%20median%20value%20of%20the%20group%26%23039%3Bs%20washout%20period%20%2827%20days%29.%20On%20Cox%20proportional%20hazards%20analysis%2C%20for%20only%20the%20%26quot%3Blong-FING%26quot%3B%20group%2C%20the%20risk%20of%20relapse%20within%20the%20first%206%20months%20of%20RTX%5C%2FOCR%20was%20increased%20as%20compared%20with%20patients%20without%20previous%20DMT%20%28hazard%20ratio%20%5BHR%5D%3A%208.78%3B%2095%25%20CI%201.72-44.86%3B%20p%20%26lt%3B%200.01%29.%20Previous%20DMT%20and%20washout%20period%20duration%20of%20FING%20had%20no%20effect%20on%20B-cell%20levels%20at%206%20months.%20Beyond%20the%20first%206%20months%20of%20RTX%5C%2FOCR%2C%20age%20%26lt%3B40%20years%20was%20associated%20with%20increased%20risk%20of%20relapse%20%28HR%3A%203.93%3B%2095%25%20CI%201.30-11.89%3B%20p%20%3D%200.01%29%2C%20male%20sex%20with%20increased%20risk%20of%20new%20T2%20lesions%20%28HR%3A%202.26%3B%2095%25%20CI%201.08-4.74%3B%20p%20%3D%200.03%29%2C%20and%20EDSS%20%5Cu22652%20with%20increased%20risk%20of%20disability%20accumulation%20%28HR%3A%203.01%3B%2095%25%20CI%201.34-6.74%3B%20p%20%26lt%3B%200.01%29.%20Previous%20DMT%20had%20no%20effect%20on%20the%20effectiveness%20of%20RTX%5C%2FOCR%20beyond%206%20months%20after%20initiation.%5CnDISCUSSION%3A%20For%20patients%20switching%20from%20FING%20to%20RTX%5C%2FOCR%2C%20the%20risk%20of%20disease%20reactivation%20within%20the%20first%206%20months%20of%20treatment%20was%20increased%20as%20compared%20with%20patients%20with%20other%20DMT%20or%20no%20previous%20DMT%20only%20when%20the%20washout%20period%20exceeded%2026%20days.%20Neither%20FING%20nor%20other%20previous%20DMT%20reduced%20the%20effectiveness%20of%20RTX%5C%2FOCR%20beyond%20the%20first%206%20months%20of%20treatment.%22%2C%22date%22%3A%222024-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200231%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-12-01T09%3A50%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22NMDESKDG%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Demortiere%20et%20al.%22%2C%22parsedDate%22%3A%222024-04-23%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDemortiere%2C%20S.%2C%20Joubert%2C%20B.%2C%20Benaiteau%2C%20M.%2C%20Hilezian%2C%20F.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Stolowy%2C%20N.%2C%20Dubois%2C%20V.%2C%20Audoin%2C%20B.%2C%20Maarouf%2C%20A.%20and%20Pelletier%2C%20J.%20%282024%29%20%26%23x201C%3BAnti-IgLON5%20Disease%20With%20Inaugural%20Bilateral%20Neuropapillitis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%2C%20102%288%29%2C%20p.%20e209284.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000209284%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000209284%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anti-IgLON5%20Disease%20With%20Inaugural%20Bilateral%20Neuropapillitis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Joubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Benaiteau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natacha%22%2C%22lastName%22%3A%22Stolowy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valerie%22%2C%22lastName%22%3A%22Dubois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222024-04-23%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000209284%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-03-29T08%3A57%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22JVQG8Z5Y%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cruz%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCruz%2C%20E.S.%2C%20Fortanier%2C%20E.%2C%20Hilezian%2C%20F.%2C%20Maarouf%2C%20A.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Rico%2C%20A.%2C%20Delmont%2C%20E.%2C%20Pelletier%2C%20J.%2C%20Attarian%2C%20S.%20and%20Audoin%2C%20B.%20%282024%29%20%26%23x201C%3BFactors%20affecting%20the%20topography%20of%20nitrous%20oxide-induced%20neurological%20complications%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BEuropean%20Journal%20of%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2C%20p.%20e16291.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.16291%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fene.16291%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Factors%20affecting%20the%20topography%20of%20nitrous%20oxide-induced%20neurological%20complications%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%20Sole%22%2C%22lastName%22%3A%22Cruz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Fortanier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilien%22%2C%22lastName%22%3A%22Delmont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahram%22%2C%22lastName%22%3A%22Attarian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20factors%20underlying%20the%20topography%20of%20nitrous%20oxide%20%28N2O%29-induced%20neurological%20complications%20are%20unknown.%5CnMETHODS%3A%20We%20included%20all%20consecutive%20patients%20admitted%20to%20the%20university%20hospital%20of%20Marseille%20for%20N2O-induced%20neurological%20complications%20in%20a%20prospective%20observational%20study.%20Patients%20underwent%20neurological%20examination%2C%20spinal%20cord%20magnetic%20resonance%20imaging%2C%20and%20nerve%20conduction%20studies%20within%20the%20first%204%5Cu2009weeks%20after%20admission.%5CnRESULTS%3A%20In%20total%2C%2061%20patients%20were%20included%3A%2045%25%20with%20myeloneuropathy%2C%2034%25%20with%20isolated%20myelopathy%2C%20and%2021%25%20with%20isolated%20neuropathy.%20On%20multivariable%20analysis%2C%20the%20odds%20of%20myelopathy%20were%20associated%20with%20the%20amount%20of%20weekly%20N2O%20consumption%20%28~600%5Cu2009g%20cylinder%20per%20week%2C%20odds%20ratio%20%5BOR%5D%20%3D%5Cu20091.11%2C%2095%25%20confidence%20interval%20%5BCI%5D%20%3D%5Cu20091.001-1.24%29.%20The%20extent%20of%20the%20myelopathy%20%28number%20of%20vertebral%20segments%29%20was%20correlated%20with%20the%20number%20of%20~600-g%20cylinders%20consumed%20weekly%20%28%5Cu03c1%5Cu2009%3D%5Cu20090.40%2C%20p%5Cu2009%26lt%3B%5Cu20090.005%29.%20The%20odds%20of%20neuropathy%20were%20associated%20with%20the%20duration%20of%20consumption%20%28per%20month%3B%20OR%5Cu2009%3D%5Cu20091.29%2C%2095%25%20CI%5Cu2009%3D%5Cu20091.05-1.58%29.%20Mean%20lower-limb%20motor%20nerve%20amplitude%20was%20correlated%20with%20the%20duration%20of%20consumption%20%28in%20months%3B%20%5Cu03c1%5Cu2009%3D%5Cu2009-0.34%2C%20p%5Cu2009%26lt%3B%5Cu20090.05%29.%5CnCONCLUSIONS%3A%20The%20odds%20of%20myelopathy%20increased%20with%20the%20amount%20of%20N2O%20consumption%2C%20and%20the%20odds%20of%20neuropathy%20increased%20with%20the%20duration%20of%20N2O%20exposure%2C%20which%20suggests%20distinct%20pathophysiological%20mechanisms%20underlying%20these%20two%20neurological%20complications.%22%2C%22date%22%3A%222024-03-26%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fene.16291%22%2C%22ISSN%22%3A%221468-1331%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-09-19T07%3A43%3A51Z%22%7D%7D%2C%7B%22key%22%3A%22DN66MWNE%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jouvenot%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-25%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BJouvenot%2C%20G.%2C%20Courbon%2C%20G.%2C%20Lefort%2C%20M.%2C%20Rollot%2C%20F.%2C%20Casey%2C%20R.%2C%20Le%20Page%2C%20E.%2C%20Michel%2C%20L.%2C%20Edan%2C%20G.%2C%20de%20Seze%2C%20J.%2C%20Kremer%2C%20L.%2C%20Bigaut%2C%20K.%2C%20Vukusic%2C%20S.%2C%20Mathey%2C%20G.%2C%20Ciron%2C%20J.%2C%20Ruet%2C%20A.%2C%20Maillart%2C%20E.%2C%20Labauge%2C%20P.%2C%20Zephir%2C%20H.%2C%20Papeix%2C%20C.%2C%20Defer%2C%20G.%2C%20Lebrun-Frenay%2C%20C.%2C%20Moreau%2C%20T.%2C%20Laplaud%2C%20D.A.%2C%20Berger%2C%20E.%2C%20Stankoff%2C%20B.%2C%20Clavelou%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Pelletier%2C%20J.%2C%20Al-Khedr%2C%20A.%2C%20Casez%2C%20O.%2C%20Bourre%2C%20B.%2C%20Cabre%2C%20P.%2C%20Wahab%2C%20A.%2C%20Magy%2C%20L.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Doghri%2C%20I.%2C%20Moulin%2C%20S.%2C%20Ben-Nasr%2C%20H.%2C%20Labeyrie%2C%20C.%2C%20Hankiewicz%2C%20K.%2C%20Neau%2C%20J.-P.%2C%20Pottier%2C%20C.%2C%20Nifle%2C%20C.%2C%20Collongues%2C%20N.%2C%20Kerbrat%2C%20A.%20and%20OFSEP%20Investigators%20%282024%29%20%26%23x201C%3BHigh-Efficacy%20Therapy%20Discontinuation%20vs%20Continuation%20in%20Patients%2050%20Years%20and%20Older%20With%20Nonactive%20MS%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJAMA%20neurology%26lt%3B%5C%2Fi%26gt%3B%2C%20p.%20e240395.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamaneurol.2024.0395%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamaneurol.2024.0395%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22High-Efficacy%20Therapy%20Discontinuation%20vs%20Continuation%20in%20Patients%2050%20Years%20and%20Older%20With%20Nonactive%20MS%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Jouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guilhem%22%2C%22lastName%22%3A%22Courbon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Lefort%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9rome%22%2C%22lastName%22%3A%22de%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Kremer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Bigaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al-Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Cabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ines%22%2C%22lastName%22%3A%22Doghri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Haifa%22%2C%22lastName%22%3A%22Ben-Nasr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Labeyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Neau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22OFSEP%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22IMPORTANCE%3A%20A%20recent%20randomized%20clinical%20trial%20concluded%20that%20discontinuing%20medium-efficacy%20therapy%20might%20be%20a%20reasonable%20option%20for%20older%20patients%20with%20nonactive%20multiple%20sclerosis%20%28MS%29%2C%20but%20there%20is%20a%20lack%20of%20data%20on%20discontinuing%20high-efficacy%20therapy%20%28HET%29.%20In%20younger%20patients%2C%20the%20discontinuation%20of%20natalizumab%20and%20fingolimod%20is%20associated%20with%20a%20risk%20of%20rebound%20of%20disease%20activity.%5CnOBJECTIVE%3A%20To%20determine%20whether%20discontinuing%20HET%20in%20patients%2050%20years%20and%20older%20with%20nonactive%20MS%20is%20associated%20with%20an%20increased%20risk%20of%20relapse%20compared%20with%20continuing%20HET.%5CnDESIGN%2C%20SETTING%2C%20AND%20PARTICIPANTS%3A%20This%20observational%20cohort%20study%20used%20data%20from%2038%20referral%20centers%20from%20the%20French%20MS%20registry%20%28Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20%5BOFSEP%5D%20database%29.%20Among%2084704%20patients%20in%20the%20database%2C%20data%20were%20extracted%20for%201857%20patients%2050%20years%20and%20older%20with%20relapsing-remitting%20MS%20treated%20by%20HET%20and%20with%20no%20relapse%20or%20magnetic%20resonance%20imaging%20activity%20for%20at%20least%202%20years.%20After%20verification%20of%20the%20medical%20records%2C%201620%20patients%20were%20classified%20as%20having%20discontinued%20HET%20or%20having%20remained%20taking%20treatment%20and%20were%20matched%201%3A1%20using%20a%20dynamic%20propensity%20score%20%28including%20age%2C%20sex%2C%20disease%20phenotype%2C%20disability%2C%20treatment%20of%20interest%2C%20and%20time%20since%20last%20inflammatory%20activity%29.%20Patients%20were%20included%20from%20February%202008%20to%20November%202021%2C%20with%20a%20mean%20%28SD%29%20follow-up%20of%205.1%20%282.9%29%20years.%20Data%20were%20extracted%20in%20June%202022.%5CnEXPOSURES%3A%20Natalizumab%2C%20fingolimod%2C%20rituximab%2C%20and%20ocrelizumab.%5CnMAIN%20OUTCOMES%20AND%20MEASURES%3A%20Time%20to%20first%20relapse.%5CnRESULTS%3A%20Of%201620%20included%20patients%2C%201175%20%2872.5%25%29%20were%20female%2C%20and%20the%20mean%20%28SD%29%20age%20was%2054.7%20%284.8%29%20years.%20Among%20the%201452%20in%20the%20HET%20continuation%20group%20and%20168%20in%20the%20HET%20discontinuation%20group%2C%20154%20patients%20in%20each%20group%20were%20matched%20using%20propensity%20scores%20%28mean%20%5BSD%5D%20age%2C%2057.7%20%5B5.5%5D%20years%3B%20mean%20%5BSD%5D%20delay%20since%20the%20last%20inflammatory%20activity%2C%205.6%20%5B3.8%5D%20years%3B%20mean%20%5BSD%5D%20follow-up%20duration%20after%20propensity%20score%20matching%2C%202.5%20%5B2.1%5D%20years%29.%20Time%20to%20first%20relapse%20was%20significantly%20reduced%20in%20the%20HET%20discontinuation%20group%20compared%20with%20the%20HET%20continuation%20group%20%28hazard%20ratio%2C%204.1%3B%2095%25%20CI%2C%202.0-8.5%3B%20P%5Cu2009%26lt%3B%5Cu2009.001%29%20but%20differed%20between%20HETs%2C%20with%20a%20hazard%20ratio%20of%207.2%20%2895%25%20CI%2C%202.1-24.5%3B%20P%5Cu2009%3D%5Cu2009.001%29%20for%20natalizumab%2C%204.5%20%2895%25%20CI%2C%201.3-15.5%3B%20P%5Cu2009%3D%5Cu2009.02%29%20for%20fingolimod%2C%20and%201.1%20%2895%25%20CI%2C%200.3-4.8%3B%20P%5Cu2009%3D%5Cu2009.85%29%20for%20anti-CD20%20therapy.%5CnCONCLUSION%20AND%20RELEVANCE%3A%20As%20in%20younger%20patients%2C%20in%20patients%2050%20years%20and%20older%20with%20nonactive%20MS%2C%20the%20risk%20of%20relapse%20increased%20significantly%20after%20stopping%20HETs%20that%20impact%20immune%20cell%20trafficking%20%28natalizumab%20and%20fingolimod%29.%20There%20was%20no%20significant%20increase%20in%20risk%20after%20stopping%20HETs%20that%20deplete%20B-cells%20%28anti-CD20%20therapy%29.%20This%20result%20may%20inform%20decisions%20about%20stopping%20HETs%20in%20clinical%20practice.%22%2C%22date%22%3A%222024-03-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1001%5C%2Fjamaneurol.2024.0395%22%2C%22ISSN%22%3A%222168-6157%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22PMBPCACZ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Benallegue%20et%20al.%22%2C%22parsedDate%22%3A%222024-03-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBenallegue%2C%20N.%2C%20Rollot%2C%20F.%2C%20Wiertlewski%2C%20S.%2C%20Casey%2C%20R.%2C%20Debouverie%2C%20M.%2C%20Kerbrat%2C%20A.%2C%20De%20Seze%2C%20J.%2C%20Ciron%2C%20J.%2C%20Ruet%2C%20A.%2C%20Labauge%2C%20P.%2C%20Maillart%2C%20E.%2C%20Zephir%2C%20H.%2C%20Papeix%2C%20C.%2C%20Defer%2C%20G.%2C%20Lebrun-Frenay%2C%20C.%2C%20Moreau%2C%20T.%2C%20Berger%2C%20E.%2C%20Stankoff%2C%20B.%2C%20Clavelou%2C%20P.%2C%20Heinzlef%2C%20O.%2C%20Pelletier%2C%20J.%2C%20Thouvenot%2C%20E.%2C%20Al%20Khedr%2C%20A.%2C%20Bourre%2C%20B.%2C%20Casez%2C%20O.%2C%20Cabre%2C%20P.%2C%20Wahab%2C%20A.%2C%20Magy%2C%20L.%2C%20Vukusic%2C%20S.%2C%20Laplaud%2C%20D.-A.%20and%20OFSEP%20%28Observatoire%20Fran%26%23xE7%3Bais%20de%20la%20Scl%26%23xE9%3Brose%20en%20Plaques%29%20Investigators%20%282024%29%20%26%23x201C%3BHighly%20Effective%20Therapies%20as%20First-Line%20Treatment%20for%20Pediatric-Onset%20Multiple%20Sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJAMA%20Neurology%26lt%3B%5C%2Fi%26gt%3B%2C%2081%283%29%2C%20pp.%20273%26%23x2013%3B282.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamaneurol.2023.5566%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamaneurol.2023.5566%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Highly%20Effective%20Therapies%20as%20First-Line%20Treatment%20for%20Pediatric-Onset%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nail%22%2C%22lastName%22%3A%22Benallegue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Wiertlewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debouverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Kerbrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al%20Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Cabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David-Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22OFSEP%20%28Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%29%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Moderately%20effective%20therapies%20%28METs%29%20have%20been%20the%20main%20treatment%20in%20pediatric-onset%20multiple%20sclerosis%20%28POMS%29%20for%20years.%20Despite%20the%20expanding%20use%20of%20highly%20effective%20therapies%20%28HETs%29%2C%20treatment%20strategies%20for%20POMS%20still%20lack%20consensus.To%20assess%20the%20real-world%20association%20of%20HET%20as%20an%20index%20treatment%20compared%20with%20MET%20with%20disease%20activity.This%20was%20a%20retrospective%20cohort%20study%20conducted%20from%20January%201%2C%202010%2C%20to%20December%208%2C%202022%2C%20until%20the%20last%20recorded%20visit.%20The%20median%20follow-up%20was%205.8%20years.%20A%20total%20of%2036%20French%20MS%20centers%20participated%20in%20the%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20%28OFSEP%29%20cohort.%20Of%20the%20%20total%20participants%20in%20OFSEP%2C%20only%20treatment-naive%20children%20with%20relapsing-remitting%20POMS%20who%20received%20a%20first%20HET%20or%20MET%20before%20adulthood%20and%20at%20least%201%20follow-up%20clinical%20visit%20were%20included%20in%20the%20study.%20All%20eligible%20participants%20were%20included%20in%20the%20study%2C%20and%20none%20declined%20to%20participate.HET%20or%20MET%20at%20treatment%20initiation.The%20primary%20outcome%20was%20the%20time%20to%20first%20relapse%20after%20treatment.%20Secondary%20outcomes%20were%20annualized%20relapse%20rate%20%28ARR%29%2C%20magnetic%20resonance%20imaging%20%28MRI%29%20activity%2C%20time%20to%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%20progression%2C%20tertiary%20education%20attainment%2C%20and%20treatment%20safety%5C%2Ftolerability.%20An%20adapted%20statistical%20method%20was%20used%20to%20model%20the%20logarithm%20of%20event%20rate%20by%20penalized%20splines%20of%20time%2C%20allowing%20adjustment%20for%20effects%20of%20covariates%20that%20is%20sensitive%20to%20nonlinearity%20and%20interactions.Of%20the%203841%20children%20%285.2%25%20of%2074%5Cu202f367%20total%20participants%20in%20OFSEP%29%2C%20530%20patients%20%28mean%20%5BSD%5D%20age%2C%2016.0%20%5B1.8%5D%20years%3B%20364%20female%20%5B68.7%25%5D%29%20were%20included%20in%20the%20study.%20In%20study%20patients%2C%20both%20treatment%20strategies%20were%20associated%20with%20a%20reduced%20risk%20of%20first%20relapse%20within%20the%20first%202%20years.%20HET%20dampened%20disease%20activity%20with%20a%2054%25%20reduction%20in%20first%20relapse%20risk%20%28adjusted%20hazard%20ratio%20%5BHR%5D%2C%200.46%3B%2095%25%20CI%2C%200.31-0.67%3B%20P%5Cu2009%26lt%3B%5Cu2009.001%29%20sustained%20over%205%20years%2C%20confirmed%20on%20MRI%20activity%20%28adjusted%20odds%20ratio%20%5BOR%5D%2C%200.34%3B%2095%25%20CI%2C%200.18-0.66%3B%20P%5Cu2009%3D%5Cu2009.001%29%2C%20and%20with%20a%20better%20tolerability%20pattern%20than%20MET.%20The%20risk%20of%20discontinuation%20at%202%20years%20was%206%20times%20higher%20with%20MET%20%28HR%2C%205.97%3B%2095%25%20CI%2C%202.92-12.20%29.%20The%20primary%20reasons%20for%20treatment%20discontinuation%20were%20lack%20of%20efficacy%20and%20intolerance.%20Index%20treatment%20was%20not%20associated%20with%20EDSS%20progression%20or%20tertiary%20education%20attainment%20%28adjusted%20OR%2C%200.51%3B%2095%25%20CI%2C%200.24-1.10%3B%20P%5Cu2009%3D%5Cu2009.09%29.Results%20of%20this%20cohort%20study%20suggest%20that%20compared%20with%20MET%2C%20initial%20HET%20in%20POMS%20was%20associated%20with%20a%20reduction%20in%20the%20risk%20of%20first%20relapse%20with%20an%20optimal%20outcome%20within%20the%20first%202%20years%20and%20was%20associated%20with%20a%20lower%20rate%20of%20treatment%20switching%20and%20a%20better%20midterm%20tolerance%20in%20children.%20These%20findings%20suggest%20prioritizing%20initial%20HET%20in%20POMS%2C%20although%20long-term%20safety%20studies%20are%20needed.%22%2C%22date%22%3A%222024-03-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1001%5C%2Fjamaneurol.2023.5566%22%2C%22ISSN%22%3A%222168-6149%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1001%5C%2Fjamaneurol.2023.5566%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22LDZE6XTS%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Androdias%20et%20al.%22%2C%22parsedDate%22%3A%222024-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAndrodias%2C%20G.%2C%20Noroy%2C%20L.%2C%20Psimaras%2C%20D.%2C%20Birzu%2C%20C.%2C%20Pelletier%2C%20J.%2C%20Beigneux%2C%20Y.%2C%20Branger%2C%20P.%2C%20Ciron%2C%20J.%2C%20Dananchet%2C%20Y.%2C%20Depaz%2C%20R.%2C%20Froment%20Tilikete%2C%20C.%2C%20Gignoux%2C%20L.%2C%20Grosset-Janin%2C%20C.%2C%20Joubert%2C%20B.%2C%20Kerschen%2C%20P.%2C%20Kwiatkowski%2C%20A.%2C%20Lebrun-Frenay%2C%20C.%2C%20Maillart%2C%20E.%2C%20Maureille%2C%20A.%2C%20Nicolas%2C%20P.%2C%20Roux%2C%20T.%2C%20Marignier%2C%20R.%2C%20Vukusic%2C%20S.%20and%20as%20the%20ICI-SEP%20Study%20Group%20%282024%29%20%26%23x201C%3BImpact%20of%20Immune%20Checkpoint%20Inhibitors%20on%20the%20Course%20of%20Multiple%20Sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2011%282%29%2C%20p.%20e200202.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200202%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200202%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20Immune%20Checkpoint%20Inhibitors%20on%20the%20Course%20of%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Androdias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louise%22%2C%22lastName%22%3A%22Noroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dimitri%22%2C%22lastName%22%3A%22Psimaras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Birzu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ysoline%22%2C%22lastName%22%3A%22Beigneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannick%22%2C%22lastName%22%3A%22Dananchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raphael%22%2C%22lastName%22%3A%22Depaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Froment%20Tilikete%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Gignoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara%22%2C%22lastName%22%3A%22Grosset-Janin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Joubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Kerschen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Kwiatkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurelien%22%2C%22lastName%22%3A%22Maureille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Nicolas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22as%20the%20ICI-SEP%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Immune%20checkpoint%20inhibitors%20%28ICIs%29%20are%20increasingly%20used%20in%20cancer%20treatment.%20Their%20mechanism%20of%20action%20raises%20the%20question%20of%20possible%20exacerbation%20of%20preexisting%20multiple%20sclerosis%20%28MS%29.%20The%20aim%20of%20our%20study%20was%20to%20assess%20the%20risk%20of%20increased%20MS%20activity%2C%20defined%20by%20the%20occurrence%20of%20a%20relapse%20and%5C%2For%20a%20new%20MRI%20lesion%2C%20after%20ICI%20initiation.%5CnMETHODS%3A%20This%20French%20multicentric%20study%20collected%20retrospective%20and%20prospective%20data%20on%20patients%20with%20MS%20treated%20with%20ICIs%20after%20a%20cancer%20diagnosis.%5CnRESULTS%3A%20We%20identified%2018%20patients%20with%20a%20median%20age%20of%2048%20years.%20Three%20of%20them%20%2817%25%29%2C%20all%20aged%2050%20years%20or%20younger%2C%20with%20a%20relapsing-remitting%20course%2C%20showed%20clinical%20and%5C%2For%20radiologic%20signs%20of%20MS%20activity%203%20to%206%20months%20after%20ICI%20initiation.%20They%20had%20stopped%20disease-modifying%20treatment%20%28DMT%29%20several%20months%20earlier%2C%20at%20the%20time%20of%20cancer%20diagnosis.%20Only%20one%20had%20both%20clinical%20and%20MRI%20activity%2C%20with%20mild%20severity%20and%20complete%20recovery.%5CnDISCUSSION%3A%20Our%20study%20suggests%20that%20the%20overall%20risk%20of%20MS%20activity%20under%20ICI%20is%20low%20and%20could%20be%20mainly%20driven%20by%20DMT%20discontinuation%2C%20as%20in%20MS%20in%20general.%20Although%20larger%20studies%20are%20needed%20for%20better%20risk%20assessment%20in%20younger%20patients%20with%20more%20active%20disease%2C%20ICI%20should%20be%20considered%20when%20needed%20in%20patients%20with%20MS.%22%2C%22date%22%3A%222024-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200202%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A05Z%22%7D%7D%2C%7B%22key%22%3A%22AZIJ7JNE%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Jeantin%20et%20al.%22%2C%22parsedDate%22%3A%222024-01-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BJeantin%2C%20L.%2C%20Januel%2C%20E.%2C%20Labauge%2C%20P.%2C%20Maillart%2C%20E.%2C%20de%20Seze%2C%20J.%2C%20Z%26%23xE9%3Bphir%2C%20H.%2C%20Pelletier%2C%20J.%2C%20Kerschen%2C%20P.%2C%20Biotti%2C%20D.%2C%20Heinzlef%2C%20O.%2C%20Guilloton%2C%20L.%2C%20Bensa%2C%20C.%2C%20Th%26%23xE9%3Baudin%2C%20M.%2C%20Vukusic%2C%20S.%2C%20Casez%2C%20O.%2C%20Maurousset%2C%20A.%2C%20Laplaud%2C%20D.%2C%20Berger%2C%20E.%2C%20Lebrun-Frenay%2C%20C.%2C%20Bourre%2C%20B.%2C%20Branger%2C%20P.%2C%20Stankoff%2C%20B.%2C%20Clavelou%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Manchon%2C%20E.%2C%20Moreau%2C%20T.%2C%20Sellal%2C%20F.%2C%20Zedet%2C%20M.%2C%20Papeix%2C%20C.%20and%20Louapre%2C%20C.%20%282024%29%20%26%23x201C%3BCOVID-19%20outcomes%20in%20patients%20with%20multiple%20sclerosis%3A%20Understanding%20changes%20from%202020%20to%202022%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%26lt%3B%5C%2Fi%26gt%3B%2C%20p.%2013524585231218149.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585231218149%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585231218149%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22COVID-19%20outcomes%20in%20patients%20with%20multiple%20sclerosis%3A%20Understanding%20changes%20from%202020%20to%202022%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lina%22%2C%22lastName%22%3A%22Jeantin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Januel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22de%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Z%5Cu00e9phir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Kerschen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Biotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Guilloton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bensa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Th%5Cu00e9audin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Maurousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Branger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Manchon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Sellal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Micka%5Cu00ebl%22%2C%22lastName%22%3A%22Zedet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Louapre%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Epidemiologic%20studies%20on%20coronavirus%20disease%202019%20%28COVID-19%29%20in%20patients%20with%20multiple%20sclerosis%20%28pwMS%29%20have%20focused%20on%20the%20first%20waves%20of%20the%20pandemic%20until%20early%202021.%5CnOBJECTIVES%3A%20We%20aimed%20to%20extend%20these%20data%20from%20the%20onset%20of%20the%20pandemic%20to%20the%20global%20coverage%20by%20vaccination%20in%20summer%202022.%5CnMETHODS%3A%20This%20retrospective%2C%20multicenter%20observational%20study%20analyzed%20COVISEP%20registry%20data%20on%20reported%20COVID-19%20cases%20in%20pwMS%20between%20January%202020%20and%20July%202022.%20Severe%20COVID-19%20was%20defined%20as%20hospitalization%20or%20higher%20severity.%5CnRESULTS%3A%20Among%202584%20pwMS%20with%20confirmed%5C%2Fhighly%20suspected%20COVID-19%2C%20severe%20infection%20rates%20declined%20from%2014.6%25%20preomicron%20wave%20to%205.7%25%20during%20omicron%20wave%20%28p%5Cu2009%26lt%3B%5Cu20090.001%29.%20Multivariate%20analysis%20identified%20age%20%28odds%20ratio%20%28OR%29%5Cu2009%3D%5Cu20091.43%2C%2095%25%20confidence%20interval%20%28CI%29%5Cu2009%3D%5Cu2009%5B1.25-1.64%5D%20per%2010%5Cu2009years%29%2C%20male%20sex%20%28OR%5Cu2009%3D%5Cu20092.01%2C%2095%25%20CI%5Cu2009%3D%5Cu2009%5B1.51-2.67%5D%29%2C%20obesity%20%28OR%5Cu2009%3D%5Cu20092.36%2C%2095%25%20CI%5Cu2009%3D%5Cu2009%5B1.52-3.68%5D%29%2C%20cardiac%20comorbidities%20%28OR%5Cu2009%3D%5Cu20092.36%2C%2095%25%20CI%5Cu2009%3D%5Cu2009%5B1.46-3.83%5D%29%2C%20higher%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%20scores%20%28OR%5Cu2009%3D%5Cu20092.09%2C%2095%25%20CI%5Cu2009%3D%5Cu2009%5B1.43-3.06%5D%20for%20EDSS%203-5.5%20and%20OR%5Cu2009%3D%5Cu20094.53%2C%2095%25%20CI%5Cu2009%3D%5Cu2009%5B3.04-6.75%5D%20for%20EDSS%20%5Cu2a7e6%29%2C%20and%20anti-CD20%20therapies%20%28OR%5Cu2009%3D%5Cu20092.67%2C%2095%25%20CI%5Cu2009%3D%5Cu2009%5B1.85-3.87%5D%29%20as%20risk%20factors%20for%20COVID-19%20severity.%20Vaccinated%20individuals%20experienced%20less%20severe%20COVID-19%2C%20whether%20on%20%28risk%20ratio%20%28RR%29%5Cu2009%3D%5Cu20090.64%2C%2095%25%20CI%5Cu2009%3D%5Cu2009%5B0.60-0.69%5D%29%20or%20off%20%28RR%5Cu2009%3D%5Cu20090.32%2C%2095%25%20CI%5Cu2009%3D%5Cu2009%5B0.30-0.33%5D%29%20anti-CD20.%5CnDISCUSSION%3A%20In%20pwMS%2C%20consistent%20risk%20factors%20were%20anti-CD20%20therapies%20and%20neurological%20disability%2C%20emerging%20as%20vital%20drivers%20of%20COVID-19%20severity%20regardless%20of%20wave%2C%20period%2C%20or%20vaccination%20status.%22%2C%22date%22%3A%222024-01-21%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585231218149%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22LKL8F93N%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Venet%20et%20al.%22%2C%22parsedDate%22%3A%222024-01-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BVenet%2C%20M.%2C%20Lepine%2C%20A.%2C%20Maarouf%2C%20A.%2C%20Biotti%2C%20D.%2C%20Boutiere%2C%20C.%2C%20Casez%2C%20O.%2C%20Cohen%2C%20M.%2C%20Durozard%2C%20P.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Giorgi%2C%20L.%2C%20Maillart%2C%20E.%2C%20Mathey%2C%20G.%2C%20Mazzola%2C%20L.%2C%20Rico%2C%20A.%2C%20Camdessanche%2C%20J.-P.%2C%20Deiva%2C%20K.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282024%29%20%26%23x201C%3BControl%20of%20disease%20activity%20with%20large%20extended-interval%20dosing%20of%20rituximab%5C%2Focrelizumab%20in%20highly%20active%20pediatric%20multiple%20sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%26lt%3B%5C%2Fi%26gt%3B%2C%20p.%2013524585231223069.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585231223069%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585231223069%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Control%20of%20disease%20activity%20with%20large%20extended-interval%20dosing%20of%20rituximab%5C%2Focrelizumab%20in%20highly%20active%20pediatric%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Melany%22%2C%22lastName%22%3A%22Venet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Lepine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Biotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikael%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Giorgi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Mazzola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kumaran%22%2C%22lastName%22%3A%22Deiva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22Recent%20studies%20in%20adults%20suggested%20that%20extended-interval%20dosing%20of%20rituximab%5C%2Focrelizumab%20%28RTX%5C%2FOCR%29%20larger%20than%2012%20months%20was%20safe%20and%20could%20improve%20safety.%20This%20was%20an%20observational%20cohort%20study%20of%20very%20active%20pediatric-onset%20multiple%20sclerosis%20%28PoMS%29%20%28median%20%28range%29%20age%2C%2016%20%2812-17%29%20years%29%20treated%20with%20RTX%5C%2FOCR%20with%206%20month%20standard-interval%20dosing%20%28n%20%3D%209%29%20or%20early%20extended-interval%20dosing%20%28n%20%3D%2012%2C%20median%20%28range%29%20interval%2018%20months%20%2812-25%29%29.%20Within%20a%20median%20%28range%29%20follow-up%20of%2031%20%2812-63%29%20months%20after%20RTX%5C%2FOCR%20onset%2C%20one%20patient%20%28standard-interval%29%20experienced%20relapse%20and%20no%20patient%20showed%20disability%20worsening%20or%20new%20T2-weighted%20lesions.%20This%20study%20suggests%20that%20the%20effectiveness%20of%20RTX%5C%2FOCR%20is%20maintained%20with%20a%20median%20extended-interval%20dosing%20of%2018%20months%20in%20patients%20with%20very%20active%20PoMS.%22%2C%22date%22%3A%222024-01-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585231223069%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-09-12T07%3A59%3A43Z%22%7D%7D%2C%7B%22key%22%3A%22G3L3VG3S%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Soustelle%20et%20al.%22%2C%22parsedDate%22%3A%222024%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSoustelle%2C%20L.%2C%20Mchinda%2C%20S.%2C%20Hertanu%2C%20A.%2C%20Gherib%2C%20S.%2C%20Pini%2C%20L.%2C%20Guye%2C%20M.%2C%20Ranjeva%2C%20J.-P.%2C%20Varma%2C%20G.%2C%20Alsop%2C%20D.C.%2C%20Pelletier%2C%20J.%2C%20Girard%2C%20O.M.%20and%20Duhamel%2C%20G.%20%282024%29%20%26%23x201C%3BInhomogeneous%20magnetization%20transfer%20%28ihMT%29%20imaging%20reveals%20variable%20recovery%20profiles%20of%20active%20MS%20lesions%20according%20to%20size%20and%20localization%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BImaging%20Neuroscience%20%28Cambridge%2C%20Mass.%29%26lt%3B%5C%2Fi%26gt%3B%2C%202%2C%20p.%20imag%26%23x2013%3B2%26%23x2013%3B00235.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1162%5C%2Fimag_a_00235%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1162%5C%2Fimag_a_00235%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Inhomogeneous%20magnetization%20transfer%20%28ihMT%29%20imaging%20reveals%20variable%20recovery%20profiles%20of%20active%20MS%20lesions%20according%20to%20size%20and%20localization%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%22%2C%22lastName%22%3A%22Soustelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samira%22%2C%22lastName%22%3A%22Mchinda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreea%22%2C%22lastName%22%3A%22Hertanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soraya%22%2C%22lastName%22%3A%22Gherib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauriane%22%2C%22lastName%22%3A%22Pini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gopal%22%2C%22lastName%22%3A%22Varma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20C.%22%2C%22lastName%22%3A%22Alsop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%20M.%22%2C%22lastName%22%3A%22Girard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Duhamel%22%7D%5D%2C%22abstractNote%22%3A%22This%20work%20aims%20at%20exploiting%20the%20unique%20myelin%20specificity%20of%20the%20inhomogeneous%20magnetization%20transfer%20%28ihMT%29%20technique%20to%20characterize%20the%20recovery%20dynamics%20of%20active%20multiple%20sclerosis%20%28MS%29%20lesions.%20IhMT%20and%20three%20other%20myelin-sensitive%20techniques%2C%20conventional%20MT%2C%20T1-weighted%2C%20and%20diffusion%20tensor%20imaging%2C%20were%20applied%20in%20a%2012-month%20longitudinal%20study%20performed%20on%20relapsing-remitting%20MS%20patients.%20An%20exponential%20recovery%20model%20was%20used%20to%20fit%20the%20variations%20over%20time%20of%20the%20metrics%20derived%20from%20each%20MR%20technique%20within%20new%20active%20lesions.%20A%20principal%20component%20analysis%20was%20performed%20on%20the%20model%20parameters%20obtained%20for%20all%20MR%20myelin-sensitive%20techniques%20across%20all%20active%20lesions%20of%20all%20patients%20to%20identify%20specific%20recovery%20profiles.%20The%20results%20show%20that%20the%20recovery%20profiles%20of%20myelin-sensitive%20MR%20metrics%20in%20active%20MS%20lesions%20vary%20according%20to%20the%20localization%20and%20size%20of%20lesions.%20The%20distance%20of%20lesions%20from%20the%20ventricles%20is%20positively%20associated%20with%20the%20recovery%20rates%20of%20ihMTR%20and%20T1w-MPRAGE%3A%20the%20further%20the%20lesion%20is%20from%20the%20ventricles%2C%20the%20higher%20the%20recovery%20rate%20of%20these%20metrics.%20Lesion%20size%20is%20positively%20associated%20with%20initial%20loss%20and%20negatively%20associated%20with%20final%20recovery%20of%20ihMTR%20and%20other%20MR%20metrics%3A%20small%20lesions%20have%20lower%20initial%20loss%20and%20greater%20final%20recovery%20of%20MR%20metrics%20than%20large%20lesions.%20Thanks%20to%20the%20specificity%20of%20the%20ihMT%20technique%20for%20myelin%2C%20these%20features%20can%20be%20interpreted%20in%20terms%20of%20remyelination.%20This%20study%20thus%20provides%20longitudinal%20in%20vivo%20support%20for%20the%20pathological%20observations%20of%20higher%20remyelination%20in%20small%20lesions%20compared%20with%20large%20ones%20and%20faster%20remyelination%20in%20lesions%20away%20from%20the%20ventricles.%20These%20results%20support%20the%20use%20of%20ihMT%20and%20other%20measures%20for%20quantifying%20remyelination%20rates%20in%20clinical%20studies%20of%20remyelination%20therapies.%22%2C%22date%22%3A%222024%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1162%5C%2Fimag_a_00235%22%2C%22ISSN%22%3A%222837-6056%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%2274RX9758%22%2C%224U7D3E9U%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%22YXS7B6S7%22%2C%22M2AY8I5W%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222025-11-27T09%3A21%3A05Z%22%7D%7D%2C%7B%22key%22%3A%225HMB7XU4%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rollot%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRollot%2C%20F.%2C%20Uhry%2C%20Z.%2C%20Dantony%2C%20E.%2C%20Vukusic%2C%20S.%2C%20Debouverie%2C%20M.%2C%20Le%20Page%2C%20E.%2C%20Ciron%2C%20J.%2C%20Ruet%2C%20A.%2C%20De%20S%26%23xE8%3Bze%2C%20J.%2C%20Z%26%23xE9%3Bphir%2C%20H.%2C%20Labauge%2C%20P.%2C%20Defer%2C%20G.%2C%20Lebrun-Frenay%2C%20C.%2C%20Moreau%2C%20T.%2C%20Laplaud%2C%20D.A.%2C%20Berger%2C%20E.%2C%20Clavelou%2C%20P.%2C%20Pelletier%2C%20J.%2C%20Thouvenot%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Camdessanche%2C%20J.-P.%2C%20Fauvernier%2C%20M.%2C%20Remontet%2C%20L.%20and%20Leray%2C%20E.%20%282023%29%20%26%23x201C%3BComparison%20of%202%20Methods%20for%20Estimating%20Multiple%20Sclerosis%26%23x2013%3BRelated%20Mortality%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%2C%20101%2824%29%2C%20pp.%20e2483%26%23x2013%3Be2496.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000207925%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000207925%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparison%20of%202%20Methods%20for%20Estimating%20Multiple%20Sclerosis%5Cu2013Related%20Mortality%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zo%5Cu00e9%22%2C%22lastName%22%3A%22Uhry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Dantony%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debouverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9rome%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Z%5Cu00e9phir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20A.%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Fauvernier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Remontet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Objectives%5CnDetermining%20whether%20multiple%20sclerosis%20%28MS%29%20causes%20death%20is%20challenging.%20Our%20objective%20was%20to%20contrast%202%20frameworks%20to%20estimate%20probabilities%20of%20death%20attributed%20to%20MS%20%28PMS%29%20and%20other%20causes%20%28Pother%29%3A%20the%20cause-specific%20framework%20%28CSF%29%2C%20which%20requires%20the%20causes%20of%20death%2C%20and%20the%20excess%20mortality%20framework%20%28EMF%29%2C%20which%20does%20not.%5CnMethods%5CnWe%20used%20data%20from%20the%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20%28OFSEP%2C%20n%20%3D%2037%2C524%29%20and%20from%20a%20comparative%20subset%20where%20causes%20of%20death%20were%20available%20%284%2C004%20women%20with%20relapsing-onset%20MS%20%5BR-MS%5D%29.%20In%20CSF%2C%20the%20probabilities%20were%20estimated%20using%20the%20Aalen-Johansen%20method.%20In%20EMF%2C%20they%20were%20estimated%20from%20the%20excess%20mortality%20hazard%2C%20which%20is%20the%20additional%20mortality%20among%20patients%20with%20MS%20as%20compared%20with%20the%20expected%20mortality%20in%20the%20matched%20general%20population.%20PMS%20values%20were%20estimated%20at%2030%20years%20of%20follow-up%2C%20%281%29%20with%20both%20frameworks%20in%20the%20comparative%20subset%2C%20by%20age%20group%20at%20onset%2C%20and%20%282%29%20with%20EMF%20only%20in%20the%20OFSEP%20population%2C%20by%20initial%20phenotype%2C%20sex%2C%20and%20age%20at%20onset.%5CnResults%5CnIn%20the%20comparative%20subset%2C%20the%20estimated%2030-year%20PMS%20values%20were%20greater%20using%20EMF%20than%20CSF%3A%2010.9%25%20%2895%25%20CI%208.3%5Cu201313.6%29%20vs%208.7%25%20%286.4%5Cu201311.8%29%20among%20the%20youngest%20and%2020.4%25%20%2811.3%5Cu201329.5%29%20vs%2016.2%25%20%288.7%5Cu201330.2%29%20for%20the%20oldest%20groups%2C%20respectively.%20In%20the%20CSF%2C%20probabilities%20of%20death%20from%20unknown%20causes%20ranged%20from%201.5%25%20%280.7%5Cu20133.0%29%20to%206.4%25%20%282.5%5Cu201316.4%29%2C%20and%20even%20after%20their%20reallocation%2C%20PMS%20values%20remained%20lower%20with%20CSF%20than%20with%20EMF.%20The%20estimated%20probabilities%20of%20being%20alive%20were%20close%20using%20the%202%20frameworks%2C%20and%20the%20estimated%20POther%20%28EMF%20vs%20CSF%29%20was%202.6%25%20%282.5%5Cu20132.6%29%20vs%202.1%25%20%281.2%5Cu20133.9%29%20and%2018.1%25%20%2816.9%5Cu201319.3%29%20vs%2026.4%25%20%2816.5%5Cu201342.2%29%2C%20respectively%2C%20for%20the%20youngest%20and%20oldest%20groups.%20In%20the%20OFSEP%20population%2C%20the%20estimated%2030-year%20PMS%20values%20ranged%20from%207.5%25%20%286.4%5Cu20138.7%29%20to%2024.0%25%20%2819.1%5Cu201328.9%29%20in%20patients%20with%20R-MS%20and%20from%2025.4%25%20%2821.1%5Cu201329.7%29%20to%2036.8%25%20%2828.3%5Cu201345.3%29%20in%20primary%20progressive%20patients%2C%20depending%20on%20sex%20and%20age.%5CnDiscussion%5CnEMF%20has%20the%20great%20advantage%20of%20not%20requiring%20death%20certificates%2C%20their%20quality%20being%20less%20than%20optimal.%20Conceptually%2C%20it%20also%20seems%20more%20relevant%20because%20it%20avoids%20having%20to%20state%2C%20for%20each%20individual%2C%20whether%20death%20was%20directly%20or%20indirectly%20caused%20by%20MS%20or%20whether%20it%20would%20have%20occurred%20anyway%2C%20which%20is%20especially%20difficult%20in%20such%20chronic%20diseases.%22%2C%22date%22%3A%222023-12-12%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000207925%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.neurology.org%5C%2Fdoi%5C%2F10.1212%5C%2FWNL.0000000000207925%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-03-21T14%3A51%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22CBEZGFUB%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Claverie%20et%20al.%22%2C%22parsedDate%22%3A%222023-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BClaverie%2C%20R.%2C%20Perriguey%2C%20M.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Hilezian%2C%20F.%2C%20Dubrou%2C%20C.%2C%20Vely%2C%20F.%2C%20Pelletier%2C%20J.%2C%20Audoin%2C%20B.%20and%20Maarouf%2C%20A.%20%282023%29%20%26%23x201C%3BEfficacy%20of%20Rituximab%20Outlasts%20B-Cell%20Repopulation%20in%20Multiple%20Sclerosis%3A%20Time%20to%20Rethink%20Dosing%3F%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2010%285%29%2C%20p.%20e200152.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200152%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200152%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%20of%20Rituximab%20Outlasts%20B-Cell%20Repopulation%20in%20Multiple%20Sclerosis%3A%20Time%20to%20Rethink%20Dosing%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roxane%22%2C%22lastName%22%3A%22Claverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clea%22%2C%22lastName%22%3A%22Dubrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Vely%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Patients%20with%20multiple%20sclerosis%20%28PwMS%29%20receiving%20extended%20dosing%20of%20rituximab%20%28RTX%29%20have%20exhibited%20no%20return%20of%20disease%20activity%2C%20which%20suggests%20that%20maintenance%20of%20deep%20depletion%20of%20circulating%20B%20cells%20is%20not%20necessary%20to%20maintain%20the%20efficacy%20of%20RTX%20in%20MS.%5CnMETHODS%3A%20This%20was%20a%20prospective%20monocentric%20observational%20study%20including%20all%20consecutive%20PwMS%20who%20started%20or%20continued%20RTX%20after%202019%2C%20when%20the%20medical%20staff%20decided%20to%20extend%20the%20dosing%20interval%20up%20to%2024%20months%20for%20all%20patients.%20Circulating%20B-cell%20subsets%20were%20monitored%20regularly%20and%20systematically%20in%20case%20of%20relapse.%20The%20first%20extended%20interval%20was%20analyzed.%5CnRESULTS%3A%20We%20included%20236%20PwMS%20%2881%25%20with%20relapsing-remitting%20MS%3B%20mean%20%5BSD%5D%20age%2043%20%5B12%5D%20years%3B%20median%20%5Brange%5D%20EDSS%20score%204%20%5B0-8%5D%3B%20mean%20relapse%20rate%20during%20the%20year%20before%20RTX%20start%201.09%20%5B0.99%5D%3B%2041.5%25%20with%20MRI%20activity%29.%20The%20median%20number%20of%20RTX%20infusions%20before%20extension%20was%204%20%281-13%29.%20At%20the%20time%20of%20the%20analysis%2C%20the%20median%20delay%20in%20dosing%20was%2017%20months%20%288-39%29%3B%20the%20median%20proportion%20of%20circulating%20CD19%2B%20B%20cells%20was%207%25%20%280-25%29%20of%20total%20lymphocytes%20and%20that%20of%20CD27%2B%20memory%20B%20cells%20was%204%25%20%280-16%29%20of%20total%20B%20cells.%20The%20mean%20annual%20relapse%20rate%20did%20not%20differ%20before%20and%20after%20the%20extension%3A%200.03%20%280.5%29%20and%200.04%20%280.15%29%20%28p%20%3D%200.51%29.%20Similarly%2C%20annual%20relapse%20rates%20did%20not%20differ%20before%20and%20after%20extension%20in%20patients%20with%20EDSS%20score%20%5Cu22643%20%28n%20%3D%2079%29%20or%20disease%20duration%20%5Cu22645%20years%20%28n%20%3D%2071%29%20at%20RTX%20onset.%20During%20the%20%26quot%3Bextended%20dosing%26quot%3B%20period%2C%20MRI%20demonstrated%20no%20lesion%20accrual%20in%20228%20of%20the%20236%20patients%20%2897%25%29.%20Five%20patients%20experienced%20clinical%20relapse%2C%20which%20was%20confirmed%20by%20MRI.%20In%20these%20patients%2C%20the%20level%20of%20B-cell%20subset%20reconstitution%20at%20the%20time%20of%20the%20relapse%20did%20not%20differ%20from%20that%20for%20patients%20with%20the%20same%20extension%20window.%5CnDISCUSSION%3A%20The%20efficacy%20of%20RTX%20outlasted%20substantial%20reconstitution%20of%20circulating%20B%20cells%20in%20PwMS%2C%20which%20suggests%20that%20renewal%20of%20the%20immune%20system%20underlies%20the%20prolonged%20effect%20of%20RTX%20in%20MS.%20These%20findings%20suggest%20that%20extended%20interval%20dosing%20of%20RTX%20that%20leads%20to%20a%20significant%20reconstitution%20of%20circulating%20B%20cells%20is%20safe%20in%20PwMS%2C%20could%20reduce%20the%20risk%20of%20infection%2C%20and%20could%20improve%20vaccine%20efficacy.%22%2C%22date%22%3A%222023-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200152%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-12-01T09%3A50%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22HL5B8A5J%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Testud%20et%20al.%22%2C%22parsedDate%22%3A%222023-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BTestud%2C%20B.%2C%20Fabiani%2C%20N.%2C%20Demorti%26%23xE8%3Bre%2C%20S.%2C%20Mchinda%2C%20S.%2C%20Medina%2C%20N.L.%2C%20Pelletier%2C%20J.%2C%20Guye%2C%20M.%2C%20Audoin%2C%20B.%2C%20Stellmann%2C%20J.P.%20and%20Callot%2C%20V.%20%282023%29%20%26%23x201C%3BContribution%20of%20the%20MP2RAGE%207T%20Sequence%20in%20MS%20Lesions%20of%20the%20Cervical%20Spinal%20Cord%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BAJNR.%20American%20journal%20of%20neuroradiology%26lt%3B%5C%2Fi%26gt%3B%2C%2044%289%29%2C%20pp.%201101%26%23x2013%3B1107.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3174%5C%2Fajnr.A7964%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3174%5C%2Fajnr.A7964%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Contribution%20of%20the%20MP2RAGE%207T%20Sequence%20in%20MS%20Lesions%20of%20the%20Cervical%20Spinal%20Cord%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Testud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Fabiani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Demorti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Mchinda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%20L.%22%2C%22lastName%22%3A%22Medina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20P.%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Callot%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20PURPOSE%3A%20The%20detection%20of%20spinal%20cord%20lesions%20in%20patients%20with%20MS%20is%20challenging.%20Recently%2C%20the%203D%20MP2RAGE%20sequence%20demonstrated%20its%20usefulness%20at%203T.%20Benefiting%20from%20the%20high%20spatial%20resolution%20provided%20by%20ultra-high-field%20MR%20imaging%20systems%2C%20we%20aimed%20to%20evaluate%20the%20contribution%20of%20the%203D%20MP2RAGE%20sequence%20acquired%20at%207T%20for%20the%20detection%20of%20MS%20lesions%20in%20the%20cervical%20spine.%5CnMATERIALS%20AND%20METHODS%3A%20Seventeen%20patients%20with%20MS%20participated%20in%20this%20study.%20They%20were%20examined%20at%20both%203T%20and%207T.%20The%20MR%20imaging%20examination%20included%20a%20Magnetic%20Imaging%20in%20MS%20%28MAGNIMS%29%20protocol%20with%20an%20axial%20T2%2A-WI%20gradient%20recalled-echo%20sequence%20%28%26quot%3Boptimized%20MAGNIMS%20protocol%26quot%3B%29%20and%20a%200.9-mm%20isotropic%203D%20MP2RAGE%20sequence%20at%203T%2C%20as%20well%20as%20a%200.7-mm%20isotropic%20and%200.3-mm%20in-plane-resolution%20anisotropic%203D%20MP2RAGE%20sequences%20at%207T.%20Each%20data%20set%20was%20read%20by%20a%20consensus%20of%20radiologists%2C%20neurologists%2C%20and%20neuroscientists.%20The%20number%20of%20lesions%20and%20their%20topography%2C%20as%20well%20as%20the%20visibility%20of%20the%20lesions%20from%20one%20set%20to%20another%2C%20were%20carefully%20analyzed.%5CnRESULTS%3A%20A%20total%20of%2055%20lesions%20were%20detected.%20The%20absolute%20number%20of%20visible%20lesions%20differed%20among%20the%204%20sequences%20%28linear%20mixed%20effect%20ANOVA%2C%20P%20%3D%20.020%29.%20The%20highest%20detection%20was%20observed%20for%20the%20two%207T%20sequences%20with%2051%20lesions%20each%20%2892.7%25%20of%20the%20total%29.%20The%20optimized%203T%20MAGNIMS%20protocol%20and%20the%203T%20MP2RAGE%20isotropic%20sequence%20detected%2041%20%2874.5%25%29%20and%2035%20lesions%20%2863.6%25%29%2C%20respectively.%5CnCONCLUSIONS%3A%20The%207T%20MP2RAGE%20sequences%20detected%20more%20lesions%20than%20the%203T%20sets.%20Isotropic%20and%20anisotropic%20acquisitions%20performed%20comparably.%20Ultra-high-resolution%20sequences%20obtained%20at%207T%20improve%20the%20identification%20and%20delineation%20of%20lesions%20of%20the%20cervical%20spinal%20cord%20in%20MS.%22%2C%22date%22%3A%222023-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3174%5C%2Fajnr.A7964%22%2C%22ISSN%22%3A%221936-959X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22ZFC2Q648%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%2C%22XTA6KS7L%22%2C%22PCMV2W5C%22%5D%2C%22dateModified%22%3A%222025-11-27T09%3A21%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22RTM5VRM7%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Demortiere%20et%20al.%22%2C%22parsedDate%22%3A%222023-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BDemortiere%2C%20S.%2C%20Maarouf%2C%20A.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Hilezian%2C%20F.%2C%20Durozard%2C%20P.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282023%29%20%26%23x201C%3BDisease%20Evolution%20in%20Women%20With%20Highly%20Active%20MS%20Who%20Suspended%20Natalizumab%20During%20Pregnancy%20vs%20Rituximab%5C%2FOcrelizumab%20Before%20Conception%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2010%285%29%2C%20p.%20e200161.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200161%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200161%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Disease%20Evolution%20in%20Women%20With%20Highly%20Active%20MS%20Who%20Suspended%20Natalizumab%20During%20Pregnancy%20vs%20Rituximab%5C%2FOcrelizumab%20Before%20Conception%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederic%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20In%20women%20with%20highly%20active%20multiple%20sclerosis%20%28MS%29%2C%20suspending%20rituximab%20%28RTX%29%20for%20planning%20pregnancy%20is%20associated%20with%20low%20disease%20reactivation.%20Whether%20this%20strategy%20reduces%20the%20risk%20of%20disease%20reactivity%20as%20compared%20with%20suspending%20natalizumab%20%28NTZ%29%203%20months%20after%20conception%20is%20unclear.%5CnMETHODS%3A%20We%20retrospectively%20included%20women%20with%20MS%20followed%20in%20our%20department%20during%20pregnancy%20and%201%20year%20after%20birth%20who%20suspended%20NTZ%20at%20the%20end%20of%20the%20first%20trimester%20%28option%20mostly%20proposed%20before%202016%29%20or%20suspended%20RTX%5C%2Focrelizumab%20%28RTX%5C%2FOCR%29%20in%20the%20year%20before%20conception%20%28option%20proposed%20since%202016%29.%5CnRESULTS%3A%20In%20women%20who%20suspended%20NTZ%2C%2045%20pregnancies%20resulted%20in%203%20miscarriages%20and%2042%20live%20births%2C%20including%201%20newborn%20with%20major%20malformations.%20In%20women%20who%20suspended%20RTX%5C%2FOCR%2C%2037%20pregnancies%20resulted%20in%203%20miscarriages%20and%2033%20live%20births%3B%201%20pregnancy%20was%20terminated%20for%20malformation.%20During%20pregnancy%2C%20relapse%20occurred%20in%203%5C%2F42%20%287.1%25%29%20patients%20of%20the%20NTZ%20group%20and%201%5C%2F33%20%283%25%29%20of%20the%20RTX%5C%2FOCR%20group%20%28p%20%3D%200.6%29.%20After%20delivery%2C%20relapse%20occurred%20in%209%5C%2F42%20%2821.4%25%29%20patients%20of%20the%20NTZ%20group%20and%200%5C%2F33%20of%20the%20RTX%5C%2FOCR%20group%20%28p%20%26lt%3B%200.01%29.%20In%20the%20NTZ%20group%2C%208%5C%2F9%20relapses%20occurred%20in%20patients%20who%20restarted%20NTZ%20less%20than%204%20weeks%20after%20delivery.%20The%20proportion%20of%20patients%20with%20gadolinium-enhanced%20and%5C%2For%20new%20T2%20lesions%20on%20brain%20or%20spinal%20cord%20MRI%20performed%20after%20delivery%20was%20higher%20in%20the%20NTZ%20than%20RTX%5C%2FOCR%20group%20%2814%5C%2F40%20%5B35%25%5D%20vs%201%5C%2F31%20%5B3%25%5D%20patients%2C%20p%20%3D%200.001%29%2C%20the%20proportion%20with%20EDSS%20score%20progression%20during%20the%20period%20including%20pregnancy%20and%20the%20year%20after%20delivery%20was%20higher%20%287%5C%2F42%20%5B17%25%5D%20vs%200%5C%2F33%20patients%2C%20p%20%3D%200.01%29%2C%20and%20the%20proportion%20fulfilling%20NEDA-3%20during%20this%20period%20was%20lower%20%2821%5C%2F40%20%5B53%25%5D%20vs%2030%5C%2F31%20%5B97%25%5D%20patients%2C%20p%20%26lt%3B%200.001%29.%5CnDISCUSSION%3A%20Suspending%20RTX%5C%2FOCR%20in%20the%20year%20before%20conception%20in%20women%20with%20highly%20active%20MS%20was%20associated%20with%20no%20disease%20reactivation%20during%20and%20after%20pregnancy.%20As%20previously%20reported%2C%20stopping%20NTZ%20at%20the%20end%20of%20the%20first%20trimester%20was%20associated%20with%20disease%20reactivation.%20In%20women%20receiving%20NTZ%20who%20are%20planning%20pregnancy%2C%20a%20bridge%20to%20RTX%5C%2FOCR%20for%20pregnancy%20or%20continuing%20NTZ%20until%20week%2034%20are%20both%20reasonable%20clinical%20decisions.%20The%20RTX%5C%2FOCR%20option%20is%20more%20comfortable%20for%20women%20and%20reduces%20the%20exposure%20of%20infants%20to%20monoclonal%20antibodies.%22%2C%22date%22%3A%222023-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200161%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-08-29T07%3A43%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22NFLUCCND%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Heim%20et%20al.%22%2C%22parsedDate%22%3A%222023-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHeim%2C%20X.%2C%20Hubert%2C%20A.M.%2C%20Raouak%2C%20I.%2C%20Nzepa%2C%20A.C.%2C%20Mege%2C%20J.-L.%2C%20Delmont%2C%20E.%2C%20Attarian%2C%20S.%2C%20Koric%2C%20L.%2C%20Pelletier%2C%20J.%2C%20Brodovitch%2C%20A.%20and%20Boucraut%2C%20J.%20%282023%29%20%26%23x201C%3BValidation%20of%20ELISA%20assays%20for%20the%20calculation%20of%20FLC%20indices%20for%20the%20diagnosis%20of%20intrathecal%20immunoglobulin%20synthesis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BClinical%20Chemistry%20and%20Laboratory%20Medicine%20%28CCLM%29%26lt%3B%5C%2Fi%26gt%3B%2C%2061%289%29%2C%20pp.%201623%26%23x2013%3B1629.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1515%5C%2Fcclm-2022-0602%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1515%5C%2Fcclm-2022-0602%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Validation%20of%20ELISA%20assays%20for%20the%20calculation%20of%20FLC%20indices%20for%20the%20diagnosis%20of%20intrathecal%20immunoglobulin%20synthesis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Heim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20Michele%22%2C%22lastName%22%3A%22Hubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Issam%22%2C%22lastName%22%3A%22Raouak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anthony%20Charles%22%2C%22lastName%22%3A%22Nzepa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Louis%22%2C%22lastName%22%3A%22Mege%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilien%22%2C%22lastName%22%3A%22Delmont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahram%22%2C%22lastName%22%3A%22Attarian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lejla%22%2C%22lastName%22%3A%22Koric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Brodovitch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Boucraut%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%20Define%20the%20cutoff%20thresholds%20of%20the%20Kappa%20%28K%29%20and%20Lambda%20%28L%29%20free%20light%20chains%20%28FLC%29%20indices%20for%20the%20detection%20of%20intrathecal%20immunoglobulin%20synthesis%20%28IIS%29%20using%20the%20new%20K%20and%20L%20FLC%20ELISA%20from%20SEBIA.%20The%20reference%20technique%2C%20which%20is%20not%20readily%20standardized%20between%20laboratories%2C%20is%20based%20on%20the%20demonstration%20of%20oligoclonal%20banding%20%28OCB%29%20in%20cerebrospinal%20fluid%20%28CSF%29%20which%20is%20absent%20in%20serum.%20For%20the%20past%206%20years%2C%20we%20have%20also%20routinely%20calculated%20the%20K%20FLC%20index%20using%20The%20Binding%20Site%20%28TBS%29%20reagents%20on%20an%20Optilite%20instrument%2C%20an%20approach%20increasingly%20used%20as%20an%20alternative%20and%5C%2For%20a%20complement%20to%20electrophoretic%20analysis.%20Methods%20We%20analyzed%20391%20serum%5C%2FCSF%20pairs%20divided%20into%20three%20groups.%20The%20first%20group%20were%20cases%20without%20OCB%20and%20with%20normal%20albumin%20CSF%5C%2Fserum%20ratio%20%28n%3D174%29.%20The%20second%20group%20were%20cases%20with%20specific%20OCB%20%28n%3D73%29.%20The%20last%20group%20included%20patients%20with%20increased%20albumin%20CSF%5C%2Fsera%20ratio%20without%20OCB%20%28n%3D142%29.%20Results%20Analysis%20of%20the%20first%20group%20determined%20that%20the%20cutoffs%20for%20detection%20of%20IIS%20are%20respectively%202.55%20and%201.02%20for%5Cu00a0the%20K%20FLC%20and%20L%20FLC%20indices.%20Of%20the%2073%20cases%20with%20IIS%2C%20only%5Cu00a02%20had%20a%20K%20FLC%20index%20below%20this%20threshold%20%28sensitivity%20of%2097.26%25%29%2C%20while%2016%20out%20of%2073%20cases%20%2878.08%25%29%20and%2013%20out%20of%2072%20cases%20%2881.94%25%29%20had%20an%20IgG%20and%20L%20FLC%20index%20below%20the%20cutoffs%2C%20respectively.%20Additionally%2C%20we%20illustrate%20equivalent%20performances%20for%20prediction%20of%20the%20presence%20of%20OCB%20between%20SEBIA%20and%20TBS%20methods.%20Conclusions%20Sebia%20K%20FLC%20and%20L%20FLC%20assays%20are%20adequate%20alternative%20methods%20for%20the%20diagnosis%20of%20IIS.%22%2C%22date%22%3A%222023-08-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1515%5C%2Fcclm-2022-0602%22%2C%22ISSN%22%3A%221437-4331%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.degruyter.com%5C%2Fdocument%5C%2Fdoi%5C%2F10.1515%5C%2Fcclm-2022-0602%5C%2Fhtml%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A46Z%22%7D%7D%2C%7B%22key%22%3A%22PTRQE4IA%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Brocard%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBrocard%2C%20G.%2C%20Casey%2C%20R.%2C%20Dufay%2C%20N.%2C%20Marignier%2C%20R.%2C%20Michel%2C%20L.%2C%20Hisbergues%2C%20M.%2C%20Ayrignac%2C%20X.%2C%20Lehmann%2C%20S.%2C%20Thouvenot%2C%20E.%2C%20Gallot%2C%20G.%2C%20Collongues%2C%20N.%2C%20Herpe%2C%20Y.-E.%2C%20Lebrun-Frenay%2C%20C.%2C%20Cotton%2C%20F.%2C%20De%20S%26%23xE8%3Bze%2C%20J.%2C%20Guillemin%2C%20F.%2C%20Moreau%2C%20T.%2C%20Pelletier%2C%20J.%2C%20Stankoff%2C%20B.%2C%20Vukusic%2C%20S.%2C%20Zephir%2C%20H.%2C%20Laplaud%2C%20D.%20and%20OFSEP%20investigators%20and%20biobanks%20%282023%29%20%26%23x201C%3BThe%20biological%20sample%20collection%20of%20the%20OFSEP%20French%20MS%20registry%3A%20An%20essential%20tool%20dedicated%20to%20researchers%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20and%20Related%20Disorders%26lt%3B%5C%2Fi%26gt%3B%2C%2077%2C%20p.%20104872.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.msard.2023.104872%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.msard.2023.104872%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20biological%20sample%20collection%20of%20the%20OFSEP%20French%20MS%20registry%3A%20An%20essential%20tool%20dedicated%20to%20researchers%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Brocard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Dufay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Hisbergues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Lehmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geraldine%22%2C%22lastName%22%3A%22Gallot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves-Edouard%22%2C%22lastName%22%3A%22Herpe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Cotton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francis%22%2C%22lastName%22%3A%22Guillemin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22OFSEP%20investigators%20and%20biobanks%22%7D%5D%2C%22abstractNote%22%3A%22Today%26%23039%3Bs%20medicine%20strives%20to%20be%20personalized%2C%20preventive%2C%20predictive%20and%20participatory.%20This%20implies%20to%20have%20access%20to%20multimodal%20data%20to%20better%20characterize%20patients%20groups%20and%20to%20combine%20clinical%20and%20imaging%20data%20with%20high-quality%20biological%20samples.%20Collecting%20such%20data%20is%20one%20of%20the%20objectives%20of%20the%20Observatoire%20fran%5Cu00e7ais%20de%20la%20scl%5Cu00e9rose%20en%20plaques%20%28OFSEP%29%2C%20the%20French%20MS%20registry.%20On%20December%202022%2C%20the%20OFSEP%20biocollection%20includes%204%2C888%20patients%20with%20scientific%20characteristics%20and%20about%2090%2C000%20samples.%20Thanks%20to%20its%20richness%2C%20this%20biocollection%20open%20for%20the%20scientific%20community%2C%20contributes%20to%20address%20unmet%20needs%20in%20MS%20through%20identification%20of%20multiomics%20determinants%20of%20MS%20activity%2C%20progression%20and%20secondary%20effects.%22%2C%22date%22%3A%222023-07-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.msard.2023.104872%22%2C%22ISSN%22%3A%222211-0356%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22Q43ZBAMD%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gavoille%20et%20al.%22%2C%22parsedDate%22%3A%222023-03-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BGavoille%2C%20A.%2C%20Rollot%2C%20F.%2C%20Casey%2C%20R.%2C%20Debouverie%2C%20M.%2C%20Page%2C%20E.L.%2C%20Ciron%2C%20J.%2C%20Seze%2C%20J.D.%2C%20Ruet%2C%20A.%2C%20Maillart%2C%20E.%2C%20Labauge%2C%20P.%2C%20Zephir%2C%20H.%2C%20Papeix%2C%20C.%2C%20Defer%2C%20G.%2C%20Lebrun-Frenay%2C%20C.%2C%20Moreau%2C%20T.%2C%20Laplaud%2C%20D.A.%2C%20Berger%2C%20E.%2C%20Stankoff%2C%20B.%2C%20Clavelou%2C%20P.%2C%20Thouvenot%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Pelletier%2C%20J.%2C%20Khedr%2C%20A.A.%2C%20Casez%2C%20O.%2C%20Bourre%2C%20B.%2C%20Cabre%2C%20P.%2C%20Wahab%2C%20A.%2C%20Magy%2C%20L.%2C%20Camdessanche%2C%20J.-P.%2C%20Maurousset%2C%20A.%2C%20Moulin%2C%20S.%2C%20Ben%2C%20N.H.%2C%20Boulos%2C%20D.D.%2C%20Hankiewicz%2C%20K.%2C%20Neau%2C%20J.-P.%2C%20Pottier%2C%20C.%2C%20Nifle%2C%20C.%2C%20Rabilloud%2C%20M.%2C%20Subtil%2C%20F.%2C%20Vukusic%2C%20S.%20and%20Investigators%2C%20%20on%20behalf%20of%20O.F.%20de%20la%20S.%20en%20P.%20%28OFSEP%29%20%282023%29%20%26%23x201C%3BInvestigating%20the%20Long-term%20Effect%20of%20Pregnancy%20on%20the%20Course%20of%20Multiple%20Sclerosis%20Using%20Causal%20Inference%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%2C%20100%2812%29%2C%20pp.%20e1296%26%23x2013%3Be1308.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000206774%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000206774%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Investigating%20the%20Long-term%20Effect%20of%20Pregnancy%20on%20the%20Course%20of%20Multiple%20Sclerosis%20Using%20Causal%20Inference%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Gavoille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debouverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%20Le%22%2C%22lastName%22%3A%22Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%20De%22%2C%22lastName%22%3A%22Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%20Al%22%2C%22lastName%22%3A%22Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Cabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Magy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Maurousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Moulin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nasr%20Haifa%22%2C%22lastName%22%3A%22Ben%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dalia%20Dimitri%22%2C%22lastName%22%3A%22Boulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Neau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Rabilloud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Subtil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22on%20behalf%20of%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20%28OFSEP%29%22%2C%22lastName%22%3A%22Investigators%22%7D%5D%2C%22abstractNote%22%3A%22Background%20and%20Objectives%20The%20question%20of%20the%20long-term%20safety%20of%20pregnancy%20is%20a%20major%20concern%20in%20patients%20with%20multiple%20sclerosis%20%28MS%29%2C%20but%20its%20study%20is%20biased%20by%20reverse%20causation%20%28women%20with%20higher%20disability%20are%20less%20likely%20to%20experience%20pregnancy%29.%20Using%20a%20causal%20inference%20approach%2C%20we%20aimed%20to%20estimate%20the%20unbiased%20long-term%20effects%20of%20pregnancy%20on%20disability%20and%20relapse%20risk%20in%20patients%20with%20MS%20and%20secondarily%20the%20short-term%20effects%20%28during%20the%20perpartum%20and%20postpartum%20years%29%20and%20delayed%20effects%20%28occurring%20beyond%201%20year%20after%20delivery%29.%5CnMethods%20We%20conducted%20an%20observational%20cohort%20study%20with%20data%20from%20patients%20with%20MS%20followed%20in%20the%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20registry%20between%201990%20and%202020.%20We%20included%20female%20patients%20with%20MS%20aged%2018%5Cu201345%20years%20at%20MS%20onset%2C%20clinically%20followed%20up%20for%20more%20than%202%20years%2C%20and%20with%20%5Cu22653%20Expanded%20Disease%20Status%20Scale%20%28EDSS%29%20measurements.%20Outcomes%20were%20the%20mean%20EDSS%20score%20at%20the%20end%20of%20follow-up%20and%20the%20annual%20probability%20of%20relapse%20during%20follow-up.%20Counterfactual%20outcomes%20were%20predicted%20using%20the%20longitudinal%20targeted%20maximum%20likelihood%20estimator%20in%20the%20entire%20study%20population.%20The%20patients%20exposed%20to%20at%20least%201%20pregnancy%20during%20their%20follow-up%20were%20compared%20with%20the%20counterfactual%20situation%20in%20which%2C%20contrary%20to%20what%20was%20observed%2C%20they%20would%20not%20have%20been%20exposed%20to%20any%20pregnancy.%20Short-term%20and%20delayed%20effects%20were%20analyzed%20from%20the%20first%20pregnancy%20of%20early-exposed%20patients%20%28who%20experienced%20it%20during%20their%20first%203%20years%20of%20follow-up%29.%5CnResults%20We%20included%209%2C100%20patients%2C%20with%20a%20median%20follow-up%20duration%20of%207.8%20years%2C%20of%20whom%202%2C125%20%2823.4%25%29%20patients%20were%20exposed%20to%20at%20least%201%20pregnancy.%20Pregnancy%20had%20no%20significant%20long-term%20causal%20effect%20on%20the%20mean%20EDSS%20score%20at%209%20years%20%28causal%20mean%20difference%20%5B95%25%20CI%5D%20%3D%200.00%20%5B%5Cu22120.16%20to%200.15%5D%29%20or%20on%20the%20annual%20probability%20of%20relapse%20%28causal%20risk%20ratio%20%5B95%25%20CI%5D%20%3D%200.95%20%5B0.93%5Cu20131.38%5D%29.%20For%20the%201%2C253%20early-exposed%20patients%2C%20pregnancy%20significantly%20decreased%20the%20probability%20of%20relapse%20during%20the%20perpartum%20year%20and%20significantly%20increased%20it%20during%20the%20postpartum%20year%2C%20but%20no%20significant%20delayed%20effect%20was%20found%20on%20the%20EDSS%20and%20relapse%20rate.%5CnDiscussion%20Using%20a%20causal%20inference%20approach%2C%20we%20found%20no%20evidence%20of%20significantly%20deleterious%20or%20beneficial%20long-term%20effects%20of%20pregnancy%20on%20disability.%20The%20beneficial%20effects%20found%20in%20other%20studies%20were%20probably%20related%20to%20a%20reverse%20causation%20bias.%22%2C%22date%22%3A%222023%5C%2F03%5C%2F21%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000206774%22%2C%22ISSN%22%3A%220028-3878%2C%201526-632X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fn.neurology.org%5C%2Fcontent%5C%2F100%5C%2F12%5C%2Fe1296%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-03-11T08%3A54%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22UP99ABS7%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sabath%5Cu00e9%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSabath%26%23xE9%3B%2C%20C.%2C%20Casey%2C%20R.%2C%20Vukusic%2C%20S.%2C%20Leray%2C%20E.%2C%20Mathey%2C%20G.%2C%20De%20S%26%23xE8%3Bze%2C%20J.%2C%20Ciron%2C%20J.%2C%20Wiertlewski%2C%20S.%2C%20Ruet%2C%20A.%2C%20Pelletier%2C%20J.%2C%20Z%26%23xE9%3Bphir%2C%20H.%2C%20Michel%2C%20L.%2C%20Lebrun-Frenay%2C%20C.%2C%20Moisset%2C%20X.%2C%20Thouvenot%2C%20E.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Bakchine%2C%20S.%2C%20Stankoff%2C%20B.%2C%20Al%20Khedr%2C%20A.%2C%20Cabre%2C%20P.%2C%20Maillart%2C%20E.%2C%20Berger%2C%20E.%2C%20Heinzlef%2C%20O.%2C%20Hankiewicz%2C%20K.%2C%20Moreau%2C%20T.%2C%20Gout%2C%20O.%2C%20Bourre%2C%20B.%2C%20Wahab%2C%20A.%2C%20Labauge%2C%20P.%2C%20Montcuquet%2C%20A.%2C%20Defer%2C%20G.%2C%20Maurousset%2C%20A.%2C%20Maubeuge%2C%20N.%2C%20Dimitri%20Boulos%2C%20D.%2C%20Ben%20Nasr%2C%20H.%2C%20Nifle%2C%20C.%2C%20Casez%2C%20O.%2C%20Laplaud%2C%20D.-A.%20and%20Foucher%2C%20Y.%20%282023%29%20%26%23x201C%3BImproving%20the%20decision%20to%20switch%20from%20first-%20to%20second-line%20therapy%20in%20multiple%20sclerosis%3A%20A%20dynamic%20scoring%20system%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20Journal%26lt%3B%5C%2Fi%26gt%3B%2C%2029%282%29%2C%20pp.%20236%26%23x2013%3B247.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221139156%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221139156%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Improving%20the%20decision%20to%20switch%20from%20first-%20to%20second-line%20therapy%20in%20multiple%20sclerosis%3A%20A%20dynamic%20scoring%20system%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Sabath%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Wiertlewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Z%5Cu00e9phir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Moisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Bakchine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullatif%22%2C%22lastName%22%3A%22Al%20Khedr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Cabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Gout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Montcuquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Maurousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Maubeuge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dalia%22%2C%22lastName%22%3A%22Dimitri%20Boulos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ha%5Cu00effa%22%2C%22lastName%22%3A%22Ben%20Nasr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Nifle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David-Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yohann%22%2C%22lastName%22%3A%22Foucher%22%7D%5D%2C%22abstractNote%22%3A%22Background%3AIn%20relapsing-remitting%20multiple%20sclerosis%20%28RRMS%29%2C%20early%20identification%20of%20suboptimal%20responders%20can%20prevent%20disability%20progression.Objective%3AWe%20aimed%20to%20develop%20and%20validate%20a%20dynamic%20score%20to%20guide%20the%20early%20decision%20to%20switch%20from%20first-%20to%20second-line%20therapy.Methods%3AUsing%20time-dependent%20propensity%20scores%20%28PS%29%20from%20a%20French%20cohort%20of%2012%2C823%20patients%20with%20RRMS%2C%20we%20constructed%20one%20training%20and%20two%20validation%20PS-matched%20cohorts%20to%20compare%20the%20switched%20patients%20to%20second-line%20treatment%20and%20the%20maintained%20patients.%20We%20used%20a%20frailty%20Cox%20model%20for%20predicting%20individual%20hazard%20ratios%20%28iHRs%29.Results%3AFrom%20the%20validation%20PS-matched%20cohort%20of%20348%20independent%20patients%20with%20iHR%20%3F%200.69%2C%20we%20reported%20the%205-year%20relapse-free%20survival%20at%200.14%20%2895%25%20confidence%20interval%20%28CI%29%200.09%3F0.22%29%20for%20the%20waiting%20group%20and%200.40%20%2895%25%20CI%200.32%3F0.51%29%20for%20the%20switched%20group.%20From%20the%20validation%20PS-matched%20cohort%20of%20518%20independent%20patients%20with%20iHR%20%26gt%3B%200.69%2C%20these%20values%20were%200.37%20%2895%25%20CI%200.30%3F0.46%29%20and%200.44%20%2895%25%20CI%200.37%3F0.52%29%2C%20respectively.Conclusions%3ABy%20using%20the%20proposed%20dynamic%20score%2C%20we%20estimated%20that%20at%20least%20one-third%20of%20patients%20could%20benefit%20from%20an%20earlier%20switch%20to%20prevent%20relapse.%22%2C%22date%22%3A%222023-02-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585221139156%22%2C%22ISSN%22%3A%221352-4585%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221139156%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A41Z%22%7D%7D%2C%7B%22key%22%3A%22ND67CEXQ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wilson%20et%20al.%22%2C%22parsedDate%22%3A%222023-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BWilson%2C%20S.%2C%20Calocer%2C%20F.%2C%20Rollot%2C%20F.%2C%20Fauvernier%2C%20M.%2C%20Remontet%2C%20L.%2C%20Tron%2C%20L.%2C%20Vukusic%2C%20S.%2C%20Le%20Page%2C%20E.%2C%20Debouverie%2C%20M.%2C%20Ciron%2C%20J.%2C%20Ruet%2C%20A.%2C%20De%20S%26%23xE8%3Bze%2C%20J.%2C%20Zephir%2C%20H.%2C%20Moreau%2C%20T.%2C%20Lebrun-Fr%26%23xE9%3Bnay%2C%20C.%2C%20Laplaud%2C%20D.-A.%2C%20Clavelou%2C%20P.%2C%20Labauge%2C%20P.%2C%20Berger%2C%20E.%2C%20Pelletier%2C%20J.%2C%20Heinzlef%2C%20O.%2C%20Thouvenot%2C%20E.%2C%20Camdessanch%26%23xE9%3B%2C%20J.P.%2C%20Leray%2C%20E.%2C%20Dejardin%2C%20O.%20and%20Defer%2C%20G.%20%282023%29%20%26%23x201C%3BEffects%20of%20socioeconomic%20status%20on%20excess%20mortality%20in%20patients%20with%20multiple%20sclerosis%20in%20France%3A%20A%20retrospective%20observational%20cohort%20study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BThe%20Lancet%20Regional%20Health.%20Europe%26lt%3B%5C%2Fi%26gt%3B%2C%2024%2C%20p.%20100542.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lanepe.2022.100542%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.lanepe.2022.100542%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Effects%20of%20socioeconomic%20status%20on%20excess%20mortality%20in%20patients%20with%20multiple%20sclerosis%20in%20France%3A%20A%20retrospective%20observational%20cohort%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Wilson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Floriane%22%2C%22lastName%22%3A%22Calocer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Fauvernier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Remontet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22Tron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Le%20Page%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debouverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Fr%5Cu00e9nay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David-Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Dejardin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20The%20effects%20of%20socio-economic%20status%20on%20mortality%20in%20patients%20with%20multiple%20sclerosis%20is%20not%20well%20known.%20The%20objective%20was%20to%20examine%20mortality%20due%20to%20multiple%20sclerosis%20according%20to%20socio-economic%20status.%5CnMETHODS%3A%20A%20retrospective%20observational%20cohort%20design%20was%20used%20with%20recruitment%20from%2018%20French%20multiple%20sclerosis%20expert%20centers%20participating%20in%20the%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques.%20All%20patients%20lived%20in%20metropolitan%20France%20and%20had%20a%20definite%20or%20probable%20diagnosis%20of%20multiple%20sclerosis%20according%20to%20either%20Poser%20or%20McDonald%20criteria%20with%20an%20onset%20of%20disease%20between%201960%20and%202015.%20Initial%20phenotype%20was%20either%20relapsing-onset%20or%20primary%20progressive%20onset.%20Vital%20status%20was%20updated%20on%20January%201st%202016.%20Socio-economic%20status%20was%20measured%20by%20an%20ecological%20index%2C%20the%20European%20Deprivation%20Index%20and%20was%20attributed%20to%20each%20patient%20according%20to%20their%20home%20address.%20Excess%20death%20rates%20were%20studied%20according%20to%20socio-economic%20status%20using%20additive%20excess%20hazard%20models%20with%20multidimensional%20penalised%20splines.%20The%20initial%20hypothesis%20was%20a%20potential%20socio-economic%20gradient%20in%20excess%20mortality.%5CnFINDINGS%3A%20A%20total%20of%2034%2C169%20multiple%20sclerosis%20patients%20were%20included%20%2888%25%20relapsing%20onset%20%28n%5Cu00a0%3D%5Cu00a030%2C083%29%2C%2012%25%20progressive%20onset%20%28n%5Cu00a0%3D%5Cu00a04086%29%29%2C%20female%5C%2Fmale%20sex%20ratio%202.7%20for%20relapsing-onset%20and%201.3%20for%20progressive-onset%29.%20Mean%20age%20at%20disease%20onset%20was%2031.6%20%28SD%5Cu00a0%3D%5Cu00a09.8%29%20for%20relapsing-onset%20and%2042.7%20%28SD%5Cu00a0%3D%5Cu00a010.8%29%20for%20progressive-onset.%20At%20the%20end%20of%20follow-up%2C%201849%20patients%20had%20died%20%284.4%25%20for%20relapsing-onset%20%28n%5Cu00a0%3D%5Cu00a01311%29%20and%2013.2%25%20for%20progressive-onset%20%28n%5Cu00a0%3D%5Cu00a0538%29%29.%20A%20socio-economic%20gradient%20was%20found%20for%20relapsing-onset%20patients%3B%20more%20deprived%20patients%20had%20a%20greater%20excess%20death%20rate.%20At%20thirty%20years%20of%20disease%20duration%20and%20a%20year%20of%20onset%20of%20symptoms%20of%201980%2C%20survival%20probability%20difference%20%28or%20deprivation%20gap%29%20between%20less%20deprived%20relapsing-onset%20patients%20%28EDI%5Cu00a0%3D%5Cu00a0-6%29%20and%20more%20deprived%20relapsing-onset%20patients%20%28EDI%5Cu00a0%3D%5Cu00a012%29%20was%2016.6%25%20%2895%25%20confidence%20interval%20%28CI%29%20%5B10.3%25-22.9%25%5D%29%20for%20men%20and%2012.3%25%20%2895%25CI%20%5B7.6%25-17.0%25%5D%29%20for%20women.%20No%20clear%20socio-economic%20mortality%20gradient%20was%20found%20in%20progressive-onset%20patients.%5CnINTERPRETATION%3A%20Socio-economic%20status%20was%20associated%20with%20mortality%20due%20to%20multiple%20sclerosis%20in%20relapsing-onset%20patients.%20Improvements%20in%20overall%20care%20of%20more%20socio-economically%20deprived%20patients%20with%20multiple%20sclerosis%20could%20help%20reduce%20these%20socio-economic%20inequalities%20in%20multiple%20sclerosis-related%20mortality.%5CnFUNDING%3A%20This%20study%20was%20funded%20by%20the%20ARSEP%20foundation%20%26quot%3BFondation%20pour%20l%26%23039%3Baide%20%5Cu00e0%20la%20recherche%20sur%20la%20Scl%5Cu00e9rose%20en%20Plaques%26quot%3B%20%28Grant%20Reference%20Number%201122%29.%20Data%20collection%20has%20been%20supported%20by%20a%20grant%20provided%20by%20the%20French%20State%20and%20handled%20by%20the%20%26quot%3BAgence%20Nationale%20de%20la%20Recherche%2C%26quot%3B%20within%20the%20framework%20of%20the%20%26quot%3BInvestments%20for%20the%20Future%26quot%3B%20programme%2C%20under%20the%20reference%20ANR-10-COHO-002%2C%20Observatoire%20Fran%5Cu00e7ais%20de%20la%20Scl%5Cu00e9rose%20en%20Plaques%20%28OFSEP%29.%22%2C%22date%22%3A%222023-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.lanepe.2022.100542%22%2C%22ISSN%22%3A%222666-7762%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22NLCL528K%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A02%3A05Z%22%7D%7D%2C%7B%22key%22%3A%229RCMCNCD%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Levraut%20et%20al.%22%2C%22parsedDate%22%3A%222023-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLevraut%2C%20M.%2C%20Laurent-Chabalier%2C%20S.%2C%20Ayrignac%2C%20X.%2C%20Bigaut%2C%20K.%2C%20Rival%2C%20M.%2C%20Squalli%2C%20S.%2C%20Z%26%23xE9%3Bphir%2C%20H.%2C%20Alberto%2C%20T.%2C%20Pekar%2C%20J.-D.%2C%20Ciron%2C%20J.%2C%20Biotti%2C%20D.%2C%20Puissant-Lubrano%2C%20B.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Tholance%2C%20Y.%2C%20Casez%2C%20O.%2C%20Toussaint%2C%20B.%2C%20Marion%2C%20J.%2C%20Moreau%2C%20T.%2C%20Lakomy%2C%20D.%2C%20Thomasset%2C%20A.%2C%20Maillart%2C%20E.%2C%20Sterlin%2C%20D.%2C%20Maurousset%2C%20A.%2C%20Rocher%2C%20A.%2C%20Laplaud%2C%20D.A.%2C%20Bigot-Corbel%2C%20E.%2C%20Bertho%2C%20P.-O.%2C%20Pelletier%2C%20J.%2C%20Boucraut%2C%20J.%2C%20Labauge%2C%20P.%2C%20Vincent%2C%20T.%2C%20De%20S%26%23xE8%3Bze%2C%20J.%2C%20Jahn%2C%20I.%2C%20Seitz-Polski%2C%20B.%2C%20Thouvenot%2C%20E.%2C%20Lebrun-Frenay%2C%20C.%20and%20Soci%26%23xE9%3Bt%26%23xE9%3B%20Francophone%20de%20la%20Scl%26%23xE9%3Brose%20En%20Plaques%20%28SFSEP%29%20%282023%29%20%26%23x201C%3BKappa%20Free%20Light%20Chain%20Biomarkers%20Are%20Efficient%20for%20the%20Diagnosis%20of%20Multiple%20Sclerosis%3A%20A%20Large%20Multicenter%20Cohort%20Study%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%2010%281%29%2C%20p.%20e200049.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200049%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000200049%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Kappa%20Free%20Light%20Chain%20Biomarkers%20Are%20Efficient%20for%20the%20Diagnosis%20of%20Multiple%20Sclerosis%3A%20A%20Large%20Multicenter%20Cohort%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Levraut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabine%22%2C%22lastName%22%3A%22Laurent-Chabalier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K%5Cu00e9vin%22%2C%22lastName%22%3A%22Bigaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Rival%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanae%22%2C%22lastName%22%3A%22Squalli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Z%5Cu00e9phir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tifanie%22%2C%22lastName%22%3A%22Alberto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-David%22%2C%22lastName%22%3A%22Pekar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Biotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9n%5Cu00e9dicte%22%2C%22lastName%22%3A%22Puissant-Lubrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannick%22%2C%22lastName%22%3A%22Tholance%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Toussaint%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeanne%22%2C%22lastName%22%3A%22Marion%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%22%2C%22lastName%22%3A%22Lakomy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Thomasset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Sterlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Maurousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Auriane%22%2C%22lastName%22%3A%22Rocher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edith%22%2C%22lastName%22%3A%22Bigot-Corbel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Olivier%22%2C%22lastName%22%3A%22Bertho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%22%2C%22lastName%22%3A%22Boucraut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Vincent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Jahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barbara%22%2C%22lastName%22%3A%22Seitz-Polski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Soci%5Cu00e9t%5Cu00e9%20Francophone%20de%20la%20Scl%5Cu00e9rose%20En%20Plaques%20%28SFSEP%29%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Kappa%20free%20light%20chains%20%28KFLC%29%20seem%20to%20efficiently%20diagnose%20MS.%20However%2C%20extensive%20cohort%20studies%20are%20lacking%20to%20establish%20consensus%20cut-offs%2C%20notably%20to%20rule%20out%20non-MS%20autoimmune%20CNS%20disorders.%20Our%20objectives%20were%20to%20%281%29%20determine%20diagnostic%20performances%20of%20CSF%20KFLC%2C%20KFLC%20index%2C%20and%20KFLC%20intrathecal%20fraction%20%28IF%29%20threshold%20values%20that%20allow%20us%20to%20separate%20MS%20from%20different%20CNS%20disorder%20control%20populations%20and%20compare%20them%20with%20oligoclonal%20bands%26%23039%3B%20%28OCB%29%20performances%20and%20%282%29%20to%20identify%20independent%20factors%20associated%20with%20KFLC%20quantification%20in%20MS.%5CnMETHODS%3A%20We%20conducted%20a%20retrospective%20multicenter%20study%20involving%2013%20French%20MS%20centers.%20Patients%20were%20included%20if%20they%20had%20a%20noninfectious%20and%20nontumoral%20CNS%20disorder%2C%20eligible%20data%20concerning%20CSF%20and%20serum%20KFLC%2C%20albumin%2C%20and%20OCB.%20Patients%20were%20classified%20into%204%20groups%20according%20to%20their%20diagnosis%3A%20MS%2C%20clinically%20isolated%20syndrome%20%28CIS%29%2C%20other%20inflammatory%20CNS%20disorders%20%28OIND%29%2C%20and%20noninflammatory%20CNS%20disorder%20controls%20%28NINDC%29.%5CnRESULTS%3A%20One%20thousand%20six%20hundred%20twenty-one%20patients%20were%20analyzed%20%28675%20MS%2C%2090%20CIS%2C%20297%20OIND%2C%20and%20559%20NINDC%29.%20KFLC%20index%20and%20KFLC%20IF%20had%20similar%20performances%20in%20diagnosing%20MS%20from%20nonselected%20controls%20and%20OIND%20%28p%20%3D%200.123%20and%20p%20%3D%200.991%20for%20area%20under%20the%20curve%20%5BAUC%5D%20comparisons%29%20and%20performed%20better%20than%20CSF%20KFLC%20%28p%20%26lt%3B%200.001%20for%20all%20AUC%20comparisons%29.%20A%20KFLC%20index%20of%208.92%20best%20separated%20MS%5C%2FCIS%20from%20the%20entire%20nonselected%20control%20population%2C%20with%20better%20performances%20than%20OCB%20%28p%20%26lt%3B%200.001%20for%20AUC%20comparison%29.%20A%20KFLC%20index%20of%2011.56%20best%20separated%20MS%20from%20OIND%2C%20with%20similar%20performances%20than%20OCB%20%28p%20%3D%200.065%29.%20In%20the%20multivariate%20analysis%20model%2C%20female%20gender%20%28p%20%3D%200.003%29%2C%20young%20age%20%28p%20%3D%200.013%29%2C%20and%20evidence%20of%20disease%20activity%20%28p%20%26lt%3B%200.001%29%20were%20independent%20factors%20associated%20with%20high%20KFLC%20index%20values%20in%20patients%20with%20MS%2C%20whereas%20MS%20phenotype%2C%20immune-modifying%20treatment%20use%20at%20sampling%2C%20and%20the%20FLC%20analyzer%20type%20did%20not%20influence%20KFLC%20index.%5CnDISCUSSION%3A%20KFLC%20biomarkers%20are%20efficient%20tools%20to%20separate%20patients%20with%20MS%20from%20controls%2C%20even%20when%20compared%20with%20other%20patients%20with%20CNS%20autoimmune%20disorder.%20Given%20these%20results%2C%20we%20suggest%20using%20KFLC%20index%20or%20KFLC%20IF%20as%20a%20criterion%20to%20diagnose%20MS.%5CnCLASSIFICATION%20OF%20EVIDENCE%3A%20This%20study%20provides%20Class%20III%20evidence%20that%20KFLC%20index%20or%20IF%20can%20be%20used%20to%20differentiate%20patients%20with%20MS%20from%20nonselected%20controls%20and%20from%20patients%20with%20other%20autoimmune%20CNS%20disorders.%22%2C%22date%22%3A%222023-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000200049%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22NLCL528K%22%5D%2C%22dateModified%22%3A%222025-02-14T09%3A15%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22WNJ2KN5W%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Roos%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-25%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRoos%2C%20I.%2C%20Malpas%2C%20C.%2C%20Leray%2C%20E.%2C%20Casey%2C%20R.%2C%20Horakova%2C%20D.%2C%20Havrdova%2C%20E.K.%2C%20Debouverie%2C%20M.%2C%20Patti%2C%20F.%2C%20De%20Seze%2C%20J.%2C%20Izquierdo%2C%20G.%2C%20Eichau%2C%20S.%2C%20Edan%2C%20G.%2C%20Prat%2C%20A.%2C%20Girard%2C%20M.%2C%20Ozakbas%2C%20S.%2C%20Grammond%2C%20P.%2C%20Zephir%2C%20H.%2C%20Ciron%2C%20J.%2C%20Maillart%2C%20E.%2C%20Moreau%2C%20T.%2C%20Amato%2C%20M.P.%2C%20Labauge%2C%20P.%2C%20Alroughani%2C%20R.%2C%20Buzzard%2C%20K.%2C%20Skibina%2C%20O.%2C%20Terzi%2C%20M.%2C%20Laplaud%2C%20D.A.%2C%20Berger%2C%20E.%2C%20Grand%26%23x2019%3BMaison%2C%20F.%2C%20Lebrun-Frenay%2C%20C.%2C%20Cartechini%2C%20E.%2C%20Boz%2C%20C.%2C%20Lechner-Scott%2C%20J.%2C%20Clavelou%2C%20P.%2C%20Stankoff%2C%20B.%2C%20Prevost%2C%20J.%2C%20Kappos%2C%20L.%2C%20Pelletier%2C%20J.%2C%20Shaygannejad%2C%20V.%2C%20Yamout%2C%20B.I.%2C%20Khoury%2C%20S.J.%2C%20Gerlach%2C%20O.%2C%20Spitaleri%2C%20D.L.A.%2C%20Van%20Pesch%2C%20V.%2C%20Gout%2C%20O.%2C%20Turkoglu%2C%20R.%2C%20Heinzlef%2C%20O.%2C%20Thouvenot%2C%20E.%2C%20McCombe%2C%20P.A.%2C%20Soysal%2C%20A.%2C%20Bourre%2C%20B.%2C%20Slee%2C%20M.%2C%20Castillo-Trivino%2C%20T.%2C%20Bakchine%2C%20S.%2C%20Ampapa%2C%20R.%2C%20Butler%2C%20E.G.%2C%20Wahab%2C%20A.%2C%20Macdonell%2C%20R.A.%2C%20Aguera-Morales%2C%20E.%2C%20Cabre%2C%20P.%2C%20Ben%2C%20N.H.%2C%20Van%20der%20Walt%2C%20A.%2C%20Laureys%2C%20G.%2C%20Van%20Hijfte%2C%20L.%2C%20Ramo-Tello%2C%20C.M.%2C%20Maubeuge%2C%20N.%2C%20Hodgkinson%2C%20S.%2C%20S%26%23xE1%3Bnchez-Menoyo%2C%20J.L.%2C%20Barnett%2C%20M.H.%2C%20Labeyrie%2C%20C.%2C%20Vucic%2C%20S.%2C%20Sidhom%2C%20Y.%2C%20Gouider%2C%20R.%2C%20Csepany%2C%20T.%2C%20Sotoca%2C%20J.%2C%20de%20Gans%2C%20K.%2C%20Al-Asmi%2C%20A.%2C%20Fragoso%2C%20Y.D.%2C%20Vukusic%2C%20S.%2C%20Butzkueven%2C%20H.%2C%20Kalincik%2C%20T.%20and%20MSBase%20and%20OFSEP%20%282022%29%20%26%23x201C%3BDisease%20Reactivation%20After%20Cessation%20of%20Disease-Modifying%20Therapy%20in%20Patients%20With%20Relapsing-Remitting%20Multiple%20Sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%26lt%3B%5C%2Fi%26gt%3B%2C%2099%2817%29%2C%20pp.%20e1926%26%23x2013%3Be1944.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000201029%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FWNL.0000000000201029%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Disease%20Reactivation%20After%20Cessation%20of%20Disease-Modifying%20Therapy%20in%20Patients%20With%20Relapsing-Remitting%20Multiple%20Sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Izanne%22%2C%22lastName%22%3A%22Roos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Malpas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dana%22%2C%22lastName%22%3A%22Horakova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%20Kubala%22%2C%22lastName%22%3A%22Havrdova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debouverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Patti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillermo%22%2C%22lastName%22%3A%22Izquierdo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sara%22%2C%22lastName%22%3A%22Eichau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Prat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Girard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serkan%22%2C%22lastName%22%3A%22Ozakbas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Grammond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Pia%22%2C%22lastName%22%3A%22Amato%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raed%22%2C%22lastName%22%3A%22Alroughani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katherine%22%2C%22lastName%22%3A%22Buzzard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olga%22%2C%22lastName%22%3A%22Skibina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Murat%22%2C%22lastName%22%3A%22Terzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Grand%27Maison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabetta%22%2C%22lastName%22%3A%22Cartechini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cavit%22%2C%22lastName%22%3A%22Boz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeannette%22%2C%22lastName%22%3A%22Lechner-Scott%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Prevost%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludwig%22%2C%22lastName%22%3A%22Kappos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vahid%22%2C%22lastName%22%3A%22Shaygannejad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bassem%20I.%22%2C%22lastName%22%3A%22Yamout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samia%20J.%22%2C%22lastName%22%3A%22Khoury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oliver%22%2C%22lastName%22%3A%22Gerlach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniele%20L.%20A.%22%2C%22lastName%22%3A%22Spitaleri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Van%20Pesch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Gout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Recai%22%2C%22lastName%22%3A%22Turkoglu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Heinzlef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pamela%20Ann%22%2C%22lastName%22%3A%22McCombe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aysun%22%2C%22lastName%22%3A%22Soysal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Slee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tamara%22%2C%22lastName%22%3A%22Castillo-Trivino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Serge%22%2C%22lastName%22%3A%22Bakchine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Radek%22%2C%22lastName%22%3A%22Ampapa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ernest%20Gerard%22%2C%22lastName%22%3A%22Butler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abir%22%2C%22lastName%22%3A%22Wahab%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20A.%22%2C%22lastName%22%3A%22Macdonell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Aguera-Morales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Cabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nasr%20Haifa%22%2C%22lastName%22%3A%22Ben%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anneke%22%2C%22lastName%22%3A%22Van%20der%20Walt%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Laureys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liesbeth%22%2C%22lastName%22%3A%22Van%20Hijfte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%20M.%22%2C%22lastName%22%3A%22Ramo-Tello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Maubeuge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Hodgkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%20Luis%22%2C%22lastName%22%3A%22S%5Cu00e1nchez-Menoyo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20H.%22%2C%22lastName%22%3A%22Barnett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Celine%22%2C%22lastName%22%3A%22Labeyrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steve%22%2C%22lastName%22%3A%22Vucic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Youssef%22%2C%22lastName%22%3A%22Sidhom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Riadh%22%2C%22lastName%22%3A%22Gouider%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tunde%22%2C%22lastName%22%3A%22Csepany%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javier%22%2C%22lastName%22%3A%22Sotoca%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Koen%22%2C%22lastName%22%3A%22de%20Gans%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdullah%22%2C%22lastName%22%3A%22Al-Asmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yara%20Dadalti%22%2C%22lastName%22%3A%22Fragoso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helmut%22%2C%22lastName%22%3A%22Butzkueven%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomas%22%2C%22lastName%22%3A%22Kalincik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22MSBase%20and%20OFSEP%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20To%20evaluate%20the%20rate%20of%20return%20of%20disease%20activity%20after%20cessation%20of%20multiple%20sclerosis%20%28MS%29%20disease-modifying%20therapy.%5CnMETHODS%3A%20This%20was%20a%20retrospective%20cohort%20study%20from%202%20large%20observational%20MS%20registries%3A%20MSBase%20and%20OFSEP.%20Patients%20with%20relapsing-remitting%20MS%20who%20had%20ceased%20a%20disease-modifying%20therapy%20and%20were%20followed%20up%20for%20the%20subsequent%2012%20months%20were%20included%20in%20the%20analysis.%20The%20primary%20study%20outcome%20was%20annualized%20relapse%20rate%20in%20the%2012%20months%20after%20disease-modifying%20therapy%20discontinuation%20stratified%20by%20patients%20who%20did%2C%20and%20did%20not%2C%20commence%20a%20subsequent%20therapy.%20The%20secondary%20endpoint%20was%20the%20predictors%20of%20first%20relapse%20and%20disability%20accumulation%20after%20treatment%20discontinuation.%5CnRESULTS%3A%20A%20total%20of%2014%2C213%20patients%2C%20with%2018%2C029%20eligible%20treatment%20discontinuation%20epochs%2C%20were%20identified%20for%207%20therapies.%20Annualized%20rates%20of%20relapse%20%28ARRs%29%20started%20to%20increase%202%20months%20after%20natalizumab%20cessation%20%28month%202-4%20ARR%200.47%2C%2095%25%20CI%200.43-0.51%29.%20Commencement%20of%20a%20subsequent%20therapy%20within%202-4%20months%20reduced%20the%20magnitude%20of%20disease%20reactivation%20%28mean%20ARR%20difference%3A%200.15%2C%200.08-0.22%29.%20After%20discontinuation%20of%20fingolimod%2C%20rates%20of%20relapse%20increased%20overall%20%28month%201-2%20ARR%3A%200.80%2C%200.70-0.89%29%20and%20stabilized%20faster%20in%20patients%20who%20started%20a%20new%20therapy%20within%201-2%20months%20%28mean%20ARR%20difference%3A%200.14%2C%20-0.01%20to%200.29%29.%20The%20magnitude%20of%20disease%20reactivation%20for%20other%20therapies%20was%20low%20but%20reduced%20further%20by%20commencement%20of%20another%20treatment%201-10%20months%20after%20treatment%20discontinuation.%20Predictors%20of%20relapse%20were%20a%20higher%20relapse%20rate%20in%20the%20year%20before%20cessation%2C%20female%20sex%2C%20younger%20age%2C%20and%20higher%20EDSS%20score.%20Commencement%20of%20a%20subsequent%20therapy%20reduced%20both%20the%20risk%20of%20relapse%20%28HR%200.76%2C%2095%25%20CI%200.72-0.81%29%20and%20disability%20accumulation%20%280.73%2C%200.65-0.80%29.%5CnDISCUSSION%3A%20The%20rate%20of%20disease%20reactivation%20after%20treatment%20cessation%20differs%20among%20MS%20treatments%2C%20with%20the%20peaks%20of%20relapse%20activity%20ranging%20from%201%20to%2010%20months%20in%20untreated%20cohorts%20that%20discontinued%20different%20therapies.%20These%20results%20suggest%20that%20untreated%20intervals%20should%20be%20minimized%20after%20stopping%20antitrafficking%20therapies%20%28natalizumab%20and%20fingolimod%29.%5CnCLASSIFICATION%20OF%20EVIDENCE%3A%20This%20study%20provides%20Class%20III%20that%20disease%20reactivation%20occurs%20within%20months%20of%20discontinuation%20of%20MS%20disease-modifying%20therapies.%20The%20risk%20of%20disease%20activity%20is%20reduced%20by%20commencement%20of%20a%20subsequent%20therapy.%22%2C%22date%22%3A%222022-10-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FWNL.0000000000201029%22%2C%22ISSN%22%3A%221526-632X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22NLCL528K%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-04-16T14%3A27%3A35Z%22%7D%7D%2C%7B%22key%22%3A%226GQS6B3H%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maarouf%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMaarouf%2C%20A.%2C%20Audoin%2C%20B.%2C%20Gherib%2C%20S.%2C%20El%20Mendili%2C%20M.M.%2C%20Viout%2C%20P.%2C%20Pariollaud%2C%20F.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Rico%2C%20A.%2C%20Guye%2C%20M.%2C%20Ranjeva%2C%20J.-P.%2C%20Zaaraoui%2C%20W.%20and%20Pelletier%2C%20J.%20%282022%29%20%26%23x201C%3BGrey-matter%20sodium%20concentration%20as%20an%20individual%20marker%20of%20multiple%20sclerosis%20severity%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20Journal%26lt%3B%5C%2Fi%26gt%3B%2C%2028%2812%29%2C%20pp.%201903%26%23x2013%3B1912.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221102587%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221102587%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Grey-matter%20sodium%20concentration%20as%20an%20individual%20marker%20of%20multiple%20sclerosis%20severity%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soraya%22%2C%22lastName%22%3A%22Gherib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%20Mounir%22%2C%22lastName%22%3A%22El%20Mendili%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Viout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanelly%22%2C%22lastName%22%3A%22Pariollaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wafaa%22%2C%22lastName%22%3A%22Zaaraoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%5D%2C%22abstractNote%22%3A%22Objective%3AQuantification%20of%20brain%20injury%20in%20patients%20with%20variable%20disability%20despite%20similar%20disease%20duration%20may%20be%20relevant%20to%20identify%20the%20mechanisms%20underlying%20disability%20in%20multiple%20sclerosis%20%28MS%29.%20We%20aimed%20to%20compare%20grey-matter%20sodium%20abnormalities%20%28GMSAs%29%2C%20a%20parameter%20reflecting%20neuronal%20and%20astrocyte%20dysfunction%2C%20in%20MS%20patients%20with%20benign%20multiple%20sclerosis%20%28BMS%29%20and%20non-benign%20multiple%20sclerosis%20%28NBMS%29.Methods%3AWe%20identified%20never-treated%20BMS%20patients%20in%20our%20local%20MS%20database%20of%201352%20patients.%20A%20group%20with%20NBMS%20was%20identified%20with%20same%20disease%20duration.%20All%20participants%20underwent%2023Na%20magnetic%20resonance%20imaging%20%28MRI%29.%20The%20existence%20of%20GMSA%20was%20detected%20by%20statistical%20analysis.Results%3AIn%20total%2C%20102%20individuals%20were%20included%20%2821%20BMS%2C%2025%20NBMS%20and%2056%20controls%29.%20GMSA%20was%20detected%20in%2010%20BMS%20and%2019%20NBMS%20%2811%5C%2F16%20relapsing-remitting%20multiple%20sclerosis%20%28RRMS%29%20and%208%5C%2F9%20secondary%20progressive%20multiple%20sclerosis%20%28SPMS%29%20patients%29%20%28p%3F%3D%3F0.05%29.%20On%20logistic%20regression%20including%20the%20presence%20or%20absence%20of%20GMSA%2C%20thalamic%20volume%2C%20cortical%20grey-matter%20volume%20and%20T2-weighted%20lesion%20load%2C%20thalamic%20volume%20was%20independently%20associated%20with%20BMS%20status%20%28odds%20ratio%20%28OR%29%3F%3D%3F0.64%20for%20each%20unit%29.%20Nonetheless%2C%20the%20absence%20of%20GMSA%20was%20independently%20associated%20when%20excluding%20patients%20with%20significant%20cognitive%20alteration%20%28n%3F%3D%3F7%29%20from%20the%20BMS%20group%20%28OR%3F%3D%3F4.6%29.Conclusion%3ADetection%20of%20GMSA%20in%20individuals%20and%20thalamic%20volume%20are%20promising%20to%20differentiate%20BMS%20from%20NBMS%20as%20compared%20with%20cortical%20or%20whole%20grey-matter%20atrophy%20and%20T2-weighted%20lesions.%22%2C%22date%22%3A%222022-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585221102587%22%2C%22ISSN%22%3A%221352-4585%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585221102587%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22QU2QXBVV%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%22P66W67T8%22%2C%226KPLZTET%22%2C%22F2AGIUQU%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A22Z%22%7D%7D%2C%7B%22key%22%3A%22JMKK2PYJ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Poullet%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPoullet%2C%20Z.%2C%20Pique%2C%20J.%2C%20Maarouf%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Papeix%2C%20C.%2C%20Maillart%2C%20E.%2C%20Collongues%2C%20N.%2C%20Ayrignac%2C%20X.%2C%20Zephir%2C%20H.%2C%20Deschamps%2C%20R.%2C%20Ciron%2C%20J.%2C%20Pelletier%2C%20J.%2C%20Marignier%2C%20R.%20and%20Audoin%2C%20B.%20%282022%29%20%26%23x201C%3BPure%20Relapsing%20Short%20Myelitis%3A%20Part%20of%20the%20Multiple%20Sclerosis%20Spectrum%20or%20New%20Entity%3F%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%209%284%29%2C%20p.%20e1167.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001167%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001167%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Pure%20Relapsing%20Short%20Myelitis%3A%20Part%20of%20the%20Multiple%20Sclerosis%20Spectrum%20or%20New%20Entity%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Z%5Cu00e9lia%22%2C%22lastName%22%3A%22Poullet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Pique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Ayrignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Deschamps%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20Pure%20relapsing%20short%20myelitis%20with%20clinical%20and%20paraclinical%20features%20suggesting%20multiple%20sclerosis%20%28MS%29%20has%20been%20described%20recently.%20Here%2C%20we%20evaluated%20the%20existence%20of%20this%20potential%20new%20form%20of%20MS%20by%20retrospectively%20searching%20for%20similar%20cases%20in%20the%20databases%20of%20the%20French%20tertiary%20MS%20centers.%5CnMETHODS%3A%20Patients%20were%20included%20based%20on%20the%20present%20criteria%3A%20at%20least%202%20short%20%28%26lt%3B3%20vertebral%20segments%29%20myelitis%20episodes%3B%20minimum%20follow-up%20of%203%20years%3B%20no%20MS-like%20brain%20lesion%20during%20all%20the%20follow-up%3B%20tested%20negative%20for%20both%20anti-myelin%20oligodendrocyte%20glycoprotein%20and%20anti-aquaporin%204%20antibodies%20in%20serum%3B%20presence%20of%20oligoclonal%20bands%20in%20CSF%3B%20and%20comprehensive%20workup%20to%20exclude%20alternative%20diagnoses.%5CnRESULTS%3A%20Eighteen%20patients%20fulfilled%20all%20criteria.%20The%20sex%20ratio%20%28females%5C%2Fmales%29%20was%205%5C%2F1%3B%20the%20median%20%28range%29%20age%20at%20first%20relapse%20was%2035.5%20%2825-54%29%20years%2C%20the%20disease%20duration%20was%2080.5%20%2850-308%29%20months%2C%20and%20the%20annualized%20relapse%20rate%20was%200.36%20%280.1-0.5%29.%20The%20median%20%28range%29%20number%20of%20relapses%20per%20patient%20was%202%20%282-5%29%2C%20and%20the%20median%20%28range%29%20Expanded%20Disability%20Status%20Scale%20score%20at%20last%20follow-up%20was%201%20%280-7.5%29.%20In%20CSF%2C%20the%20median%20%28range%29%20protein%20level%20was%200.34%20g%5C%2FL%20%280.18-0.77%29%2C%20and%20the%20median%20%28range%29%20number%20of%20mononuclear%20cells%20was%203%20%280-28%29.%20Spinal%20cord%20MRI%20demonstrated%20a%20median%20%28range%29%20number%20of%202%20%281-5%29%20lesions%20per%20examination%20and%203%20%5B1-7%5D%20on%20the%20last%20examination.%20Fifty-five%20percent%20of%20lesions%20involved%20the%20cervical%20levels.%20Secondary%20progressive%20evolution%20occurred%20in%203%20of%2018%20%2817%25%29%20patients.%5CnDISCUSSION%3A%20Pure%20spinal%20MS%20could%20be%20a%20rare%20entity%20in%20the%20MS%20disease%20spectrum.%20However%2C%20the%20existence%20of%20a%20distinct%20entity%20in%20the%20inflammatory%20CNS%20disorders%20cannot%20be%20excluded.%22%2C%22date%22%3A%222022-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000001167%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%22NLCL528K%22%5D%2C%22dateModified%22%3A%222025-04-16T14%3A27%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22BA7BKXEL%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Januel%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BJanuel%2C%20E.%2C%20De%20Seze%2C%20J.%2C%20Vermersch%2C%20P.%2C%20Maillart%2C%20E.%2C%20Bourre%2C%20B.%2C%20Pique%2C%20J.%2C%20Moisset%2C%20X.%2C%20Bensa%2C%20C.%2C%20Maarouf%2C%20A.%2C%20Pelletier%2C%20J.%2C%20Vukusic%2C%20S.%2C%20Audoin%2C%20B.%20and%20Louapre%2C%20C.%20%282022%29%20%26%23x201C%3BPost-vaccine%20COVID-19%20in%20patients%20with%20multiple%20sclerosis%20or%20neuromyelitis%20optica%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20Journal%26lt%3B%5C%2Fi%26gt%3B%2C%2028%287%29%2C%20pp.%201155%26%23x2013%3B1159.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585211049737%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585211049737%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Post-vaccine%20COVID-19%20in%20patients%20with%20multiple%20sclerosis%20or%20neuromyelitis%20optica%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edouard%22%2C%22lastName%22%3A%22Januel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20Seze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Vermersch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Pique%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Moisset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bensa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Louapre%22%7D%5D%2C%22abstractNote%22%3A%22Introduction%3ARecent%20studies%20suggested%20that%20anti-CD20%20and%20fingolimod%20may%20be%20associated%20with%20lower%20anti-spike%20protein-based%20immunoglobulin-G%20response%20following%20COVID-19%20vaccination.%20We%20evaluated%20if%20COVID-19%20occurred%20despite%20vaccination%20among%20patients%20with%20multiple%20sclerosis%20%28MS%29%20and%20neuromyelitis%20optica%20%28NMO%29%2C%20using%20the%20COVISEP%20registry.Case%20series%3AWe%20report%2018%20cases%20of%20COVID-19%20after%20two%20doses%20of%20BNT162b2-vaccination%2C%2013%20of%20which%20treated%20with%20anti-CD20%20and%20four%20with%20fingolimod.%20COVID-19%20severity%20was%20mild.Discussion%3AThese%20results%20reinforce%20the%20recommendation%20for%20a%20third%20COVID-19%20vaccine%20dose%20among%20anti-CD20%20treated%20patients%20and%20stress%20the%20need%20for%20a%20prospective%20clinical%20and%20biological%20study%20on%20COVID-19%20vaccine%20efficacy%20among%20MS%20and%20NMO%20patients.%22%2C%22date%22%3A%222022-06-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F13524585211049737%22%2C%22ISSN%22%3A%221352-4585%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F13524585211049737%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A22Z%22%7D%7D%2C%7B%22key%22%3A%2284AE3N8N%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rollot%20et%20al.%22%2C%22parsedDate%22%3A%222022-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRollot%2C%20F.%2C%20Couturier%2C%20J.%2C%20Casey%2C%20R.%2C%20Wiertlewski%2C%20S.%2C%20Debouverie%2C%20M.%2C%20Pelletier%2C%20J.%2C%20De%20S%26%23xE8%3Bze%2C%20J.%2C%20Labauge%2C%20P.%2C%20Ruet%2C%20A.%2C%20Thouvenot%2C%20E.%2C%20Ciron%2C%20J.%2C%20Berger%2C%20E.%2C%20Gout%2C%20O.%2C%20Clavelou%2C%20P.%2C%20Stankoff%2C%20B.%2C%20Casez%2C%20O.%2C%20Bourre%2C%20B.%2C%20Zephir%2C%20H.%2C%20Moreau%2C%20T.%2C%20Lebrun-Frenay%2C%20C.%2C%20Maillart%2C%20E.%2C%20Edan%2C%20G.%2C%20Neau%2C%20J.-P.%2C%20Montcuquet%2C%20A.%2C%20Cabre%2C%20P.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Defer%2C%20G.%2C%20Nasr%2C%20H.B.%2C%20Maurousset%2C%20A.%2C%20Hankiewicz%2C%20K.%2C%20Pottier%2C%20C.%2C%20Leray%2C%20E.%2C%20Vukusic%2C%20S.%20and%20Laplaud%2C%20D.-A.%20%282022%29%20%26%23x201C%3BComparative%20Effectiveness%20of%20Natalizumab%20Versus%20Anti-CD20%20in%20Highly%20Active%20Relapsing-Remitting%20Multiple%20Sclerosis%20After%20Fingolimod%20Withdrawal%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurotherapeutics%3A%20The%20Journal%20of%20the%20American%20Society%20for%20Experimental%20NeuroTherapeutics%26lt%3B%5C%2Fi%26gt%3B%2C%2019%282%29%2C%20pp.%20476%26%23x2013%3B490.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs13311-022-01202-1%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs13311-022-01202-1%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparative%20Effectiveness%20of%20Natalizumab%20Versus%20Anti-CD20%20in%20Highly%20Active%20Relapsing-Remitting%20Multiple%20Sclerosis%20After%20Fingolimod%20Withdrawal%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Rollot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justine%22%2C%22lastName%22%3A%22Couturier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Casey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Wiertlewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Debouverie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22De%20S%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Thouvenot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Gout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Stankoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Zephir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisabeth%22%2C%22lastName%22%3A%22Maillart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Edan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Neau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Montcuquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Cabre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Haifa%20Ben%22%2C%22lastName%22%3A%22Nasr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aude%22%2C%22lastName%22%3A%22Maurousset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karolina%22%2C%22lastName%22%3A%22Hankiewicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Corinne%22%2C%22lastName%22%3A%22Pottier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Leray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David-Axel%22%2C%22lastName%22%3A%22Laplaud%22%7D%5D%2C%22abstractNote%22%3A%22In%20France%2C%20two%20therapeutic%20strategies%20can%20be%20offered%20after%20fingolimod%20%28FNG%29%20withdrawal%20to%20highly%20active%20relapsing-remitting%20multiple%20sclerosis%20%28RRMS%29%20patients%3A%20natalizumab%20%28NTZ%29%20or%20anti-CD20.%20We%20compared%20the%20effectiveness%20of%20these%20two%20strategies%20as%20a%20switch%20for%20FNG%20within%20the%20OFSEP%20database.%20The%20primary%20endpoint%20was%20the%20time%20to%20first%20relapse.%20Other%20outcomes%20were%20the%20relapse%20rates%20over%203-month%20periods%2C%20time%20to%20worsening%20the%20EDSS%20score%2C%20proportion%20of%20patients%20with%20worsened%2024-month%20MRI%2C%20time%20to%20treatment%20discontinuation%2C%20and%20incidence%20rates%20of%20serious%20adverse%20events.%20The%20dynamics%20of%20event%20rates%20over%20time%20were%20modeled%20using%20multidimensional%20penalized%20splines%2C%20allowing%20the%20possibility%20to%20model%20the%20effects%20of%20covariates%20in%20a%20flexible%20way%2C%20considering%20non-linearity%20and%20interactions.%20A%20total%20of%20740%20patients%20were%20included%20%28337%20under%20anti-CD20%20and%20403%20under%20NTZ%29.%20There%20was%20no%20difference%20between%20the%20two%20treatments%20regarding%20the%20dynamic%20of%20the%20first%20occurrence%20of%20relapse%2C%20with%20a%20monthly%20probability%20of%205.0%25%20at%20initiation%20and%201.0%25%20after%206%5Cu00a0months.%20The%20rate%20of%20EDSS%20worsening%20increased%20in%20both%20groups%20until%206%5Cu00a0months%20and%20then%20decreased.%20No%20difference%20in%20the%20proportion%20of%20patients%20with%20new%20T2%20lesions%20at%2024%5Cu00a0months%20was%20observed.%20After%2018%5Cu00a0months%20of%20follow-up%2C%20a%20greater%20risk%20of%20NTZ%20discontinuation%20was%20found%20compared%20to%20anti-CD20.%20This%20study%20showed%20no%20difference%20between%20NTZ%20and%20anti-CD20%20after%20the%20FNG%20switch%20regarding%20the%20clinical%20and%20radiological%20activity.%20The%20effect%20of%20these%20treatments%20was%20optimal%20after%206%5Cu00a0months%20and%20there%20was%20more%20frequent%20discontinuation%20of%20NTZ%20after%2018%5Cu00a0months%2C%20probably%20mainly%20related%20to%20JC%20virus%20seroconversions.%22%2C%22date%22%3A%222022-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs13311-022-01202-1%22%2C%22ISSN%22%3A%221878-7479%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22NLCL528K%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222025-04-16T14%3A27%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22JZB2NE65%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Perriguey%20et%20al.%22%2C%22parsedDate%22%3A%222022-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPerriguey%2C%20M.%2C%20Maarouf%2C%20A.%2C%20Stellmann%2C%20J.-P.%2C%20Rico%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Demortiere%2C%20S.%2C%20Durozard%2C%20P.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282022%29%20%26%23x201C%3BHypogammaglobulinemia%20and%20Infections%20in%20Patients%20With%20Multiple%20Sclerosis%20Treated%20With%20Rituximab%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%209%281%29%2C%20p.%20e1115.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001115%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001115%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hypogammaglobulinemia%20and%20Infections%20in%20Patients%20With%20Multiple%20Sclerosis%20Treated%20With%20Rituximab%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Perriguey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Patrick%22%2C%22lastName%22%3A%22Stellmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%20AND%20OBJECTIVES%3A%20To%20determine%20the%20frequency%20of%20hypogammaglobulinemia%20and%20infections%20in%20patients%20with%20multiple%20sclerosis%20%28PwMS%29%20receiving%20rituximab%20%28RTX%29.%5CnMETHODS%3A%20This%20prospective%20observational%20study%20included%20all%20consecutive%20PwMS%20receiving%20RTX%20at%20the%20university%20hospital%20of%20Marseille%2C%20France%2C%20between%202015%20and%202020.%20Patient%20visits%20occurred%20at%20least%20every%206%20months.%5CnRESULTS%3A%20We%20included%20188%20patients%20%28151%20with%20relapsing-remitting%20MS%3B%20the%20mean%20age%20was%2043.4%20years%20%5BSD%2012.9%5D%2C%20median%20disease%20duration%2010%20years%20%5Brange%200-36%5D%2C%20median%20Expanded%20Disability%20Status%20Scale%205%20%5Brange%200-8%5D%2C%20median%20follow-up%203.5%20years%20%5Brange%201-5.8%5D%2C%20and%20median%20number%20of%20RTX%20infusions%205%20%5Brange%201-9%5D%29.%20Overall%2C%20317%20symptomatic%20infections%20and%2013%20severe%20infections%20occurred%20in%20133%20of%20188%20%2870.7%25%29%20and%2011%20of%20188%20%285.9%25%29%20patients%2C%20respectively.%20After%204%20years%2C%2024.4%25%20of%20patients%20%2895%25%20CI%2018.0-33.1%29%20were%20free%20of%20any%20infection%20and%2092.0%25%20%2895%25%20CI%2087.1-97.1%29%20had%20not%20experienced%20a%20severe%20infection.%20At%20RTX%20onset%2C%20the%20immunoglobulin%20G%20%28IgG%29%20level%20was%20abnormal%20in%2032%20of%20188%20%2817%25%29%20patients.%20After%20RTX%2C%20IgG%20level%20was%20%26lt%3B7%2C%20%26lt%3B6%2C%20%26lt%3B4%20and%20%26lt%3B2%20g%5C%2FL%20for%2083%20%2844%25%29%2C%2044%20%2823.4%25%29%2C%208%20%284.2%25%29%20and%201%20%280.53%25%29%20patients%2C%20respectively.%20The%20risk%20of%20infection%20was%20associated%20with%20reduced%20IgG%20levels%20%28multivariate%20Cox%20proportional%20hazards%20hazard%20ratio%20%5BHR%5D%20%3D%200.86%2C%2095%25%20CI%200.75-0.98%2C%20p%20%3D%200.03%29.%20The%20risk%20of%20reduced%20IgG%20level%20%26lt%3B6%20g%5C%2FL%20increased%20with%20age%20%28HR%20%3D%201.36%2C%2095%25%20CI%201.05-1.75%2C%20p%20%3D%200.01%29.%5CnDISCUSSION%3A%20In%20PwMS%20receiving%20RTX%2C%20reduced%20IgG%20level%20was%20frequent%20and%20interacted%20with%20the%20risk%20of%20infection.%22%2C%22date%22%3A%222022-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000001115%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%2C%229L2KHJ5X%22%2C%22NLCL528K%22%5D%2C%22dateModified%22%3A%222025-12-01T09%3A50%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22GAIYH54I%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rico%20et%20al.%22%2C%22parsedDate%22%3A%222021-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BRico%2C%20A.%2C%20Ninove%2C%20L.%2C%20Maarouf%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Durozard%2C%20P.%2C%20Demortiere%2C%20S.%2C%20Saba%20Villarroel%2C%20P.M.%2C%20Amroun%2C%20A.%2C%20Fouri%26%23xE9%3B%2C%20T.%2C%20de%20Lamballerie%2C%20X.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282021%29%20%26%23x201C%3BDetermining%20the%20best%20window%20for%20BNT162b2%20mRNA%20vaccination%20for%20SARS-CoV-2%20in%20patients%20with%20multiple%20sclerosis%20receiving%20anti-CD20%20therapy%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20Journal%20-%20Experimental%2C%20Translational%20and%20Clinical%26lt%3B%5C%2Fi%26gt%3B%2C%207%284%29%2C%20p.%2020552173211062142.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F20552173211062142%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F20552173211062142%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Determining%20the%20best%20window%20for%20BNT162b2%20mRNA%20vaccination%20for%20SARS-CoV-2%20in%20patients%20with%20multiple%20sclerosis%20receiving%20anti-CD20%20therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Ninove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Durozard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%20Mariela%22%2C%22lastName%22%3A%22Saba%20Villarroel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdennour%22%2C%22lastName%22%3A%22Amroun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Toscane%22%2C%22lastName%22%3A%22Fouri%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22de%20Lamballerie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22We%20studied%20the%20serologic%20response%20to%20the%20BNT162b2%20mRNA%20vaccine%20at%20four%20weeks%20after%20the%20second%20dose%20in%20patients%20with%20RRMS%20treated%20with%20rituximab%20with%20extended-interval%20dosing%20%28n%5Cu2009%3D%5Cu200926%29.%20At%20four%20weeks%2C%2073%25%20of%20patients%20were%20seropositive.%20No%20patient%20without%20B%20cells%20at%20the%20first%20dose%20%28n%5Cu2009%3D%5Cu20094%29%20was%20seropositive.%20Four%20of%20seven%20%2857%25%29%20patients%20with%20B-cell%20proportion%20%26gt%3B0%25%20and%20%5Cu22645%25%20were%20seropositive.%20All%20patients%20with%20B-cell%20proportion%20%26gt%3B5%25%20%28n%5Cu2009%3D%5Cu200915%29%20were%20seropositive.%20In%20all%20patients%2C%20quantitative%20ELISA%20measures%20after%20vaccination%20were%20correlated%20with%20B-cell%20counts%20measured%20before%20vaccination.%20In%20patients%20receiving%20rituximab%2C%20seropositivity%20after%20BNT162b2%20mRNA%20vaccination%20emerged%20only%20after%20B-cell%20repopulation.%22%2C%22date%22%3A%222021-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F20552173211062142%22%2C%22ISSN%22%3A%222055-2173%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222022-12-03T05%3A53%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22DXZ6FCYF%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hilezian%20et%20al.%22%2C%22parsedDate%22%3A%222021-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHilezian%2C%20F.%2C%20Maarouf%2C%20A.%2C%20Boutiere%2C%20C.%2C%20Rico%2C%20A.%2C%20Demortiere%2C%20S.%2C%20Kerschen%2C%20P.%2C%20Sene%2C%20T.%2C%20Bensa-Koscher%2C%20C.%2C%20Giannesini%2C%20C.%2C%20Capron%2C%20J.%2C%20Mekinian%2C%20A.%2C%20Camdessanch%26%23xE9%3B%2C%20J.-P.%2C%20Androdias%2C%20G.%2C%20Marignier%2C%20R.%2C%20Collongues%2C%20N.%2C%20Casez%2C%20O.%2C%20Coclitu%2C%20C.%2C%20Vaillant%2C%20M.%2C%20Mathey%2C%20G.%2C%20Ciron%2C%20J.%2C%20Pelletier%2C%20J.%20and%20Audoin%2C%20B.%20%282021%29%20%26%23x201C%3BTNF-%26%23x3B1%3B%20inhibitors%20used%20as%20steroid-sparing%20maintenance%20monotherapy%20in%20parenchymal%20CNS%20sarcoidosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BJournal%20of%20Neurology%2C%20Neurosurgery%20%26amp%3B%20Psychiatry%26lt%3B%5C%2Fi%26gt%3B%2C%2092%288%29%2C%20pp.%20890%26%23x2013%3B896.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2020-325665%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1136%5C%2Fjnnp-2020-325665%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22TNF-%5Cu03b1%20inhibitors%20used%20as%20steroid-sparing%20maintenance%20monotherapy%20in%20parenchymal%20CNS%20sarcoidosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Hilezian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clemence%22%2C%22lastName%22%3A%22Boutiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Demortiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Kerschen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Sene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bensa-Koscher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Giannesini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Capron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arsene%22%2C%22lastName%22%3A%22Mekinian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Camdessanch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Androdias%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Marignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Collongues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Casez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catalina%22%2C%22lastName%22%3A%22Coclitu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Vaillant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Mathey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%22%2C%22lastName%22%3A%22Ciron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22Objective%20To%20assess%20the%20efficacy%20of%20tumour%20necrosis%20factor-%5Cu03b1%20%28TNF-%5Cu03b1%29%20inhibitors%20used%20as%20steroid-sparing%20monotherapy%20in%20central%20nervous%20system%20%28CNS%29%20parenchymal%20sarcoidosis.%5CnMethods%20The%20French%20Multiple%20Sclerosis%20and%20Neuroinflammation%20Centers%20retrospectively%20identified%20patients%20with%20definite%20or%20probable%20CNS%20sarcoidosis%20treated%20with%20TNF-%5Cu03b1%20inhibitors%20as%20steroid-sparing%20monotherapy.%20Only%20patients%20with%20CNS%20parenchymal%20involvement%20demonstrated%20by%20MRI%20and%20imaging%20follow-up%20were%20included.%20The%20primary%20outcome%20was%20the%20minimum%20dose%20of%20steroids%20reached%20that%20was%20not%20associated%20with%20clinical%20or%20imaging%20worsening%20during%20a%20minimum%20of%203%20months%20after%20dosing%20change.%5CnResults%20Of%20the%20identified%2038%20patients%20with%20CNS%20sarcoidosis%20treated%20with%20TNF-%5Cu03b1%20inhibitors%2C%2023%20fulfilled%20all%20criteria%20%2813%20females%29.%20Treatments%20were%20infliximab%20%28n%3D22%29%20or%20adalimumab%20%28n%3D1%29%20for%20a%20median%20%28IQR%29%20of%2024%20%2817%5Cu201340%29%20months.%20At%20treatment%20initiation%2C%20the%20mean%20%28SD%29%20age%20was%2041.5%20%2810.5%29%20years%20and%20median%20%28IQR%29%20disease%20duration%2022%20%2814%5Cu201349.5%29%20months.%20Overall%2C%2060%25%20of%20patients%20received%20other%20immunosuppressive%20agents%20before%20a%20TNF-%5Cu03b1%20inhibitor.%20The%20mean%20%28SD%29%20minimum%20dose%20of%20steroids%20was%2031.5%20%2833%29%20mg%20before%20TNF-%5Cu03b1%20inhibitor%20initiation%20and%206.5%20%285.5%29%20mg%20after%20%28p%3D0.001%29.%20In%20all%2C%2065%25%20of%20patients%20achieved%20steroids%20dosing%20%26lt%3B6%20mg%5C%2Fday%3B%2061%25%20showed%20clinical%20improvement%2C%2030%25%20stability%20and%209%25%20disease%20worsening.%20Imaging%20revealed%20improvement%20in%2074%25%20of%20patients%20and%20stability%20in%2026%25.%5CnConclusion%20TNF-%5Cu03b1%20inhibitors%20can%20greatly%20reduce%20steroids%20dosing%20in%20patients%20with%20CNS%20parenchymal%20sarcoidosis%2C%20even%20refractory.%5CnClassification%20of%20evidence%20This%20study%20provides%20Class%20IV%20evidence%20that%20TNF-%5Cu03b1%20inhibitor%20used%20as%20steroid-sparing%20monotherapy%20is%20effective%20for%20patients%20with%20CNS%20parenchymal%20sarcoidosis.%22%2C%22date%22%3A%222021%5C%2F08%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1136%5C%2Fjnnp-2020-325665%22%2C%22ISSN%22%3A%220022-3050%2C%201468-330X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjnnp.bmj.com%5C%2Fcontent%5C%2F92%5C%2F8%5C%2F890%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%2C%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222025-08-29T07%3A43%3A03Z%22%7D%7D%2C%7B%22key%22%3A%222XRJ3MAZ%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fissolo%20et%20al.%22%2C%22parsedDate%22%3A%222021-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BFissolo%2C%20N.%2C%20Pignolet%2C%20B.%2C%20Rio%2C%20J.%2C%20Vermersch%2C%20P.%2C%20Ruet%2C%20A.%2C%20deS%26%23xE8%3Bze%2C%20J.%2C%20Labauge%2C%20P.%2C%20Vukusic%2C%20S.%2C%20Papeix%2C%20C.%2C%20Martinez-Almoyna%2C%20L.%2C%20Tourbah%2C%20A.%2C%20Clavelou%2C%20P.%2C%20Moreau%2C%20T.%2C%20Pelletier%2C%20J.%2C%20Lebrun-Frenay%2C%20C.%2C%20Bourre%2C%20B.%2C%20Defer%2C%20G.%2C%20Montalban%2C%20X.%2C%20Brassat%2C%20D.%20and%20Comabella%2C%20M.%20%282021%29%20%26%23x201C%3BSerum%20Neurofilament%20Levels%20and%20PML%20Risk%20in%20Patients%20With%20Multiple%20Sclerosis%20Treated%20With%20Natalizumab%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BNeurology%28R%29%20Neuroimmunology%20%26amp%3B%20Neuroinflammation%26lt%3B%5C%2Fi%26gt%3B%2C%208%284%29%2C%20p.%20e1003.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001003%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1212%5C%2FNXI.0000000000001003%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Serum%20Neurofilament%20Levels%20and%20PML%20Risk%20in%20Patients%20With%20Multiple%20Sclerosis%20Treated%20With%20Natalizumab%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicol%5Cu00e1s%22%2C%22lastName%22%3A%22Fissolo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beatrice%22%2C%22lastName%22%3A%22Pignolet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jordi%22%2C%22lastName%22%3A%22Rio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Vermersch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Ruet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22deS%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Labauge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22Vukusic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Papeix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Martinez-Almoyna%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ayman%22%2C%22lastName%22%3A%22Tourbah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Clavelou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lebrun-Frenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Bourre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Defer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Montalban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Brassat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manuel%22%2C%22lastName%22%3A%22Comabella%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20The%20study%20aimed%20to%20assess%20the%20potential%20for%20serum%20neurofilament%20light%20chain%20%28NFL%29%20levels%20to%20predict%20the%20risk%20of%20progressive%20multifocal%20leukoencephalopathy%20%28PML%29%20in%20natalizumab%20%28NTZ%29-treated%20patients%20with%20multiple%20sclerosis%20%28MS%29%20and%20to%20discriminate%20PML%20from%20MS%20relapses.%5CnMETHODS%3A%20NFL%20levels%20were%20measured%20with%20single%20molecule%20array%20%28Simoa%29%20in%204%20cohorts%3A%20%281%29%20a%20prospective%20cohort%20of%20patients%20with%20MS%20who%20developed%20PML%20under%20NTZ%20therapy%20%28pre-PML%29%20and%20non-PML%20NTZ-treated%20patients%20%28NTZ-ctr%29%3B%20%282%29%20a%20cohort%20of%20patients%20whose%20blood%20was%20collected%20during%20PML%3B%20%283%29%20an%20independent%20cohort%20of%20non-PML%20NTZ-treated%20patients%20with%20serum%20NFL%20determinations%20at%202%20years%20%28replication%20cohort%29%3B%20and%20%284%29%20a%20cohort%20of%20patients%20whose%20blood%20was%20collected%20during%20exacerbations.%5CnRESULTS%3A%20Serum%20NFL%20levels%20were%20significantly%20increased%20after%202%20years%20of%20NTZ%20treatment%20in%20pre-PML%20patients%20compared%20with%20NTZ-ctr.%20The%20prognostic%20performance%20of%20serum%20NFL%20levels%20to%20predict%20PML%20development%20at%202%20years%20was%20similar%20in%20the%20NTZ-ctr%20group%20and%20replication%20cohort.%20Serum%20NFL%20levels%20also%20distinguished%20PML%20from%20MS%20relapses%20and%20were%208-fold%20higher%20during%20PML%20compared%20with%20relapses.%5CnCONCLUSIONS%3A%20These%20results%20support%20the%20use%20of%20serum%20NFL%20levels%20in%20clinical%20practice%20to%20identify%20patients%20with%20relapsing-remitting%20MS%20at%20higher%20PML%20risk%20and%20to%20differentiate%20PML%20from%20clinical%20relapses%20in%20NTZ-treated%20patients.%5CnCLASSIFICATION%20OF%20EVIDENCE%3A%20This%20study%20provides%20Class%20I%20evidence%20that%20serum%20NFL%20levels%20can%20identify%20NTZ-treated%20patients%20with%20MS%20who%20will%20develop%20PML%20with%20a%20sensitivity%20of%2067%25%20and%20specificity%20of%2080%25.%22%2C%22date%22%3A%222021-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1212%5C%2FNXI.0000000000001003%22%2C%22ISSN%22%3A%222332-7812%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%22B2M3AZVC%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A02%3A04Z%22%7D%7D%2C%7B%22key%22%3A%229VNZ397A%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Perez%20et%20al.%22%2C%22parsedDate%22%3A%222021-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPerez%2C%20T.%2C%20Rico%2C%20A.%2C%20Bouti%26%23xE8%3Bre%2C%20C.%2C%20Maarouf%2C%20A.%2C%20Roudot%2C%20M.%2C%20Honor%26%23xE9%3B%2C%20S.%2C%20Pelletier%2C%20J.%2C%20Bertault-Peres%2C%20P.%20and%20Audoin%2C%20B.%20%282021%29%20%26%23x201C%3BComparison%20of%20rituximab%20originator%20%28MabThera%26%23xAE%3B%29%20to%20biosimilar%20%28Truxima%26%23xAE%3B%29%20in%20patients%20with%20multiple%20sclerosis%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20%28Houndmills%2C%20Basingstoke%2C%20England%29%26lt%3B%5C%2Fi%26gt%3B%2C%2027%284%29%2C%20pp.%20585%26%23x2013%3B592.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520912170%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520912170%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Comparison%20of%20rituximab%20originator%20%28MabThera%5Cu00ae%29%20to%20biosimilar%20%28Truxima%5Cu00ae%29%20in%20patients%20with%20multiple%20sclerosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Perez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mence%22%2C%22lastName%22%3A%22Bouti%5Cu00e8re%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adil%22%2C%22lastName%22%3A%22Maarouf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marjorie%22%2C%22lastName%22%3A%22Roudot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Honor%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bertault-Peres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Rituximab%26%23039%3Bs%20originator%20MabThera%5Cu00ae%20or%20Rituxan%5Cu00ae%20has%20demonstrated%20high%20efficacy%20in%20multiple%20sclerosis%20%28MS%29.%20Because%20of%20the%20patent%20expiration%2C%20rituximab%20biosimilars%20have%20been%20developed.%20However%2C%20because%20a%20biosimilar%20is%20not%20the%20exact%20copy%20of%20the%20originator%2C%20the%20efficacy%20and%20safety%20of%20a%20biosimilar%20may%20significantly%20differ.%5CnOBJECTIVES%3A%20To%20compare%20the%20efficacy%20and%20safety%20of%20the%20biosimilar%20Truxima%5Cu00ae%20and%20the%20originator%20MabThera%5Cu00ae%20in%20MS.%5CnMETHODS%3A%20Consecutive%20MS%20patients%20receiving%20MabThera%5Cu00ae%20or%20Truxima%5Cu00ae%20were%20prospectively%20followed%20during%201%5Cu2009year%20after%20treatment%20introduction.%20Allocation%20to%20each%20treatment%20depended%20on%20the%20period%20of%20introduction%20and%20not%20the%20physician%26%23039%3Bs%20choice.%20Lymphocyte%20count%2C%20clinical%20and%20magnetic%20resonance%20imaging%20%28MRI%29%20activity%2C%20Expanded%20Disability%20Status%20Scale%20%28EDSS%29%2C%20and%20adverse%20events%20were%20compared.%5CnRESULTS%3A%20In%20total%2C%20105%20and%2040%20patients%20received%20MabThera%5Cu00ae%20and%20Truxima%5Cu00ae%2C%20respectively.%20The%20two%20groups%20did%20not%20differ%20in%20baseline%20characteristics.%20Effect%20on%20CD19%2B%20lymphocytes%20and%20disease%20activity%20were%20similar%20during%20follow-up.%20EDSS%20remained%20stable%2C%20with%20no%20difference%20between%20groups.%20Adverse%20events%20were%20similar%20between%20groups.%5CnCONCLUSION%3A%20The%20efficacy%20and%20safety%20of%20the%20rituximab%20biosimilar%20Truxima%5Cu00ae%20seem%20equivalent%20to%20the%20originator%20MabThera%5Cu00ae%20in%20MS%20patients.%20Truxima%5Cu00ae%20could%20represent%20a%20relatively%20cheap%20and%20safe%20therapeutic%20alternative%20to%20MabThera%5Cu00ae%20and%20could%20improve%20access%20to%20highly%20efficient%20therapy%20for%20MS%20in%20low-%20or%20middle-income%20countries.%22%2C%22date%22%3A%222021-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1177%5C%2F1352458520912170%22%2C%22ISSN%22%3A%221477-0970%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22KJQH9V8M%22%5D%2C%22dateModified%22%3A%222025-03-28T08%3A42%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22PE62KWZP%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Massire%20et%20al.%22%2C%22parsedDate%22%3A%222021-02-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMassire%2C%20A.%2C%20Seiler%2C%20C.%2C%20Troalen%2C%20T.%2C%20Girard%2C%20O.M.%2C%20Lehmann%2C%20P.%2C%20Brun%2C%20G.%2C%20Bartoli%2C%20A.%2C%20Audoin%2C%20B.%2C%20Bartolomei%2C%20F.%2C%20Pelletier%2C%20J.%2C%20Callot%2C%20V.%2C%20Kober%2C%20T.%2C%20Ranjeva%2C%20J.-P.%20and%20Guye%2C%20M.%20%282021%29%20%26%23x201C%3BT1-Based%20Synthetic%20Magnetic%20Resonance%20Contrasts%20Improve%20Multiple%20Sclerosis%20and%20Focal%20Epilepsy%20Imaging%20at%207%20T%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BInvestigative%20Radiology%26lt%3B%5C%2Fi%26gt%3B%2C%2056%282%29%2C%20pp.%20127%26%23x2013%3B133.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FRLI.0000000000000718%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FRLI.0000000000000718%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22T1-Based%20Synthetic%20Magnetic%20Resonance%20Contrasts%20Improve%20Multiple%20Sclerosis%20and%20Focal%20Epilepsy%20Imaging%20at%207%20T%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Massire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Seiler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Troalen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%20M.%22%2C%22lastName%22%3A%22Girard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Lehmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Brun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Axel%22%2C%22lastName%22%3A%22Bartoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Bartolomei%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Callot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobias%22%2C%22lastName%22%3A%22Kober%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20Ultra-high%20field%20magnetic%20resonance%20imaging%20%28MRI%29%20%28%5Cu22657%20T%29%20is%20a%20unique%20opportunity%20to%20improve%20the%20clinical%20diagnosis%20of%20brain%20pathologies%2C%20such%20as%20multiple%20sclerosis%20or%20focal%20epilepsy.%20However%2C%20several%20shortcomings%20of%207%20T%20MRI%2C%20such%20as%20radiofrequency%20field%20inhomogeneities%2C%20could%20degrade%20image%20quality%20and%20hinder%20radiological%20interpretation.%20To%20address%20these%20challenges%2C%20an%20original%20synthetic%20MRI%20method%20based%20on%20T1%20mapping%20achieved%20with%20the%20magnetization-prepared%202%20rapid%20acquisition%20gradient%20echo%20%28MP2RAGE%29%20sequence%20was%20developed.%20The%20radiological%20quality%20of%20on-demand%20T1-based%20contrasts%20generated%20by%20this%20technique%20was%20evaluated%20in%20multiple%20sclerosis%20and%20focal%20epilepsy%20imaging%20at%207%20T.%5CnMATERIALS%20AND%20METHODS%3A%20This%20retrospective%20study%20was%20carried%20out%20from%20October%202017%20to%20September%202019%20and%20included%2021%20patients%20with%20different%20phenotypes%20of%20multiple%20sclerosis%20and%2035%20patients%20with%20focal%20epilepsy%20who%20underwent%20MRI%20brain%20examinations%20using%20a%20whole-body%20investigative%207%20T%20magnetic%20resonance%20system.%20The%20quality%20of%202%20proposed%20synthetic%20contrast%20images%20were%20assessed%20and%20compared%20with%20conventional%20images%20acquired%20at%207%20T%20using%20the%20MP2RAGE%20sequence%20by%204%20radiologists%2C%20evaluating%203%20qualitative%20criteria%3A%20signal%20homogeneity%2C%20contrast%20intensity%2C%20and%20lesion%20visualization.%20Statistical%20analyses%20were%20performed%20on%20reported%20quality%20scores%20using%20Wilcoxon%20rank%20tests%20and%20further%20multiple%20comparisons%20tests.%20Intraobserver%20and%20interobserver%20reliabilities%20were%20calculated%20as%20well.%5CnRESULTS%3A%20Radiological%20quality%20scores%20were%20reported%20higher%20for%20synthetic%20images%20when%20compared%20with%20original%20images%2C%20regardless%20of%20contrast%2C%20pathologies%2C%20or%20raters%20considered%2C%20with%20significant%20differences%20found%20for%20all%203%20criteria%20%28P%20%26lt%3B%200.0001%2C%20Wilcoxon%20rank%20test%29.%20None%20of%20the%204%20radiologists%20ever%20rated%20a%20synthetic%20image%20%26quot%3Bmarkedly%20worse%26quot%3B%20than%20an%20original%20image.%20Synthetic%20images%20were%20rated%20slightly%20less%20satisfying%20for%20only%203%20epileptic%20patients%2C%20without%20precluding%20lesion%20identification.%5CnCONCLUSION%3A%20T1-based%20synthetic%20MRI%20with%20the%20MP2RAGE%20sequence%20provided%20on-demand%20contrasts%20and%20high-quality%20images%20to%20the%20radiologist%2C%20facilitating%20lesion%20visualization%20in%20multiple%20sclerosis%20and%20focal%20epilepsy%2C%20while%20reducing%20the%20magnetic%20resonance%20examination%20total%20duration%20by%20removing%20an%20additional%20sequence.%22%2C%22date%22%3A%222021-02-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FRLI.0000000000000718%22%2C%22ISSN%22%3A%221536-0210%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%2274RX9758%22%2C%22ZFC2Q648%22%2C%226GBQDAVI%22%2C%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%22HHEPZHEJ%22%2C%226KPLZTET%22%2C%22XTA6KS7L%22%2C%22CXAMISN8%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22ZX3JGUA8%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Luciani%20et%20al.%22%2C%22parsedDate%22%3A%222021%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLuciani%2C%20L.%2C%20Ninove%2C%20L.%2C%20Zandotti%2C%20C.%2C%20Chalvignac%2C%20V.%2C%20Lagier%2C%20D.%2C%20Baume%2C%20J.%2C%20M%26%23xE9%3Blade%2C%20J.%2C%20Piorkowski%2C%20G.%2C%20Coutard%2C%20B.%2C%20Lepidi%2C%20H.%2C%20Pelletier%2C%20J.%2C%20Audoin%2C%20B.%2C%20Rico-Lamy%2C%20A.%20and%20Nougair%26%23xE8%3Bde%2C%20A.%20%282021%29%20%26%23x201C%3BFatal%20underhanded%20chronic%20enterovirus%20infection%20associated%20with%20anti-CD20%20monotherapy%20for%20central%20nervous%20system%20demyelinating%20disease%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BMultiple%20Sclerosis%20Journal%26lt%3B%5C%2Fi%26gt%3B%2C%2027%282%29%2C%20pp.%20320%26%23x2013%3B323.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-ItemURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520923978%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520923978%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Fatal%20underhanded%20chronic%20enterovirus%20infection%20associated%20with%20anti-CD20%20monotherapy%20for%20central%20nervous%20system%20demyelinating%20disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9a%22%2C%22lastName%22%3A%22Luciani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Ninove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Zandotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Chalvignac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Lagier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Baume%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22M%5Cu00e9lade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9raldine%22%2C%22lastName%22%3A%22Piorkowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Coutard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hubert%22%2C%22lastName%22%3A%22Lepidi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Audoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Rico-Lamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Nougair%5Cu00e8de%22%7D%5D%2C%22abstractNote%22%3A%22We%20report%20a%20fatal%20case%20of%20coxsackievirus%20B4%20chronic%20infection%20in%20a%2030-year-old%20woman%20with%20a%20diagnosis%20of%20myelin%20oligodendrocyte%20glycoprotein%20antibody-associated%20disorder%20controlled%20by%20rituximab%20monotherapy%20for%203%5Cu2009years.%20Initially%20presenting%20as%20self-limited%20meningitis%2C%20the%20infection%20remained%20silent%20for%208%5Cu2009months%20before%20the%20sudden%20onset%20of%20fulminant%20myocarditis.%20Analysis%20of%20the%20complete%20genome%20showed%20that%20the%20same%20virus%20was%20responsible%20for%20both%20episodes.%22%2C%22date%22%3A%22f%5Cu00e9vrier%201%2C%202021%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1177%5C%2F1352458520923978%22%2C%22ISSN%22%3A%221352-4585%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1177%5C%2F1352458520923978%22%2C%22collections%22%3A%5B%22B4EWFM7E%22%2C%226KPLZTET%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A54Z%22%7D%7D%2C%7B%22key%22%3A%2248D6AR6P%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pelletier%20et%20al.%22%2C%22parsedDate%22%3A%222020-11-11%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPelletier%2C%20L.%2C%20Petiot%2C%20A.%2C%20Brocard%2C%20J.%2C%20Giannesini%2C%20B.%2C%20Giovannini%2C%20D.%2C%20Sanchez%2C%20C.%2C%20Travard%2C%20L.%2C%20Chivet%2C%20M.%2C%20Beaufils%2C%20M.%2C%20Kutchukian%2C%20C.%2C%20Bendahan%2C%20D.%2C%20Metzger%2C%20D.%2C%20Franzini%20Armstrong%2C%20C.%2C%20Romero%2C%20N.B.%2C%20Rendu%2C%20J.%2C%20Jacquemond%2C%20V.%2C%20Faur%26%23xE9%3B%2C%20J.%20and%20Marty%2C%20I.%20%282020%29%20%26%23x201C%3BIn%20vivo%20RyR1%20reduction%20in%20muscle%20triggers%20a%20core-like%20myopathy%2C%26%23x201D%3B%20%26lt%3Bi%26gt%3BActa%20Neuropathologica%20Communications%26lt%3B%5C%2Fi%26gt%3B%2C%208%281%29%2C%20p.%20192.%20Available%20at%3A%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-020-01068-4%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs40478-020-01068-4%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22In%20vivo%20RyR1%20reduction%20in%20muscle%20triggers%20a%20core-like%20myopathy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Petiot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Brocard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benoit%22%2C%22lastName%22%3A%22Giannesini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Giovannini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Colline%22%2C%22lastName%22%3A%22Sanchez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lauriane%22%2C%22lastName%22%3A%22Travard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Chivet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Beaufils%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Candice%22%2C%22lastName%22%3A%22Kutchukian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Bendahan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Metzger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clara%22%2C%22lastName%22%3A%22Franzini%20Armstrong%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norma%20B.%22%2C%22lastName%22%3A%22Romero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Rendu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jacquemond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Faur%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Marty%22%7D%5D%2C%22abstractNote%22%3A%22Mutations%20in%20the%20RYR1%20gene%2C%20encoding%20the%20skeletal%20muscle%20calcium%20channel%20RyR1%2C%20lead%20to%20congenital%20myopathies%2C%20through%20expression%20of%20a%20channel%20with%20abnormal%20permeability%20and%5C%2For%20in%20reduced%20amount%2C%20but%20the%20direct%20functional%20whole%20organism%20consequences%20of%20exclusive%20reduction%20in%20RyR1%20amount%20have%20never%20been%20studied.%20We%20have%20developed%20and%20characterized%20a%20mouse%20model%20with%20inducible%20muscle%20specific%20RYR1%20deletion.%20Tamoxifen-induced%20recombination%20in%20the%20RYR1%20gene%20at%20adult%20age%20resulted%20in%20a%20progressive%20reduction%20in%20the%20protein%20amount%20reaching%20a%20stable%20level%20of%2050%25%20of%20the%20initial%20amount%2C%20and%20was%20associated%20with%20a%20progressive%20muscle%20weakness%20and%20atrophy.%20Measurement%20of%20calcium%20fluxes%20in%20isolated%20muscle%20fibers%20demonstrated%20a%20reduction%20in%20the%20amplitude%20of%20RyR1-related%20calcium%20release%20mirroring%20the%20reduction%20in%20the%20protein%20amount.%20Alterations%20in%20the%20muscle%20structure%20were%20observed%2C%20with%20fibers%20atrophy%2C%20abnormal%20mitochondria%20distribution%20and%20membrane%20remodeling.%20An%20increase%20in%20the%20expression%20level%20of%20many%20proteins%20was%20observed%2C%20as%20well%20as%20an%20inhibition%20of%20the%20autophagy%20process.%20This%20model%20demonstrates%20that%20RyR1%20reduction%20is%20sufficient%20to%20recapitulate%20most%20features%20of%20Central%20Core%20Disease%2C%20and%20accordingly%20similar%20alterations%20were%20observed%20in%20muscle%20biopsies%20from%20Dusty%20Core%20Disease%20patients%20%28a%20subtype%20of%20Central%20Core%20Disease%29%2C%20pointing%20to%20common%20pathophysiological%20mechanisms%20related%20to%20RyR1%20reduction.%22%2C%22date%22%3A%22Nov%2011%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs40478-020-01068-4%22%2C%22ISSN%22%3A%222051-5960%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22NW6SZQBR%22%2C%226DHTGFMA%22%5D%2C%22dateModified%22%3A%222024-11-26T16%3A01%3A05Z%22%7D%7D%2C%7B%22key%22%3A%227HR8NUPV%22%2C%22library%22%3A%7B%22id%22%3A180164%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Soustelle%20et%20al.%22%2C%22parsedDate%22%3A%222020-09-13%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSoustelle%2C%20L.%2C%20Lamy%2C%20J.%2C%20Le%20Troter%2C%20A.%2C%20Hertanu%2C%20A.%2C%20Guye%2C%20M.%2C%20Ranjeva%2C%20J.-P.%2C%20Varma%2C%20G.%2C%20Alsop%2C%20D.C.%2C%20Pelletier%2C%20J.%2C%20Girard%2C%20O.%20and%20Duhamel%2C%20G.%20%282020%29%20%26lt%3Bi%26gt%3BA%20Motion%20Correction%20Strategy%20for%20Multi-Contrast%20based%203D%20parametric%20imaging%3A%20Application%20to%20Inhomogeneous%20Magnetization%20Transfer%20%28ihMT%29%26lt%3B%5C%2Fi%26gt%3B.%20preprint.%20Neuroscience.%20Available%20at%3A%20https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1101%5C%2F2020.09.11.292649.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22report%22%2C%22title%22%3A%22A%20Motion%20Correction%20Strategy%20for%20Multi-Contrast%20based%203D%20parametric%20imaging%3A%20Application%20to%20Inhomogeneous%20Magnetization%20Transfer%20%28ihMT%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%22%2C%22lastName%22%3A%22Soustelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Lamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Le%20Troter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreea%22%2C%22lastName%22%3A%22Hertanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Guye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Ranjeva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gopal%22%2C%22lastName%22%3A%22Varma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20C.%22%2C%22lastName%22%3A%22Alsop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Girard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Duhamel%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Purpose%5Cn%20%20%20%20%20%20%20%20%20%20%20%20To%20propose%20an%20efficient%20retrospective%20image-based%20method%20for%20motion%20correction%20of%20multi-contrast%20acquisitions%20with%20a%20low%20number%20of%20available%20images%20%28MC-MoCo%29%20and%20evaluate%20its%20use%20in%203D%20inhomogeneous%20Magnetization%20Transfer%20%28ihMT%29%20experiments%20in%20the%20human%20brain.%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Methods%5Cn%20%20%20%20%20%20%20%20%20%20%20%20A%20framework%20for%20motion%20correction%2C%20including%20image%20pre-processing%20enhancement%20and%20rigid%20registration%20to%20an%20iteratively%20improved%20target%20image%2C%20was%20developed.%20The%20proposed%20method%20was%20compared%20to%20Motion%20Correction%20with%20FMRIB%5Cu2019s%20Linear%20Image%20Registration%20Tool%20%28MCFLIRT%29%20function%20in%20FSL%20over%2013%20subjects.%20Native%20%28pre-correction%29%20and%20residual%20%28post-correction%29%20motions%20were%20evaluated%20by%20means%20of%20markers%20positioned%20at%20well-defined%20anatomical%20regions%20over%20each%20image.%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Results%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Both%20motion%20correction%20strategies%20significantly%20reduced%20inter-image%20misalignment%2C%20and%20the%20MC-MoCo%20method%20yielded%20significantly%20better%20results%20than%20MCFLIRT.%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Conclusion%5Cn%20%20%20%20%20%20%20%20%20%20%20%20MC-MoCo%20is%20a%20high-performance%20method%20for%20motion%20correction%20of%20multi-contrast%20volumes%20as%20in%203D%20ihMT%20imaging.%22%2C%22reportNumber%22%3A%22%22%2C%22reportType%22%3A%22preprint%22%2C%22institution%22%3A%22Neuroscience%22%2C%22date%22%3A%222020-09-13%22%2C%22language%22%3A%22en%22%2C%22url%22%3A%22http%3A%5C%2F%5C%2Fbiorxiv.org%5C%2Flookup%5C%2Fdoi%5C%2F10.1101%5C%2F2020.09.11.292649%22%2C%22collections%22%3A%5B%22UP3H3ICX%22%2C%22B4EWFM7E%22%2C%22XTA6KS7L%22%5D%2C%22dateModified%22%3A%222022-03-09T07%3A09%3A34Z%22%7D%7D%5D%7D
Stellmann, J.-P., Maarouf, A., Nicolescu, M., Boutiere, C., Rico, A., Zaaraoui, W., Guye, M., Pelletier, J., Ranjeva, J.-P. and Audoin, B. (2025) “Early structural hub disruption leads to premature functional adaption in multiple sclerosis,” Brain Structure & Function, 230(9), p. 172. Available at: https://doi.org/10.1007/s00429-025-03023-2.
Wilson, S., Leray, E., Calocer, F., Rollot, F., Fauvernier, M., Remontet, L., Launay, L., Vukusic, S., Le Page, E., Debouverie, M., Ciron, J., Ruet, A., Seze, J.D., Zephir, H., Moreau, T., Laplaud, D.-A., Lebrun-Frenay, C., Clavelou, P., Labauge, P., Berger, E., Pelletier, J., Heinzlef, O., Thouvenot, E., Camdessanché, J.P., Arnaud, C., Derache, N., Branger, P., Guittet, L., Defer, G. and Dejardin, O. (2025) “Influence of geographical accessibility to specialist and primary care givers on excess mortality of multiple sclerosis patients in France,” BMC neurology, 25(1), p. 441. Available at: https://doi.org/10.1186/s12883-025-04459-z.
Perriguey, M., Rigollet, C., Freeman, S.A., Graille-Avy, L., Lafontaine, J.-C., Lemarchant, B., Alberto, T., Demortière, S., Boutiere, C., Rico, A., Hilézian, F., Durozard, P., Pelletier, J., Maarouf, A., Zéphir, H. and Audoin, B. (2025) “Prevalence of hypogammaglobulinemia after non-anti-CD20 therapies and impact of switching to rituximab/ocrelizumab in multiple sclerosis,” Neurotherapeutics, 22(6). Available at: https://doi.org/10.1016/j.neurot.2025.e00760.
Melka, M., Rotard, L., Benstaali, C., Brocard, J., Giannesini, B., Jouve, F., Pelletier, L., Fauré, J., Rendu, J., Jacquemond, V. and Marty, I. (2025) “Limited pre-clinical relevance of the heterozygous RYR1-I4895T/+ mouse model due to its mild phenotype,” Journal of Neuromuscular Diseases, p. 22143602251339354. Available at: https://doi.org/10.1177/22143602251339354.
Gavoille, A., Nourredine, M., Rollot, F., Casey, R., Mathey, G., Kerbrat, A., Ciron, J., De Sèze, J., Stankoff, B., Maillart, E., Ruet, A., Labauge, P., Kwiatkowski, A., Zephir, H., Papeix, C., Defer, G., Lebrun-Frenay, C., Moreau, T., Laplaud, D.-A., Berger, E., Clavelou, P., Thouvenot, E., Heinzlef, O., Pelletier, J., Al Khedr, A., Casez, O., Bourre, B., Wahab, A., Magy, L., Moulin, S., Camdessanché, J.-P., Doghri, I., Sarov, M., Hankiewicz, K., Pottier, C., Dos Santos, A., Manchon, E., Tchikviladze, M., Rabilloud, M., Subtil, F. and Vukusic, S. (2025) “Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis,” Journal of Neurology, Neurosurgery, and Psychiatry, p. jnnp-2025-336762. Available at: https://doi.org/10.1136/jnnp-2025-336762.
Gavoille, A., Leray, E., Marignier, R., Rollot, F., Casey, R., Mathey, G., Michel, L., De Seze, J., Ciron, J., Ruet, A., Maillart, E., Labauge, P., Zephir, H., Laplaud, D.A., Papeix, C., Defer, G., Moreau, T., Berger, E., Dubessy, A.-L., Clavelou, P., Thouvenot, E., Heinzlef, O., Pelletier, J., Al Khedr, A., Casez, O., Bourre, B., Wahab, A., Magy, L., Camdessanche, J.-P., Doghri, I., Moulin, S., Labeyrie, C., Hankiewicz, K., Dos Santos, A., Pottier, C., Manchon, E., Tchikviladze, M., Lebrun-Frenay, C., Vukusic, S. and OFSEP investigators (2025) “Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis,” Neurology, 105(4), p. e213907. Available at: https://doi.org/10.1212/WNL.0000000000213907.
Robin, C., Rollot, F., Lefort, M., Casey, R., Vukusic, S., Mathey, G., Ciron, J., De Seze, J., Stankoff, B., Maillart, E., Ruet, A., Labauge, P.M., Kwiatkowski, A., Zephir, H., Papeix, C., Defer, G., Lebrun-Frenay, C., Moreau, T., Laplaud, D.A., Berger, E., Clavelou, P., Thouvenot, E., Heinzlef, O., Pelletier, J., Casez, O., Bourre, B., Wahab, A., Magy, L., Moulin, S., Camdessanche, J.-P., Doghri, I., Sarov, M., Hankiewicz, K., Pottier, C., Dos Santos, A., Manchon, E., Tchikviladze, M., Nifle, C., Kerbrat, A., Edan, G., Le Page, E., Michel, L. and as the OFSEP Investigators (2025) “Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis,” Neurology, 105(3), p. e213744. Available at: https://doi.org/10.1212/WNL.0000000000213744.
Gavoille, A., Rollot, F., Casey, R., Mathey, G., Le Page, E., Ciron, J., De Sèze, J., Ruet, A., Maillart, E., Labauge, P., Zephir, H., Kwiatkowski, A., Papeix, C., Defer, G., Lebrun-Frenay, C., Moreau, T., Laplaud, D.-A., Berger, E., Dubessy, A.-L., Clavelou, P., Thouvenot, E., Heinzlef, O., Pelletier, J., Al-Khedr, A., Casez, O., Bourre, B., Wahab, A., Magy, L., Moulin, S., Camdessanché, J.-P., Doghri, I., Sarov-Riviere, M., Hankiewicz, K., Pottier, C., Dos Santos, A., Nifle, C., Subtil, F., Vukusic, S. and OFSEP Investigators (2025) “Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis,” JAMA neurology [Preprint]. Available at: https://doi.org/10.1001/jamaneurol.2025.2550.
Demortiere, S., Stolowy, N., Perriguey, M., Boutiere, C., Rico, A., Hilezian, F., Ndjomo-Ndjomo, B.-R., Durozard, P., Stellmann, J.-P., Marignier, R., Boucraut, J., Pelletier, J., Maarouf, A. and Audoin, B. (2025) “Diagnostic Utility of Kappa Free Light Chain Index in Adults With Inaugural Optic Neuritis,” Neurology(R) Neuroimmunology & Neuroinflammation, 12(3), p. e200386. Available at: https://doi.org/10.1212/NXI.0000000000200386.
Cohen, M., Rollot, F., Debouverie, M., Zephir, H., Vukusic, S., De Seze, J., Labauge, P., Landes-Chateau, C., Mondot, L., Levraut, M., Ruet, A., Berger, E., Laplaud, D., Ciron, J., Bourre, B., Le Page, E., Papeix, C., Thouvenot, E., Al Khedr, A., Stankoff, B., Pelletier, J., Maillart, E., Casez, O., Moreau, T., Defer, G., Clavelou, P., Cabre, P., Moulin, S., Neau, J.P., Zedet, M., Hankiewicz, K., Doghri, I., Nasr, H.B., Pottier, C., Magy, L., Boulos, D.D., Heinzlef, O., Camdessanche, J.P., Coustans, M., Nifle, C., Brassat, D., Casey, R., Lebrun-Frenay, C. and OFSEP and SFSEP study groups (2025) “Secondary progression activity monitoring in MS despite an early highly active treatment the SPAM study,” European Journal of Neurology, 32(5), p. e16583. Available at: https://doi.org/10.1111/ene.16583.
Hong, J., Gaubert, M., Lefort, M., Ferré, J.C., Le Page, E., Michel, L., Labauge, P., Pelletier, J., de Seze, J., Durand-Dubief, F., Cotton, F., Edan, G., Bannier, E., Combès, B. and Kerbrat, A. (2025) “Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up,” Journal of Neurology, 272(4), p. 316. Available at: https://doi.org/10.1007/s00415-025-13068-2.
Guttieres, L., Vannelli, L., Demortiere, S., Perriguey, M., Elziere, M., Durozard, P., Boutiere, C., Rico, A., Hilezian, F., Stellmann, J.-P., Pelletier, J., Maarouf, A., Stolowy, N. and Audoin, B. (2025) “Fluorescein Angiography as a Surrogate Marker of Disease Activity in Susac Syndrome,” Neurology(R) Neuroimmunology & Neuroinflammation, 12(2), p. e200379. Available at: https://doi.org/10.1212/NXI.0000000000200379.
Mainguy, M., Casey, R., Vukusic, S., Lebrun-Frenay, C., Berger, E., Kerbrat, A., Al Khedr, A., Bourre, B., Ciron, J., Clavelou, P., De Seze, J., Defer, G., Doghri, I., Dos Santos, A., Hankiewicz, K., Labauge, P.M., Le Page, E., Magy, L., Maillart, E., Manchon, E., Michel, L., Moreau, T., Moulin, S., Pelletier, J., Pottier, C., Ruet, A., Sarov, M., Stankoff, B., Thouvenot, E., Wahab, A., Zephir, H., Leray, E. and Laplaud, D.A. (2025) “Assessing the Risk of Relapse After In Vitro Fertilization in Women With Multiple Sclerosis,” Neurology(R) Neuroimmunology & Neuroinflammation, 12(2), p. e200371. Available at: https://doi.org/10.1212/NXI.0000000000200371.
de Sèze, J., Labauge, P., Liblau, R., Martinez, M., Moreau, T., Suchet, L., Vermersch, P., Vukusic, S., Mathey, G., Michel, L., Ciron, J., Ruet, A., Maillart, E., Zephir, H., Papeix, C., Defer, G., Cohen, M., Laplaud, D.A., Berger, E., Clavelou, P., Thouvenot, E., Heinzlef, O., Pelletier, J., Giannesini, C., Casez, O., Bourre, B., Wahab, A., Magy, L., Camdessanché, J.-P., Doghri, I., Labeyrie, C., Hankiewicz, K., Neau, J.-P., Pottier, C., Dobay, P., Li, H., Levin, S., Gros, M., Ruiz, M. and Rollot, F. (2025) “LymphoTEC: a Retrospective Real-World Study on Lymphocyte Reconstitution After Lymphopenia in Patients with Multiple Sclerosis Treated with Dimethyl Fumarate in France,” Advances in Therapy [Preprint]. Available at: https://doi.org/10.1007/s12325-024-03092-5.
Durozard, P., Maarouf, A., Zaaraoui, W., Stellmann, J.-P., Boutière, C., Rico, A., Demortière, S., Guye, M., Le Troter, A., Dary, H., Ranjeva, J.-P., Audoin, B. and Pelletier, J. (2024) “Cortical Lesions as an Early Hallmark of Multiple Sclerosis: Visualization by 7 T MRI,” Investigative Radiology, 59(11), p. 747. Available at: https://doi.org/10.1097/RLI.0000000000001082.
Hay, M., Rollot, F., Casey, R., Kerbrat, A., Edan, G., Mathey, G., Labauge, P., De Sèze, J., Vukusic, S., Laplaud, D.-A., Papeix, C., Moreau, T., Thouvenot, E., Defer, G., Lebrun-Frénay, C., Ciron, J., Berger, E., Stankoff, B., Clavelou, P., Maillart, E., Heinzlef, O., Zéphir, H., Ruet, A., Casez, O., Moulin, S., Al-Khedr, A., Bourre, B., Pelletier, J., Magy, L., Neau, J.-P., Camdessanché, J.-P., Doghri, I., Wahab, A., Tchikviladzé, M., Labeyrie, C., Hankiewicz, K., Le Page, E., Michel, L. and as the OFSEP Investigators (2024) “Anti-CD20 Therapies in Drug-Naive Patients With Primary Progressive Multiple Sclerosis: A Multicenter Real-Life Study,” Neurology, 103(8), p. e209886. Available at: https://doi.org/10.1212/WNL.0000000000209886.
Maarouf, A., Stellmann, J.P., Rico, A., Boutiere, C., Demortiere, S., Durozard, P., Zaaraoui, W., Ranjeva, J.-P., Pelletier, J. and Audoin, B. (2024) “Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis,” Journal of Neurology, Neurosurgery, and Psychiatry, p. jnnp-2024-333597. Available at: https://doi.org/10.1136/jnnp-2024-333597.
Graille-Avy, L., Boutiere, C., Rigollet, C., Perriguey, M., Rico, A., Demortiere, S., Durozard, P., Hilezian, F., Vely, F., Bertault-Peres, P., Pelletier, J., Maarouf, A. and Audoin, B. (2024) “Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis,” Neurology(R) Neuroimmunology & Neuroinflammation, 11(3), p. e200231. Available at: https://doi.org/10.1212/NXI.0000000000200231.
Demortiere, S., Joubert, B., Benaiteau, M., Hilezian, F., Boutiere, C., Rico, A., Stolowy, N., Dubois, V., Audoin, B., Maarouf, A. and Pelletier, J. (2024) “Anti-IgLON5 Disease With Inaugural Bilateral Neuropapillitis,” Neurology, 102(8), p. e209284. Available at: https://doi.org/10.1212/WNL.0000000000209284.
Cruz, E.S., Fortanier, E., Hilezian, F., Maarouf, A., Boutière, C., Demortière, S., Rico, A., Delmont, E., Pelletier, J., Attarian, S. and Audoin, B. (2024) “Factors affecting the topography of nitrous oxide-induced neurological complications,” European Journal of Neurology, p. e16291. Available at: https://doi.org/10.1111/ene.16291.
Jouvenot, G., Courbon, G., Lefort, M., Rollot, F., Casey, R., Le Page, E., Michel, L., Edan, G., de Seze, J., Kremer, L., Bigaut, K., Vukusic, S., Mathey, G., Ciron, J., Ruet, A., Maillart, E., Labauge, P., Zephir, H., Papeix, C., Defer, G., Lebrun-Frenay, C., Moreau, T., Laplaud, D.A., Berger, E., Stankoff, B., Clavelou, P., Thouvenot, E., Heinzlef, O., Pelletier, J., Al-Khedr, A., Casez, O., Bourre, B., Cabre, P., Wahab, A., Magy, L., Camdessanché, J.-P., Doghri, I., Moulin, S., Ben-Nasr, H., Labeyrie, C., Hankiewicz, K., Neau, J.-P., Pottier, C., Nifle, C., Collongues, N., Kerbrat, A. and OFSEP Investigators (2024) “High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS,” JAMA neurology, p. e240395. Available at: https://doi.org/10.1001/jamaneurol.2024.0395.
Benallegue, N., Rollot, F., Wiertlewski, S., Casey, R., Debouverie, M., Kerbrat, A., De Seze, J., Ciron, J., Ruet, A., Labauge, P., Maillart, E., Zephir, H., Papeix, C., Defer, G., Lebrun-Frenay, C., Moreau, T., Berger, E., Stankoff, B., Clavelou, P., Heinzlef, O., Pelletier, J., Thouvenot, E., Al Khedr, A., Bourre, B., Casez, O., Cabre, P., Wahab, A., Magy, L., Vukusic, S., Laplaud, D.-A. and OFSEP (Observatoire Français de la Sclérose en Plaques) Investigators (2024) “Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis,” JAMA Neurology, 81(3), pp. 273–282. Available at: https://doi.org/10.1001/jamaneurol.2023.5566.
Androdias, G., Noroy, L., Psimaras, D., Birzu, C., Pelletier, J., Beigneux, Y., Branger, P., Ciron, J., Dananchet, Y., Depaz, R., Froment Tilikete, C., Gignoux, L., Grosset-Janin, C., Joubert, B., Kerschen, P., Kwiatkowski, A., Lebrun-Frenay, C., Maillart, E., Maureille, A., Nicolas, P., Roux, T., Marignier, R., Vukusic, S. and as the ICI-SEP Study Group (2024) “Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis,” Neurology(R) Neuroimmunology & Neuroinflammation, 11(2), p. e200202. Available at: https://doi.org/10.1212/NXI.0000000000200202.
Jeantin, L., Januel, E., Labauge, P., Maillart, E., de Seze, J., Zéphir, H., Pelletier, J., Kerschen, P., Biotti, D., Heinzlef, O., Guilloton, L., Bensa, C., Théaudin, M., Vukusic, S., Casez, O., Maurousset, A., Laplaud, D., Berger, E., Lebrun-Frenay, C., Bourre, B., Branger, P., Stankoff, B., Clavelou, P., Thouvenot, E., Manchon, E., Moreau, T., Sellal, F., Zedet, M., Papeix, C. and Louapre, C. (2024) “COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022,” Multiple Sclerosis (Houndmills, Basingstoke, England), p. 13524585231218149. Available at: https://doi.org/10.1177/13524585231218149.
Venet, M., Lepine, A., Maarouf, A., Biotti, D., Boutiere, C., Casez, O., Cohen, M., Durozard, P., Demortière, S., Giorgi, L., Maillart, E., Mathey, G., Mazzola, L., Rico, A., Camdessanche, J.-P., Deiva, K., Pelletier, J. and Audoin, B. (2024) “Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis,” Multiple Sclerosis (Houndmills, Basingstoke, England), p. 13524585231223069. Available at: https://doi.org/10.1177/13524585231223069.
Soustelle, L., Mchinda, S., Hertanu, A., Gherib, S., Pini, L., Guye, M., Ranjeva, J.-P., Varma, G., Alsop, D.C., Pelletier, J., Girard, O.M. and Duhamel, G. (2024) “Inhomogeneous magnetization transfer (ihMT) imaging reveals variable recovery profiles of active MS lesions according to size and localization,” Imaging Neuroscience (Cambridge, Mass.), 2, p. imag–2–00235. Available at: https://doi.org/10.1162/imag_a_00235.
Rollot, F., Uhry, Z., Dantony, E., Vukusic, S., Debouverie, M., Le Page, E., Ciron, J., Ruet, A., De Sèze, J., Zéphir, H., Labauge, P., Defer, G., Lebrun-Frenay, C., Moreau, T., Laplaud, D.A., Berger, E., Clavelou, P., Pelletier, J., Thouvenot, E., Heinzlef, O., Camdessanche, J.-P., Fauvernier, M., Remontet, L. and Leray, E. (2023) “Comparison of 2 Methods for Estimating Multiple Sclerosis–Related Mortality,” Neurology, 101(24), pp. e2483–e2496. Available at: https://doi.org/10.1212/WNL.0000000000207925.
Claverie, R., Perriguey, M., Rico, A., Boutiere, C., Demortiere, S., Durozard, P., Hilezian, F., Dubrou, C., Vely, F., Pelletier, J., Audoin, B. and Maarouf, A. (2023) “Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis: Time to Rethink Dosing?,” Neurology(R) Neuroimmunology & Neuroinflammation, 10(5), p. e200152. Available at: https://doi.org/10.1212/NXI.0000000000200152.
Testud, B., Fabiani, N., Demortière, S., Mchinda, S., Medina, N.L., Pelletier, J., Guye, M., Audoin, B., Stellmann, J.P. and Callot, V. (2023) “Contribution of the MP2RAGE 7T Sequence in MS Lesions of the Cervical Spinal Cord,” AJNR. American journal of neuroradiology, 44(9), pp. 1101–1107. Available at: https://doi.org/10.3174/ajnr.A7964.
Demortiere, S., Maarouf, A., Rico, A., Boutiere, C., Hilezian, F., Durozard, P., Pelletier, J. and Audoin, B. (2023) “Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception,” Neurology(R) Neuroimmunology & Neuroinflammation, 10(5), p. e200161. Available at: https://doi.org/10.1212/NXI.0000000000200161.
Heim, X., Hubert, A.M., Raouak, I., Nzepa, A.C., Mege, J.-L., Delmont, E., Attarian, S., Koric, L., Pelletier, J., Brodovitch, A. and Boucraut, J. (2023) “Validation of ELISA assays for the calculation of FLC indices for the diagnosis of intrathecal immunoglobulin synthesis,” Clinical Chemistry and Laboratory Medicine (CCLM), 61(9), pp. 1623–1629. Available at: https://doi.org/10.1515/cclm-2022-0602.
Brocard, G., Casey, R., Dufay, N., Marignier, R., Michel, L., Hisbergues, M., Ayrignac, X., Lehmann, S., Thouvenot, E., Gallot, G., Collongues, N., Herpe, Y.-E., Lebrun-Frenay, C., Cotton, F., De Sèze, J., Guillemin, F., Moreau, T., Pelletier, J., Stankoff, B., Vukusic, S., Zephir, H., Laplaud, D. and OFSEP investigators and biobanks (2023) “The biological sample collection of the OFSEP French MS registry: An essential tool dedicated to researchers,” Multiple Sclerosis and Related Disorders, 77, p. 104872. Available at: https://doi.org/10.1016/j.msard.2023.104872.
Gavoille, A., Rollot, F., Casey, R., Debouverie, M., Page, E.L., Ciron, J., Seze, J.D., Ruet, A., Maillart, E., Labauge, P., Zephir, H., Papeix, C., Defer, G., Lebrun-Frenay, C., Moreau, T., Laplaud, D.A., Berger, E., Stankoff, B., Clavelou, P., Thouvenot, E., Heinzlef, O., Pelletier, J., Khedr, A.A., Casez, O., Bourre, B., Cabre, P., Wahab, A., Magy, L., Camdessanche, J.-P., Maurousset, A., Moulin, S., Ben, N.H., Boulos, D.D., Hankiewicz, K., Neau, J.-P., Pottier, C., Nifle, C., Rabilloud, M., Subtil, F., Vukusic, S. and Investigators, on behalf of O.F. de la S. en P. (OFSEP) (2023) “Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference,” Neurology, 100(12), pp. e1296–e1308. Available at: https://doi.org/10.1212/WNL.0000000000206774.
Sabathé, C., Casey, R., Vukusic, S., Leray, E., Mathey, G., De Sèze, J., Ciron, J., Wiertlewski, S., Ruet, A., Pelletier, J., Zéphir, H., Michel, L., Lebrun-Frenay, C., Moisset, X., Thouvenot, E., Camdessanché, J.-P., Bakchine, S., Stankoff, B., Al Khedr, A., Cabre, P., Maillart, E., Berger, E., Heinzlef, O., Hankiewicz, K., Moreau, T., Gout, O., Bourre, B., Wahab, A., Labauge, P., Montcuquet, A., Defer, G., Maurousset, A., Maubeuge, N., Dimitri Boulos, D., Ben Nasr, H., Nifle, C., Casez, O., Laplaud, D.-A. and Foucher, Y. (2023) “Improving the decision to switch from first- to second-line therapy in multiple sclerosis: A dynamic scoring system,” Multiple Sclerosis Journal, 29(2), pp. 236–247. Available at: https://doi.org/10.1177/13524585221139156.
Wilson, S., Calocer, F., Rollot, F., Fauvernier, M., Remontet, L., Tron, L., Vukusic, S., Le Page, E., Debouverie, M., Ciron, J., Ruet, A., De Sèze, J., Zephir, H., Moreau, T., Lebrun-Frénay, C., Laplaud, D.-A., Clavelou, P., Labauge, P., Berger, E., Pelletier, J., Heinzlef, O., Thouvenot, E., Camdessanché, J.P., Leray, E., Dejardin, O. and Defer, G. (2023) “Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study,” The Lancet Regional Health. Europe, 24, p. 100542. Available at: https://doi.org/10.1016/j.lanepe.2022.100542.
Levraut, M., Laurent-Chabalier, S., Ayrignac, X., Bigaut, K., Rival, M., Squalli, S., Zéphir, H., Alberto, T., Pekar, J.-D., Ciron, J., Biotti, D., Puissant-Lubrano, B., Camdessanché, J.-P., Tholance, Y., Casez, O., Toussaint, B., Marion, J., Moreau, T., Lakomy, D., Thomasset, A., Maillart, E., Sterlin, D., Maurousset, A., Rocher, A., Laplaud, D.A., Bigot-Corbel, E., Bertho, P.-O., Pelletier, J., Boucraut, J., Labauge, P., Vincent, T., De Sèze, J., Jahn, I., Seitz-Polski, B., Thouvenot, E., Lebrun-Frenay, C. and Société Francophone de la Sclérose En Plaques (SFSEP) (2023) “Kappa Free Light Chain Biomarkers Are Efficient for the Diagnosis of Multiple Sclerosis: A Large Multicenter Cohort Study,” Neurology(R) Neuroimmunology & Neuroinflammation, 10(1), p. e200049. Available at: https://doi.org/10.1212/NXI.0000000000200049.
Roos, I., Malpas, C., Leray, E., Casey, R., Horakova, D., Havrdova, E.K., Debouverie, M., Patti, F., De Seze, J., Izquierdo, G., Eichau, S., Edan, G., Prat, A., Girard, M., Ozakbas, S., Grammond, P., Zephir, H., Ciron, J., Maillart, E., Moreau, T., Amato, M.P., Labauge, P., Alroughani, R., Buzzard, K., Skibina, O., Terzi, M., Laplaud, D.A., Berger, E., Grand’Maison, F., Lebrun-Frenay, C., Cartechini, E., Boz, C., Lechner-Scott, J., Clavelou, P., Stankoff, B., Prevost, J., Kappos, L., Pelletier, J., Shaygannejad, V., Yamout, B.I., Khoury, S.J., Gerlach, O., Spitaleri, D.L.A., Van Pesch, V., Gout, O., Turkoglu, R., Heinzlef, O., Thouvenot, E., McCombe, P.A., Soysal, A., Bourre, B., Slee, M., Castillo-Trivino, T., Bakchine, S., Ampapa, R., Butler, E.G., Wahab, A., Macdonell, R.A., Aguera-Morales, E., Cabre, P., Ben, N.H., Van der Walt, A., Laureys, G., Van Hijfte, L., Ramo-Tello, C.M., Maubeuge, N., Hodgkinson, S., Sánchez-Menoyo, J.L., Barnett, M.H., Labeyrie, C., Vucic, S., Sidhom, Y., Gouider, R., Csepany, T., Sotoca, J., de Gans, K., Al-Asmi, A., Fragoso, Y.D., Vukusic, S., Butzkueven, H., Kalincik, T. and MSBase and OFSEP (2022) “Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis,” Neurology, 99(17), pp. e1926–e1944. Available at: https://doi.org/10.1212/WNL.0000000000201029.
Maarouf, A., Audoin, B., Gherib, S., El Mendili, M.M., Viout, P., Pariollaud, F., Boutière, C., Rico, A., Guye, M., Ranjeva, J.-P., Zaaraoui, W. and Pelletier, J. (2022) “Grey-matter sodium concentration as an individual marker of multiple sclerosis severity,” Multiple Sclerosis Journal, 28(12), pp. 1903–1912. Available at: https://doi.org/10.1177/13524585221102587.
Poullet, Z., Pique, J., Maarouf, A., Boutiere, C., Rico, A., Demortiere, S., Durozard, P., Papeix, C., Maillart, E., Collongues, N., Ayrignac, X., Zephir, H., Deschamps, R., Ciron, J., Pelletier, J., Marignier, R. and Audoin, B. (2022) “Pure Relapsing Short Myelitis: Part of the Multiple Sclerosis Spectrum or New Entity?,” Neurology(R) Neuroimmunology & Neuroinflammation, 9(4), p. e1167. Available at: https://doi.org/10.1212/NXI.0000000000001167.
Januel, E., De Seze, J., Vermersch, P., Maillart, E., Bourre, B., Pique, J., Moisset, X., Bensa, C., Maarouf, A., Pelletier, J., Vukusic, S., Audoin, B. and Louapre, C. (2022) “Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica,” Multiple Sclerosis Journal, 28(7), pp. 1155–1159. Available at: https://doi.org/10.1177/13524585211049737.
Rollot, F., Couturier, J., Casey, R., Wiertlewski, S., Debouverie, M., Pelletier, J., De Sèze, J., Labauge, P., Ruet, A., Thouvenot, E., Ciron, J., Berger, E., Gout, O., Clavelou, P., Stankoff, B., Casez, O., Bourre, B., Zephir, H., Moreau, T., Lebrun-Frenay, C., Maillart, E., Edan, G., Neau, J.-P., Montcuquet, A., Cabre, P., Camdessanché, J.-P., Defer, G., Nasr, H.B., Maurousset, A., Hankiewicz, K., Pottier, C., Leray, E., Vukusic, S. and Laplaud, D.-A. (2022) “Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal,” Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, 19(2), pp. 476–490. Available at: https://doi.org/10.1007/s13311-022-01202-1.
Perriguey, M., Maarouf, A., Stellmann, J.-P., Rico, A., Boutiere, C., Demortiere, S., Durozard, P., Pelletier, J. and Audoin, B. (2022) “Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab,” Neurology(R) Neuroimmunology & Neuroinflammation, 9(1), p. e1115. Available at: https://doi.org/10.1212/NXI.0000000000001115.
Rico, A., Ninove, L., Maarouf, A., Boutiere, C., Durozard, P., Demortiere, S., Saba Villarroel, P.M., Amroun, A., Fourié, T., de Lamballerie, X., Pelletier, J. and Audoin, B. (2021) “Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy,” Multiple Sclerosis Journal - Experimental, Translational and Clinical, 7(4), p. 20552173211062142. Available at: https://doi.org/10.1177/20552173211062142.
Hilezian, F., Maarouf, A., Boutiere, C., Rico, A., Demortiere, S., Kerschen, P., Sene, T., Bensa-Koscher, C., Giannesini, C., Capron, J., Mekinian, A., Camdessanché, J.-P., Androdias, G., Marignier, R., Collongues, N., Casez, O., Coclitu, C., Vaillant, M., Mathey, G., Ciron, J., Pelletier, J. and Audoin, B. (2021) “TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis,” Journal of Neurology, Neurosurgery & Psychiatry, 92(8), pp. 890–896. Available at: https://doi.org/10.1136/jnnp-2020-325665.
Fissolo, N., Pignolet, B., Rio, J., Vermersch, P., Ruet, A., deSèze, J., Labauge, P., Vukusic, S., Papeix, C., Martinez-Almoyna, L., Tourbah, A., Clavelou, P., Moreau, T., Pelletier, J., Lebrun-Frenay, C., Bourre, B., Defer, G., Montalban, X., Brassat, D. and Comabella, M. (2021) “Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab,” Neurology(R) Neuroimmunology & Neuroinflammation, 8(4), p. e1003. Available at: https://doi.org/10.1212/NXI.0000000000001003.
Perez, T., Rico, A., Boutière, C., Maarouf, A., Roudot, M., Honoré, S., Pelletier, J., Bertault-Peres, P. and Audoin, B. (2021) “Comparison of rituximab originator (MabThera®) to biosimilar (Truxima®) in patients with multiple sclerosis,” Multiple Sclerosis (Houndmills, Basingstoke, England), 27(4), pp. 585–592. Available at: https://doi.org/10.1177/1352458520912170.
Massire, A., Seiler, C., Troalen, T., Girard, O.M., Lehmann, P., Brun, G., Bartoli, A., Audoin, B., Bartolomei, F., Pelletier, J., Callot, V., Kober, T., Ranjeva, J.-P. and Guye, M. (2021) “T1-Based Synthetic Magnetic Resonance Contrasts Improve Multiple Sclerosis and Focal Epilepsy Imaging at 7 T,” Investigative Radiology, 56(2), pp. 127–133. Available at: https://doi.org/10.1097/RLI.0000000000000718.
Luciani, L., Ninove, L., Zandotti, C., Chalvignac, V., Lagier, D., Baume, J., Mélade, J., Piorkowski, G., Coutard, B., Lepidi, H., Pelletier, J., Audoin, B., Rico-Lamy, A. and Nougairède, A. (2021) “Fatal underhanded chronic enterovirus infection associated with anti-CD20 monotherapy for central nervous system demyelinating disease,” Multiple Sclerosis Journal, 27(2), pp. 320–323. Available at: https://doi.org/10.1177/1352458520923978.
Pelletier, L., Petiot, A., Brocard, J., Giannesini, B., Giovannini, D., Sanchez, C., Travard, L., Chivet, M., Beaufils, M., Kutchukian, C., Bendahan, D., Metzger, D., Franzini Armstrong, C., Romero, N.B., Rendu, J., Jacquemond, V., Fauré, J. and Marty, I. (2020) “In vivo RyR1 reduction in muscle triggers a core-like myopathy,” Acta Neuropathologica Communications, 8(1), p. 192. Available at: https://doi.org/10.1186/s40478-020-01068-4.
Soustelle, L., Lamy, J., Le Troter, A., Hertanu, A., Guye, M., Ranjeva, J.-P., Varma, G., Alsop, D.C., Pelletier, J., Girard, O. and Duhamel, G. (2020) A Motion Correction Strategy for Multi-Contrast based 3D parametric imaging: Application to Inhomogeneous Magnetization Transfer (ihMT). preprint. Neuroscience. Available at: https://doi.org/10.1101/2020.09.11.292649.